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ABSTRACT OF THE DISSERTATION
4-HYDROXY ESTRADIOL-INDUCED OXIDANT-MEDIATED SIGNALING IS
INVOLVED IN THE DEVELOPMENT OF BREAST CANCER
by
Victor Onyishi Okoh
Florida International University, 2011
Miami, Florida
Professor Deodutta Roy, Major Professor
Breast cancer is a disease associated with excess exposures to estrogens. While the mode
of cancer causation is unknown, others have shown that oxidative stress induced by
prolonged exposure to estrogens mediates renal, liver, endometrial and mammary
tumorigenesis though the mechanism(s) underling this process is unknown. In this study,
we show that 4-hydroxyl 17β-estradiol (4-OHE2), a catechol metabolite of estrogen,
induces mammary tumorigenesis in a redox dependent manner. We found that the
mechanism of tumorigenesis involves redox activations of nuclear respiratory factor-1
(NRF1); a transcriptions factor associated with regulation of mitochondria biogenesis and
oxidative phosphorylation (OXPHOS), as well as mediation of cell survival and growth
of cells during periods of oxidative stress. Key findings from our study are as follows: (i)
Prolonged treatments of normal mammary epithelial cells with 4-OHE2, increased the
formation of intracellular reactive oxygen species (ROS). (ii) Estrogen-induced ROS
activates redox sensitive transcription factors NRF1. (iii) 4-OHE2 through activation of
serine-threonine kinase and histone acetyl transferase, phosphorylates and acetylate
NRF1 respectively. (iv) Redox mediated epigenetic modifications of NRF1 facilitates
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mammary tumorigenesis and invasive phenotypes of breast cancer cells via modulations
of genes involved in proliferation, growth and metastasis of exposed cells. (v) Animal
engraftment of transformed clones formed invasive tumors. (vi) Treatment of cells or
tumors with biological or chemical antioxidants, as well as silencing of NRF1
expressions, prevented 4-OHE2 induced mammary tumorigenesis and invasive
phenotypes of MCF-10A cells. Based on these observations, we hypothesize that 4OHE2 induced ROS epigenetically activate NRF1 through its phosphorylation and
acylation. This, in turn, through NRF1-mediated transcriptional activation of the cell
cycle genes, controls 4-OHE2 induced cell transformation and tumorigenesis.
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CHAPTER I
INTRODUCTION
Estrogens are complete breast carcinogens in experimental models as they are capable of
initiating and triggering growth and selection, resulting in palpable malignancy (1-3).
Both epidemiological and animal studies indicate that estrogens are a known risk factor
for breast cancer (1,3). However, the mechanisms by which estrogen initiate or stimulate
the progression of cancer remain the subject of a long-standing controversy, because we
have been not able to resolve whether estrogen or their metabolites are procarcinogenic.

We have previously shown that estrogen-induced tumor formation is decreased in
animals exposed to inhibitors of estrogen metabolism or to hormonally potent estrogens
with decreased metabolic conversion to catechol metabolites compared to E2 (2).
Moreover, we have shown that chronic treatment of the hamsters with vitamin C reduced
the incidence of E2-induced renal carcinogenesis by ~50% (2). Since vitamin C has no
antiestrogenic activity, its strong inhibitory effect on estrogen-induced tumorigenesis may
largely be derived from its protective effect against the oxidative damage caused by the
estrogens and its metabolites. Most of the recent studies show that hydroxyestrogens and
methoxy derivatives represent the majority of either urinary or intratumor estrogens in
human breast cancer patients, whereas they are relatively scarce in urine or mammary
glands of healthy women (4). These studies showed that 4-OH-E2 is elevated in breast
tumors as compared to normal mammary tissues which implicates its role in breast cancer
and strongly suggest the involvement of estrogen metabolites in the initiation and/or
promotion steps of breast carcinogenesis.
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Recent studies indicate that mammary tumors can develop despite a lack of a functional
ER α [2]. Although tamoxifen and other antiestrogens are considered to prevent cancer
through competition for the ER, other mechanisms cannot be ruled out as these
compounds also block metabolism and redox cycling of estrogen, and are free radical
scavengers (5). The 4-OH-E2 induces an estrogenic response in the uterus of ER null
mice, and this response is not inhibited by ICI182780 (6). These findings suggest that, in
addition, to nuclear ER-mediated genomic signaling pathways, non-genomic pathway(s)
are involved in the estrogen-dependent growth of preneoplastic and neoplastic cells. We
believe that to produce cell transformation both genomic and non-genomic actions of
estrogen are required and these two complementary mechanisms through which estrogens
produce transformed phenotype of cells. Formation of estrogen-DNA adducts in
mammary tissues have been shown by combined LS-MS-MS and LC-nano ES tandem
mass spectrometry (7). In addition, 4-hydroxycatechol estrogen conjugates with
glutathione or its hydrolytic products (cysteine and N-acetylcysteine) have been detected
in mammary tissues from ERKO/Wnt-1 mice (8). Although this type of DNA adduction
may play a role in the generation of mutations, it appears to be a late event. In our recent
studies, estrogen-induced a rapid increase of intracellular ROS formation in MCF-7 cells
(9). Based on our preliminary study showing 4-OH-E2-induced ROS formation in
MCF10A cells, the accumulation of 4-OH-E2 in estrogen target organ of the cancer will
result in increased formation of ROS in the target cells. In addition, 4-OH-E2 is also
strongly active at the estrogen receptor (10,11), which would add to the growth
stimulation of the ER-positive cells. Our preliminary data revealed that 4-OH-E2 may
also activate an additional signal transduction pathway that is different from the classical
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ER•signaling pathway. The contribution of this signal transduction system to breast
carcinogenesis is the subject of the proposed study.

In pursuing mitochondrial regulators of cell cycle progression, we discovered that
intracellular ROS levels increase as cells progress through G1 and into S phase upon E2
exposure (11). High ROS levels induce oxidative damage and arrests cells in G0/G1.
However, low physiologic ROS levels are utilized by cells for cell-to-cell communication
and in proliferation. Inhibition of estrogen-induced ROS by antioxidants prevents early
G1 gene expression. We now know that the delicate intracellular interplay between
oxidizing and reducing equivalents allows ROS to function as second messengers in the
control of cell proliferation and cell transformation (11,12). Our preliminary study
showed that MCF-10A cells treated with 4-OH-E2 rapidly produce ROS, which is
preceded by an increase in the level of Ca2+. The accumulation of 4-OH-E2 as recently
reported in the human breast tissue in cancer subjects (9) will allow increased formation
of ROS and Ca2+ in the target organ of cancer in a sensitive subpopulation. Our
preliminary study showed that the overexpression of catalase and MnSOD prevented 4OH-E2-induced anchorage-independent growth of MCF-10A cells. These studies data
indicate that 4-OH-E2-induced cell transformation may be mediated, in part, by ROS and
Ca2+ signal transduction pathways that are different from the classical nuclear ER
genomic signaling pathway. Therefore, how 4-OH-E2, through ROS signalings, produces
malignant phenotype is an issue of fundamental importance to this proposal.

3

Recently, an NRF1 and CREB pair has been identified as a key regulator of the
transcriptional program of the cell cycle in human cells because thes pair of transcription
factors showed a significant co-occurrence rate on promoters of cell cycle regulated
genes (13). NRF1 appears to play an important role as a regulator of cell cycle genes
because NRF1 binding site has been identified by comparing genome-wide locations on
genes involved in DNA replication, mitosis, and cytokinesis (14,15). Some of the genes
which contain NRF1 binding sites on their promoters included Cdc2, Cdc25C, PCNA,
and cyclin B1. In addition to NRF1’s role in controlling mitochondrial biogenesis-related
genes, these observations are consistent with a role for NRF1 in regulating genes
involved in growth and development. The expression of early G1 genes, c-myc, c-fos, cjun, cyclin D1, and NRF1 are regulated by ROS (2,16). The mRNAs of some of these
genes are induced by estrogen-induced ROS and hydrogen peroxide as well as other
inducers of oxidative stress (2,11). Based on these studies, we have proposed that 4-OHE2-induced ROS through activating the transcription factor NRF1 leads to the induction
of cell cycle genes that contain the binding site(s) for this transcription factor in their
promoters. This, in turn, supports the growth of anchorage-dependent and -independent
cells.
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CHAPTER II
HYPOTHESIS, SPECIFIC AIMS, AND RELEVANCE OF FINDINGS
Hypothesis
We hypothesize that 4-hydroxy estradiol (4-OH-E2), a catechol metabolite of 17β
estradiol (E2)-induced ROS epigenetically activate NRF1 through its phosphorylation
and acylation. This, in turn, through NRF1 mediated transcriptional activation of cell
cycle genes, controls 4-OH-E2-induced cell transformation and tumorigenesis.

Specific Aim 1:

To determine whether estrogen-induced RO/NS are involved in

estrogen-induced in vivo growth of malignant breast epithelial cells. To achieve this aim,
we would determine whether: a overexpresion of mt superoxide dismutase (SOD) or
catalase that detoxify ROS; or co-treatment with the chemical antioxidant scavengers, Nacetylcysteine and ebselen, prevents estrogen-induced cell transformation and in vivo
growth of malignant breast epithelial cells. b: Whether Knockdown of mitochondrial
biogenesis through silencing of mtTFA will lead to attenuations of RO/NS production
and whether reduced ROS production prevents estrogen-induced cell transformation and
in vivo growth of malignant breast epithelial cells.

Specific Aims 2: To determine that 4-OH-E2-induced ROS through activation of NRF1
signaling transform normal breast epithelial cells to malignant cells. To accomplish these
goals, we will determine whether the transformation of normal breast epithelial cells by
4-OH-E2 is prevented by: a) the overexpression of ROS modifiers catalase and MnSOD,
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b) silencing of NRF1. Cell transformation will be assessed by determining colony
efficiency, colony size, ductulogenic capacity, and invasiveness. We will also determine
whether silencing of NRF1 and overexpression of MnSOD or catalase prevent 4-OHE2-induced

tumor formation in three-dimensional culture mimicking in vivo

environment. The findings of this aim will reveal a new paradigm by showing that the
carcinogenic activity of 4-OH-E2 requires NRF1.

Specific Aim 3: To determine whether 4-OH-E2 induced ROS through stimulating redox
sensitive AKT kinase and histone acetyltransferase of CREB binding protein associated
factor (P/CAF), respectively, control phosphorylation and acylation of the NRF1. The 4OH-E2-induced epigenetic changes in turn activate NRF1. To test the postulate of this
aim, we will determine that: i) NRF1 stability and transactivation are regulated by 4-OHE2-induced ROS. This mechanism involves NRF1 phosphorylation by AKT kinase and
NRF1 acylation by the histone acetyltransferase CREB binding protein-associated factor
(P/CAF), respectively; and (ii) the 4-OH-E2-induced epigenetic changes have an additive
or synergistic effect on NRF1 activation. We will determine whether NRF1 transctivating
ability is modulated by controlling its phosphorylation and/or acylation; and (iii)
transcriptional activation of cell cycle genes and cell cycle progression are prevented by
silencing ofAKT, P/CAF, or NRF1. These observations will reveal the new paradigm of
4-OH-E2-induced cell cycle regulation of anchorage-independent cells by NRF1
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Relevance of findings
This study addresses an important public health issue by studying whether
phosphorylation and acetylation of NRF1 by 4-OH-E2-generated ROS promote
malignant transformation of normal breast epithelial cells. The proposed studies are
highly innovative, since they tested the novel concept that oxidants participate in 4-OHE2-induced cellular transformation and tumorigenesis.

Understanding if aberrant

activation of NRF1 signaling by 4-OH-E2-generated ROS contributes to development of
E2-dependent breast tumors provides new insights into cancer predisposition. Moreover,
it provides a novel paradigm for understanding the molecular mechanisms underlying the
carcinogenic effects of natural estrogen and other medicinal and environmental
estrogenic agents. This is a new line of research that may well set the stage for the design
and development of new and more effective NRF1 signaling-based drugs or gene
therapies for the prevention and treatment of breast cancer.
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CHAPTER III
LITERATURE REVIEW
ESTROGEN-INDUCED REACTIVE OXYGEN SPECIES-MEDIATED SIGNALINGS
CONTRIBUTE TO BREAST CANCER GROWTH
Victor Okoh, Alok Deoraj, Deodutta Roy
Department of Environmental and Occupational Health, Florida International University,
Miami, FL 33199-0001
(2010 – Biophysica Biochmica Acta, Received 22 September 2010; revised 12 October
2010; accepted 14 October 2010. Available online 29 October 2010,
doi:10.1016/j.bbcan.2010.10.005)
ABSTRACT
Elevated lifetime estrogen exposure is a major risk factor for breast cancer.
Recent advances in the understanding of breast carcinogenesis clearly indicate that
induction of estrogen receptor (ER) mediated signaling is not sufficient for the
development of breast cancer. The underlying mechanisms of breast susceptibility to
estrogen’s carcinogenic effect remain elusive. Physiologically achievable concentration
of estrogen or estrogen metabolites has been shown to generate reactive oxygen species
(ROS). Recent data indicates that these ROS can induce DNA synthesis, increased
phosphorylation of kinases, and activation of transcription factors, e.g., AP-1, NRF1,
E2F, NFkB and CREB of non genomic pathways which are responsive to both oxidants
and estrogen. Estrogen-induced ROS by increasing genomic instability and by
transducing signal through influencing redox sensitive transcription factors play
important role (s) in cell transformation, cell cycle, migration and invasion of the breast
cancer. The present review discusses emerging data in support of the role of estrogen
induced ROS-mediated signaling pathways which may contribute in the development of
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breast cancer. It is envisioned that estrogen induced ROS mediated signaling is a key
complementary mechanism that drives the carcinogenesis process. ROS mediated
signaling however occurs in the context of other estrogen induced processes such as ERmediated signaling and estrogen reactive metabolite-associated genotoxicity. Importantly,
estrogen-induced ROS can function as independent irreversible modifiers of
phosphatases and activate kinases to trigger the transcription factors of downstream target
genes which participate in cancer progression.

INTRODUCTION
Estrogen is a class of 18-carbon steroid. There are a total of 9 estrogens in humans of
which the three major ones are 17β-Estradiol (E2), Estrone (E1), Estriol (E3). These
estrogens are synthesized primarily in the ovaries of premenopausal women. Other
organs such as brain and adipose tissues also synthesize estrogens through aromatization
of testosterone [1]. Estrogens are also synthesized in male species. A relatively high
concentration of estrogen is found in rete testis fluid and in testicular vein and lymph of
rodents [2;3]. The level of estrogens in peripheral blood of men averages 69 pg/ml
compared to 199 pg/ml in non-ovulating women [4]. E2 is the predominantly circulating
and the most biologically active ovarian steroid. In addition to endogenous sources, the
body burden of estrogen may increase from the intake of synthetic medicinal estrogens,
such as 17α-ethinyl estradiol (used as oral contraceptive), mestranol, premarin (used in
hormone replacement therapy), and diethylstilbestrol (used in the treatment of highly
advanced breast and prostate cancers). Physiological estrogens are essential for the
growth and maintenance of various reproductive and non-reproductive organs in the body
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where they elicit different growth responses in tissues depending on the cell-type, type of
estrogen receptor (ER) present, dose and timing of exposure.
Elevated lifetime estrogen exposure has been shown to be a major risk factor for cancer
in hormone-dependent organs, particularly breast and endometrium [5-9]. This may help
explain the observation that breast cancer risk increases in the women who experience
early menarche (onset of menstruation) and late menopause whereas breast cancer risk is
reduced in the women who experience late menarche and early menopause [10;11]. A
cohort study by the European Prospective Investigation into Cancer and Nutrition found
that excess serum estrogens are associated with incidence of breast cancer in
premenopausal women [12]. Similarly, estrogen replacement therapy in post menopausal
women has been demonstrated to be associated with breast, cervical, and endometrial
carcinoma [13]. In experimental models, estrogens are established breast carcinogens, as
they are capable of initiating and triggering growth and selection to generate palpable
malignancy [14-18]. These findings led the International Agency for Research on Cancer
and National Toxicology Program to categorize estrogens as human carcinogens [19;20].
Post menopausal women exhibit the highest breast cancer incidence when serum
estrogens are at their lowest level [6]. In contrast, the estrogen levels in mammary tissues
are similar in pre and post menopausal women [21]. In addition, post-menopausal breast
cancer patients have significantly higher estrogen levels in breast tissues than non disease
pre or post menopausal women [22]. This finding indicates that site-specific estrogen
synthesis or estrogen load may be the major source associated with breast carcinogenesis
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and growth of breast cancer cells. However, the underlying mechanisms of breast cell
susceptibility to estrogen’s carcinogenic effect remain elusive.
The signaling pathway plays a critical role in mammary gland development. This
pathway has also been shown to be essential in promoting growth of estrogen receptor
positive (ER+) breast cancer cells. Whether this pathway alone is sufficient to induce
breast carcinogenesis is still unresolved. Mammary tumors can develop in mice lacking
functional ER alpha (ERα) [15;23]. Likewise, E2 and its catechol metabolite, 4-hydroxy
estradiol (4-OH-E2) can induce an estrogenic response in the uterus of ERα null mice,
where an antiestrogen (ICI182780) fails to inhibit such response [24]. Though tamoxifen
(TAM) and other antiestrogens inhibit breast cancer growth through their actions at the
ER, these antiestrogens also inhibit growth of cancer cells that are estrogen receptor
negative [25-27]. In addition, estrogen undergoes oxidative metabolism and generates
ROS which is implicated in carcinogenic conversion and growth of cancer cells [9;18].
TAM on the other hand can block estrogen metabolism and acts as a ROS scavenger [14].
These findings therefore suggest that other mechanism(s) independent of ER status exist
that mediate estrogen induced cellsignaling leading to malignant transformation and
growth of mammary epithelial cells. One such mechanism being investigated by us is the
role of estrogen induced mitochondria ROS in mammary carcinogenesis. Using
physiologically achievable estrogen concentrations corresponding to the estrogenic
menstrual peak, we showed that estrogen induces rapid formation of mitochondrial ROS
in MCF-7 cells [28]. Other reports support our observation that estrogen-induced ROS
production relies on mitochondria, which are the main source of ROS in the epithelial
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cell [29]. Some of the same mitogenic pathways that are sensitive to ROS levels are
regulated by carcinogenic levels of estrogen. We have recently shown that inhibitors of
mitochondrial ROS production prevent E2-induced expression of cell cycle genes
containing nuclear respiratory factor-1 (NRF1) binding sites (e.g., cyclin B1, PCNA, and
PRC1), decrease E2-induced NRF1 expression, and delay growth [30]. Together these
studies indicate that in addition to ER mediated signaling, E2 through ROS signaling can
support initiation and progression of breast cancer by alternative pathways.

In this review, we discuss a novel concept that estrogen-induced ROS can produce
genotoxic effects as well as support the development of estrogen-dependent breast
tumors. This envisioned ROS mediated mechanism most likely contributes to the process
that drives carcinogenesis, while this mechanism seems to occur in the context of other
ER-mediated signaling and estrogen reactive metabolite-associated genotoxicity. To
highlight the ROS mediated carcinogenesis mechanism, first, estrogen metabolism and
redox cycling of hydroxylated estrogens leading to the generation of genotoxic estrogen
metabolites is briefly discussed. Then, we elaborate on the role of mitochondria in
estrogen-induced generation of oxidants and emerging data on how estrogen-induced
ROS modifies redox-sensitive signal transduction pathways that contribute in the cell
transformation, cell growth and cancer progression.
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GENERATION OF GENOTOXIC METABOLITES OF ESTROGEN AS
POTENTIAL MECHANISM OF BREAST CARCINOGENICITY

A

Cells are protected from estrogen-mediated mitogenicity and genotoxicity through
conjugation of parent estrogens to sulfate and glucuronide moieties. Estrogen metabolism
and generation of genotoxic estrogen metabolites are summarized in Figure 1 and have
been previously reviewed extensively [9;31-33], therefore we have limited our discussion
in this area. Endogenous and synthetic estrogens, i.e. E1, E2, E3, 17 α ethinyl estradiol
(EE2) and equilenin (Eq) are converted

into catechol estrogens through aromatic

hydroxylation by specific cytochrome P450 isoforms/peroxidase enzymes [9;34]. The
catechol

estrogens

are

inactivated

by

methylation,

catalyzed

by

catechol

methyltransferases, as well as by glucuronidation and sulfation, catalyzed by
glucuronosyltransferases and sulfotransferases, respectively [35]. Oxidation of the
catechol estrogens moieties gives rise to estrogen semi-quinones and quinines, i.e.,
estrogen-2,3-semi-quinone and estrogen-3,4-semi-quinone [36;37]. Catechol estrogens,
particularly 4-OH-E2, via nonenzymatic autoxidation, may undergo redox cycling to
produce reactive semiquinone and quinone intermediates with concomitant production of
ROS. However, this redox reaction of catechol estrogens is enhanced in the presence of
Cu2+ or Fe

3+

and by enzymatic catalysis by cytochrome P450 oxidases or peroxidases,

which is accompanied with an increased generation of ROS. Catecholestrogens can
reduce Cu2+ or Fe 3+ ions to Cu+ or Fe2+. The Cu+ or Fe2+ ions in turn, may reduce organic
or inorganic peroxides, which are capable of initiating lipid peroxidation in the presence
of oxygen. Both iron and copper are now recognized as major transition metals that may
facilitate the formation of ROS through redox cycling of catechol compounds as well as
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by the Fenton reaction [38]. Estrogen quinones are conjugated with glutathione both in
vivo and in vitro [37;39] by glutathione transferases [40]. 4-Hydroxylated estrogen
metabolites or the diethylstilbestrol metabolite diethylstilbestrol-4, 4-quinone in a
microsomal cytochrome P450 activation system, induce 8-hydroxylation of guanine bases
of DNA. In addition to oxidant-induced damage to DNA, estrogens generate lipid
peroxidation and oxygen radical-mediated oxidation of amino acid residues of proteins to
carbonyl-containing moieties. The oxidant-induced oxidative DNA damage in estrogentarget tissue has been taken as evidence for the generation of oxygen radicals by
metabolic redox cycling of catecholestrogens or diethylstilbestrol (DES) and for their
participation in the induction of estrogen-induced cancer in animals or humans. Catechol
estrogen semiquinone/quinone can also directly react with DNA to form adducts [31].
These adducts can either be stable DNA adducts that remain in DNA or can form
depurinating adducts that destabilizes DNA’s glycosyl bond [41]. DNA adduct formation
and depurination at critical sites such as tumor suppressors or oncogenes can lead to
mutations which have been postulated to be the initiator of breast cancer [41]. Rodent
studies demonstrate that E2 induces tumors in those tissues only where E2 is
predominantly converted to 4-OH-E2 by 4-hydroxylase enzyme [42;43].

We have

previously shown that E2-induced tumor formation is decreased in animals exposed to
inhibitors of estrogen metabolism [17;18] or to hormonally potent estrogens undergoing
reduced metabolic conversion to catechol metabolites [44].

The rate of 4-OH-E2

formation is also shown to be 4-fold higher than that of 2-OH-E2 in human mammary
fibroadenomas and adenocarcinomas [45]. The 4-OH-E2 are the most prevalent estrogen
metabolite in breast tumor tissues and have a significantly higher circulating level in
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women with breast cancer [46]. Hydroxyestrogen and methoxy estrogen derivatives
account for the majority of urinary or intra-tumor estrogens in human breast cancer
patients but they are relatively scarce in the urine or mammary glands of healthy women
[16]. Oxidative cellular damage such as 8-hydroxylation of guanine bases of DNA and
lipid peroxidation have also been demonstrated in human breast and indicate the in vivo
pro-oxidant effects of the estrogen and catecholestrogen metabolites formed in this tissue
(reviewed in [9;31]). For example, elevated 4-OH-E2 levels in breast tumors and in
women with breast cancer compared to normal mammary tissues implicate 4-OH-E2 in
breast cancer and it strongly suggests that 4-OH-E2 metabolite participates in
development of breast carcinogenesis [47]. Our recent studies showed that E2 or 4-OH-E2
elicited transformed phenotypes in ERα negative MCF-10A cells through ROS-sensitive
signal transduction pathways [48-51].

When exposed to E2, 4-OH-E2, 4-

hydroxyequilenin, equilenin or its catechol metabolite, similar transformation in MCF10F and MCF-10A were observed by other researchers [52;53]. Although neither 2-OHE2 nor 2-OH-E1 is carcinogenic in vitro or in vivo [42;54;55], both 2-OH-E2 and 2-OH-E1
are capable of producing ROS and undergo metabolic redox cycling like 4-OH-E2. The
lack of carcinogenicity of 2-hydroxylated estrogen metabolites in vivo may be due to
their rapid inactivation by catechol-O-methyltransferase (COMT)-mediated Omethylation [55-57], rapid clearance [58], and weak estrogenic hormonal activity
(compared with 4-OH-E2) [59]. It may also be due to 2-MeO-E2, the major product of
COMT-mediated O-methylation of 2-OH-E2 that possesses unique anti-tumorigenic
activity. These studies support the concept that E2 and mainly its metabolite 4-OH-E2 are
carcinogenic in breast epithelial cells.
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ESTROGEN RECEPTOR MEDIATED CARCINOGENIC ACTIONS
The conventional paradigm of estrogen carcinogenic action is based on binding to ERα/β,
which has been extensively reviewed; therefore, we limited our discussion in this area.
Estrogen binding to its receptors, ERα and ERβ, initiates gene transcriptions by binding to
estrogen response elements (ERE) of genes involved in cell growth. Therefore, increases in
estrogen activity or exogenous estrogenic exposure may lead to increased cell proliferation
[60]. It is speculated that rapidly proliferating cells are error prone due to the less time
accorded for DNA proof reading and repairs. Errors incorporated into critical genes such as
oncogenes and/or tumor suppressors may likely lead to mutations and neoplastic growth.
Nevertheless, the classical concept of estrogen receptor mediated actions in cancer does not
address the fact that the majority of normal mammary epithelial cells that transform into
cancerous cells are ER negative (ER-) but are growth factor receptor positive (GFR+) [61;62].
On the other hand, about 7%-15% of normal mammary epithelial cells are ER positive (ER+)
but lack growth factor receptors (GFR-) [63]. The predominant ER+ cells in normal mammary
tissues are the stromal cells. Estrogen induced proliferative responses of normal ER- mammary
epithelial cells may be mediated by the induction of GFR+ stromal cells [64]. Interestingly, the
majority of breast cancer cells in vivo are ER+ but GFR- and do proliferate upon estrogen
exposure [65]. These observations therefore implie that ER positive phenotypic expressions
observed in majority of breast cancer cells may be manifestation of malignant transformation.
Furthermore, discrepancies between the binding affinity of various estrogens to ER and
their potency both in vitro and in vivo have been reported (Figure 2). For example, 17αestradiol has a very weak affinity for ER compared to that of
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DES and 17 α-

ethinylestradiol; but its ability to stimulate the growth of Leydig cells and other cells is
equivalent to that of DES [66]. Similarly, the receptor binding affinity of 4-OH-E2 is
50% that of DES or E2, but its ability to stimulate cell growth in the mouse uterus is
greater than either of these compounds [67]. In Noble rats, E1 is more potent than E2 in
producing growth of mammary tissues [68;69]. In addition, estrogen-induced tumor
formation is decreased in animals exposed to inhibitors of estrogen metabolism [17;18] or
to hormonally potent estrogens with decreased metabolic conversion to catechol
metabolites [44] compared to E2. The ectopic expression of Wnt-1, a proto-oncogene in
mice induced mammary hyperplasia and tumorigenesis in the absence of ERα in female
and male mice [15;23]. All these studies indicate that estrogen induced cellular responses
including carcinogenicity and growth of cancer cell are verycomplex and the
conventional paradigm as described above cannot explain all observed discrepancies.

ESTROGEN, MITOCHONDRIA, AND ROS GENERATION
Both natural and synthetic estrogenic compounds containing a phenolic structure possess
pro-oxidant and/or antioxidant activities. A balance of pro- and antioxidant effects of
estrogens depends on the nature (structure) of the estrogen and on its concentrations.
Under physiological conditions, the parent estrogen and the metabolic profile of estrogen
metabolites in a specific tissue or fluid determine its pro- or antioxidant activities. In
additionto the above-described metabolic redox cycling of hydroxylated estrogens
producing ROS, we present here the evidence supporting the role of mitochondria in
estrogen-induced generation of oxidants.
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Estrogen and mitochondria: Mitochondria are an integral component of steroidogenesis.
Key enzymes of estrogen biosynthesis (3 β-hydroxysteroid dehydrogenase and
aromatase) have been identified in the mitochondria of ovarian tumor epithelial cells
[70]. Exogenously added estrogen is preferentially and rapidly(> 50% within a few
minutes) transported to mitochondria [71]. How estrogen functions in the mitochondria
remains unclear; however, presence of ERα and ERβ in mitochondria indicates a
potential role of estrogen in the regulation of mitochondrial genome transcription [72-74].
In the human mitochondrial genome, partial or ERE ½ sites in the D-loop region, CO II,
tRNA-met, 12 S rRNA, 7 S rRNA, URF1, and URF5 were identified. We recently
reported that mitochondria are a major target of estrogen within the cell [28;75]. Estrogen
can also affect mitochondria at the protein level. Estrogen and ER agonists have been
shown to inhibit mitochondrial respiratory complexes I, II, III, IV, and mitochondrial
ATP synthase (F0F1-ATPase) [76;77], but most of these studies used cytotoxic dose of
estrogen and any physiologic responses by mitochondria were probably overlooked.
Mitochondrial proteins are encoded in the mitochondria and nuclear genomes.
Mitochondrial transcription factor A (mtTFA), which controls mtDNA copy number, is
essential for mitochondrial biogenesis [78]. When translocated into the mitochondria,
mtTFA initiates transcription and replication of the mt genome. Translation is initiated
by mitochondrial translation initiation factor 2 (MTIF2), which is encoded by the mt
genome and contains a consensus binding site for ER. The tissue-specific coactivators of
steroid receptors (including ER), such as peroxisome proliferator–activated receptorcoactivator-1 (PGC-1), and the PGC-1-related proteins, PRC and PERC, coactivate the
expression of mtTFA [79-82]. Both transcriptional activators nuclear respiratory factor 1
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and 2 (NRF1 and 2) and coactivators (PGC-1, PRC) act as important mediators in the
maintenance and proliferation of mitochondria [83]. Steroid hormones, androgens and
thyroxin, can induce changes in mitochndrial genome-derived mRNA and rRNA by
increasing mtTFA mRNA expression from the nuclear genome [84].

At the post-

translational level, an interaction between mtTFA and P53 has been shown to control
mitochondrial biogenesis [85], and P53 interacts with ER [86].

Estradiol increased

phosphorylation of a 76-kDa protein in the mitochondrial fraction of the rat corpus
luteum [87].

This report, together with the presence of protein kinases within

mitochondria, further suggests that estrogens regulate mitochondrial physiology at the
post-translational level [77].
Mitochondria and generation of estrogen induced ROS: Several enzymatic systems and
organelles produce ROS, such as NADPH oxidases at the plasma membrane, nitric oxide
synthases, xanthine oxidase, peroxisomes at endoplasmic reticulum (cytochromes P450)
and mitochondria. Mitochondria however, are the largest source of ROS in epithelial
cells. Over 90% of oxygen is consumed by mitochondria, and up to 4% of the oxygen in
the mitochondria is utilized to produce RO/NS.

The respiratory chain produces

superoxide radicals (O2-.). The major source of H2O2 in cells arises from the dismutation
of O2.- (2O2.- + 2H+ =H2O2 + O2). At physiologic pH, non-enzymatic dismutation is rapid
(~105 mol-1 sec-1), but dismutation is markedly accelerated by the superoxide dismutases
(SOD; > 109 mol-1 sec-1). H2O2 freely diffuses through cellular membrane and is a
precursor of OH-. Mitochondrial nitric oxide synthase (NOS) produces nitric oxide (NO.),
which combines with O2-. to generate peroxinitrite (ONOO-). All these RO/NS may cause

21

mitochondrial and cellular damage if present in excess (Figure 3). The physiologic
production of RO/NS by mitochondria can have profound effects on initiation of
preneoplastic foci and its promotion as well as tumor cell growth both in vivo and in vitro
(Figure 3). Multiple non-mitochondrion and mitochondrion-dependent defense system
regulate intracellular RO/NS formation and maintain an appropriate redox environment
[88]. Glutathione, a tripeptide thiol (cysteine-glutamine-glycine), and thioredoxin (Trx), a
small protein that has two cysteines in its active site, are responsible for much of the
antioxidant defense of cells but are also likely mediators of oxidative signaling. These
thiols

are

used

as

substrates

for

glutathione

peroxidases,

Trx

peroxidases

(peroxiredoxins) [75;89], and glutathione-S-transferases, enzymes that regulate the steady
state concentration of hydroperoxides (ROOH) including H2O2, and also used as
electrophiles, such as 4-hydroxy-2,3-nonenal (4HNE), which is a lipid peroxidation
product.

Earlier studies failed to identify that physiologic concentrations of estrogen stimulate
mitochondrial ROS generation.That is why possibly cytotoxic doses of estrogen and
isolated mitochondria were used. We and others have shown that mitochondria are
significant targets of estrogen [28;30]. Recently, we reported that physiological
concentrations of E2 stimulate a rapid production of intracellular ROS in epithelial cells
which depends on cell adhesion, the cytoskeleton, and integrins [28]. In our studies of E2induced ROS generation in MCF-7 and other cells, hydroxylated estrogen metabolites or
adducts immediately after addition of E2 were not detected which rules out the possibility
of ROS generation by redox cycling of hydroxylated estrogens. These events occur
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earlier than ER-mediated genomic actions. E2-induced ROS production does not depend
on the presence of ER on breast cancer cells as ER- cell line MDA-MB 468 produced
ROS equal to or more than that of ER+ MCF7, T47D, and ZR75 cell lines [28].
The ROS molecules, H2O2 and NO, also stimulate mitochondrial biogenesis, a process
that depends on the flow of molecules into and out of the organelle [90;91]. It has been
shown recently that oxidative stress causes an increase in mitochondrial mass in human
lung cells. However, the molecular mechanism underlying the increase in mitochondrial
mass and mtDNA is still unclear. Furthermore, the mitochondrial mass of mtDNA-less
cells was also significantly increased by exposure to low concentrations of H2O2,
suggesting that the increase in mitochondrial mass in replicating cells may result from an
increase in ROS production. Thus, the delayed production of estrogen-induced ROS may
occur via this mechanism, whereas the transient estrogen-induced increase in ROS may
result from estrogen activation of the mtTFA complex leading to increased oxidative
phosphorylation.

ESTROGEN-INDUCED ROS-MEDIATED OXIDATIVE DNA DAMAGES
Estrogen-induced oxidative DNA damage through ROS has been extensively reviewed
[9;31-33], therefore we have limited our discussion in this area here. 8- Hydroxy-guanine
(8-OHdG), an indicator of oxidative DNA damage, causes G->T and A->C substitutions
in DNA templates. It has been shown that breast carcinoma DNA contains dramatically
higher concentrations of base modifications, such as 8-hydroxy-guanine, 2,6-diamino-4hydroxy-5-formamidopyrimidine, and 8-hydroxyadenine [92-94]. An elevated level
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(3.35-fold higher) of 8-OHdG was observed in ER+ when compared with ER- malignant
tissues. 8-OHdG level in ER+ MCF-7 cell line was significantly higher (9.3-fold higher)
than ER- MDA-MB 231 cell line [93]. There was a higher level of 8-OHdG in the DNA
of early-stage cancer tissue than that of later-stage cancer tissue, which suggests that ROS
may play an important role in the early phase of carcinogenesis. The urinary 8-OHdG
level (1,827 +/- 1,500 pmol/kg/day) in 18 women with gynecologic cancer has been
shown to be significantly higher than in 10 women (747 +/- 425 pmol/kg/day) without
carcinoma [94]. Gene mutation induced by ROS has been observed in C-Ha-ras-1 and
p53 [95;96]. Recently, it has been shown that methylation alone induced C:G-->T:A
transitions in the p53 gene, whereas nitric oxide treatment produced more C:G-->A:T
transversions at CpG sites and, thus, increased mutational yields. Alterations in the
genome of breast cells is likely produced by oxidative attack of ROS generated by
estrogen-induced oxidative stress in combination with receptor-mediated proliferation of
oxidatively damaged cells. This view is supported by the findings of DNA damage
induced in vitro or in vivo by estrogen-induced ROS, 4-OH-E2 and both natural and
synthetic estrogens in the target organs of cancer [31;32]. Catecholestrogen through
redox cycling produce free radicals that generate various forms of free radical-induced
DNA damage [31;32]. Cotreatment with an inhibitor of IL-1β and TNF-α, pentoxifylline,
inhibited stilbene estrogen-induced increase in myeloperoxidase activities, 8-OHdG
formation, mutations in the genome and prevented the estrogen induced testicular and
uterine pre-neoplastic lesions [9]. Estrogen by stimulating nitric oxide synthase (NOS)
and the subsequent generation of NO could affect methylation and expression of genes
[97-99]. Thus, ROS/NO induced by estrogen may produce both gene mutations and gene
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silencing, which, in turn, can predispose an individual to the development of cancer.
Therefore, estrogen-induced ROS may play multiple roles in tumor initiation and
progression. Compelling evidence for the transforming capacity of ROS is the finding
that overexpression of Mox1 (the catalytic subunit of NADPH oxidase) induces
superoxide generation and transforms NIH 3T3 cells. Furthermore, Mox1-transfected
cells produce aggressive tumors in athymic mice similar in size to those produced by
Ras-transformed NIH 3T3 cells [100], illustrating the critical role of this ROS regulator
in vivo. These results are consistent with the concept that generation of genetic alterations
is required for the initiation and progression of estrogen-induced tumors.

ESTROGEN-INDUCED ROS MEDIATED REDOX SIGNALINGS
ROS fulfill the characteristics of a second messenger since they are short-lived (rapidly
generated and degraded), produced in response to a stimulus, highly diffusible (e.g.,
H2O2), and they are ubiquitously present in most cell types. In this section, we review the
ROS-mediated signaling pathways which contribute to initiation, promotion and
progression of estrogen-dependent breast tumors. Signaling proteins, including protein
tyrosine phosphatases and several transcription factors, that contain critical cysteines are
sensitive to redox changes and thus are potential targets of modifications by ROS (Figure
4). A common feature of redox signaling appears to be the oxidative modification of
critical cysteines in protein phosphatases that act on protein kinases. Kinases in turn
activate redox sensitive transcription factors that influence the expression of genes
involved in cell transformation, cell growth, and cancer progression.
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Regulation of phosphatases by estrogen-induced ROS: ROS reversibly regulate cysteinebased phosphatases, which include protein tyrosine phosphatases (PTPs), dual-specificity
phosphatases (such as, Cdc25s), low-molecular-weight PTPs, and the lipid phosphatase,
PTEN. Oxidation of PTPs can be reversed by thiol compounds, once the catalytic
cysteine forms a disulfide bond with an N-terminal cysteine. This disulfide bond can
originate from same site cysteines, as is the case with low molecular weight PTPS, from
“distant” cysteines such as with PTEN and Cdc25, or from a bond between the PTP and a
thiol, such as with PTP1B. The important step of the disulfide bond blocks the oxidation
of the thiolate to Cys-SOH by the connection to another thiolate. Oxidation and
phosphorylation have the potential of influencing each other in the signaling of PTPs and
protein tyrosine kinase (PTKs). We have used Cdc25 as a major focus of this section to
describe the redox regulation of phosphatase by estrogen-induced ROS. The Cdc25s,
dual-specificity tyrosine phosphatases, possess the necessary elements to function
directly in redox control of the cell cycle. Three homologues of Cdc25s exist in humans:
Cdc25s A, B, and C. All contain a nucleophilic catalytic cysteine within a conserved
motif that enables these enzymes to dephosphorylate phosphoproteins. The first
suggestion that Cdc25 phosphatases act as potential redox controllers of the cell cycle
was made more than 10 years ago by Mori laboratory which showed the direct
involvement of ROS in the two-cell block of the mouse embryo [101]. Embryo
development past the two-cell stage occurred when they injected the ROS modifiers SOD
or Trx in vitro. Trx was shown to act through the phosphorylation state of Cdc2 kinase
because the injection of Trx led to dephosphorylation and activation of the Cdc2 kinase
during M-phase of the second cleavage. Other studies suggested that the oxidative stress
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generated in human cells in response to UV or IR exposure degrades Cdc25s- A through
its phosphorylation on serine-123 by check point kinase (chk) [102;103]. This leads to its
ubiquitylation and its proteolytic degradation. In contrast, Finkel’s laboratory has shown
that Cdc25C undergoes rapid non proteasomal degradation in response to H2O2 treatment
in HeLa cells [104]. This response is due to a decreased half-life for Cdc25C as a result
of disulfide linkage formation between its active-site and backdoor cysteines. Cdc25C’s
response to H2O2 treatment does not depend on the Chk pathway, suggesting a direct
interaction between ROS and Cdc25C. The active-site cysteines of the Cdc25's are highly
susceptible to oxidation [105]. The rate of thiolate conversion to the sulfenic acid by
H2O2 for Cdc25B is 15-fold and 400-fold faster than that for the protein tyrosine
phosphatase PTP1B and the cellular reductant glutathione, respectively [105]. Cdc25A
(69M-1S-1) and Cdc25C (120M-1S-1), with highly homologous catalytic domains to
Cdc25B (~60% identity), are only slightly less reactive than Cdc25B (164M-1S-1). The
sulfhydryl group on cysteine residues can be oxidized to form a disulfide bond (CysSSR), sulfenic acid (Cys-SOH), sulfinic acid (Cys-SO2H) or sulfonic acid (Cys-SO3H);
the two latter being quite stable while disulfide bonds and protein sulfenic are relatively
reactive and are often considered as the mediators in redox signaling. The active-site
cysteine is protected by rapid intramolecular disulfide formation with back-door cysteines
in wild-type enzymes and these intramolecular disulfides can then be rapidly and
effectively reduced by Trx/TrxR2 but not glutathione [105]. Finkel and his associates fail
to show oxidation of Cdc25A, because they used very a high concentration of H2O2
[106].
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Rudolph’s laboratory has shown that the oxidation of Cdc25’s catalytic site cysteine
residues decrease its activity via the formation of an intramolecular disulfide bond. In
addition, the catalytic cys430 formed a disulfide bond with the invariant cys384 in some
crystals suggesting that Cdc25 may be self inhibited during oxidative stress. The
nucleophilic catalytic cysteines of phosphatases are known to be highly susceptible to
oxidation, a property that permits redox regulation of this enzyme family. Recent studies
have shown that O2.- is a more efficient regulator of PTP1B than H2O2, with a calculated
rate constant in vitro (~3 x 102 M-1sec-1) about eight times faster than for H2O2 [107].
Nevertheless, one can argue that the reaction rate would be more than 100 times faster
with H2O2 than with O2.- in cells, considering that the steady state concentration of H2O2
in the cytosol is approximately 103 times more than the concentration of O2.- [108]. As
described above, H2O2 exposure oxidized –SH group of Cdc25A faster than that of
PTP1B

[105;109].

Besides

the

widely

believed

concept

that

chk-mediated

phosphorylation leads to Cdc25 proteosome-dependent degradation; its activity appears
to be regulated by oxidation in the same way as oxidation regulates PTP1B activity.
A rapid decrease in Cdc25A activity was shown when MCF-7 cells were exposed to
physiological concentrations of estrogen [51]. A similar decrease in Cdc25A activity was
observed in H2O2 treated HeLa cells [110]. Further examination revealed a lower level of
Cdc25A –SH residues in the estrogen treated group compared to the vehicle control [51].
In addition, cotreatment with antioxidants prevented the oxidation of –SH residues in
estrogen treated cells [51] . These findings suggest that estrogen-induced ROS
oxidatively inactivates Cdc25A. A recent study showed that the oxidation of the Cdc25
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active cysteine site leads to enzyme inactivation [111;112]. We and others have also
identified an estrogen mediated protein interaction between Cdc25A and ERK in MCF-7
and hepatoma cells respectively when treated with Cdc25A inhibitor Cpd [113].
Independent of ERα/
ß, estrogen activates the MAPK pathway via ROS -dependent
inactivation of Cdc25A. An increase in Cdc25A mRNA has been reported after 6 hrs of
E2 treatment and an increased synthesis of Cdc25A protein was detected from 10 to 12
hrs after E2 treatment [114;115]. The level of Cdc25A protein did not change
immediately after E2 exposure, however, an increased in the level of its protein as early
as 3 hrs after E2 exposure was detected. This observation suggests that E2 treatment
increases Cdc25A stability. We further looked for any post-translational modification
from E2-exposure because full enzymatic activity of Cdc25A requires phosphorylation at
multiple Ser and Thr residues in the amino-terminal of the protein. In contrast to UV or
IR effects on Cdc25A in cells, we observed a rapid decrease in serine phosphorylation of
Cdc25A in response to physiological concentrations of estrogen which paralleled the
decrease in phosphatase activity. A similar decrease in the serine phosphorylation of
Cdc25A and its activity was observed in response to the exposure of cells with H2O2.
Cdc25A is also phosphorylated at tyrosine residues, and in contrast to serine
phosphorylation, tyrosine phosphorylation of Cdc25A was enhanced in cells treated with
estrogen or H2O2. Others have also shown that lower oxidant concentration increase the
rate of tyrosine phosphorylation by tyrosine phosphatase [116]. These studies did not
examine the oxidation of active site cysteines nor did they explain how tyrosine
phosphorylation occurred and how tyrosine phosphorylation inactivated phosphatase
activity. ROS activated ERK enhanced tyrosine phosphorylation of Cdc25A in E2-treated
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MCF-7 cells protects Cdc25A from degradation [117]. Tyrosine phosphorylation of
increased the half-life and accumulation of Cdc25A which may contribute to Cdc25A stimulated Cdk2 activity.
Besides the Cdc25, some of the other phophatases, such as, MKP3, PTEN, PTP1B1,
PTP2A, and PP5 [118-120] are responsive to ROS and regulate estrogen-mediated
signaling. For example, the activity of Ser/Thr protein phosphatase 5 (PP5) is responsive
to oxidative stress and estrogen. Elevated levels of PP5 protein found in human breast
cancer have been linked to the progression of human breast cancer [121]. ERK-specific
phosphatase MKP3 is another ROS responsive phosphatse that may influence
phosphorylation at Ser118 of ERα by regulation of pERK1/2 MAPK. Antioxidant
treatment by increasing MKP3 phosphatase activity blocked tamoxifen resistance [122].
These phophatases are reversibly regulated by ROS. These oxidatively modified
phophatases act on their corresponding kinases based on their temporal and spatial
localization in the cells.
Activation of kinases by estrogen-induced ROS: Structural changes to PTPs, as well as
serine/threonine and phospholipid phosphatases, are induced by ROS, and the altered
protein conformation leads to signaling cascade upregulation. Included in these cascades
are src/Abl kinase-dependent, MAPK-dependent, and PI3 kinase-dependent pathways,
leading to activation of AP-1, NF-kB, NRF1, and other redox-regulated transcription
factors.
We describe below some of the kinases which may be influenced by estrogen-induced
ROS signaling via redox regulation of phosphatases.
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A-Raf: The mitochondrial localization of protein kinases A-Raf, PKCδ, and PKC
Є is
evidence that this subcellular compartment harbors redox sensors [123;124]. The role of
the protein kinase A-Raf in the mitochondria is not clear, but A-Raf mRNA is highly
expressed in normal murine tissue [125]. In HeLa cells, epidermal growth factor (EGF)
rapidly and transiently activates A-Raf, which in turn phosphorylates the MAP kinase
activator MEK1 [125]. Interestingly, E2 can stimulate the phosphorylation of A-Raf and
it appears to participate in cell cycle progression in ER+ MCF-7 cells [126]. Thus, it
appears that mitochondrial oxidants may modulate estrogen-induced cell proliferation via
A-Raf pathway. In addition to A-Raf, other redox sensitive proteins associated with
mitochondria, PKCδ and PKCζ, have been demonstrated to activate the Raf/MEK/ERK
pathway or directly activate MAPKs, respectively [124;127]. As zinc finger domains of
Raf and PKC are targets of oxidative stimuli and Raf and PKC are localized in
mitochondria, estrogen-induced ROS may activate A-Raf and/or PKC via the MEK/ERK
pathway. Signaling pathways involving JNK and p38 MAPK are very responsive to
redox regulation. JNKs have been studied primarily in the context of stress responses and
apoptosis; however, accumulating evidence indicates that the JNK pathway also
contributes to proliferative responses. For example, JNK1-/- mouse embryonic fibroblasts
(MEFs), as well as JNK1-JNK2-/ MEFs, proliferate more slowly than do wild-type MEFs
and reach a lower saturation density, establishing that JNK is required for normal MEF
proliferation [128]. A role for JNK in cancer development is supported by recent studies.
It has been shown that skin tumorigenesis is suppressed in JNK2-deficient mice [129],
and expression of an inactive variant of the JNK substrate c-Jun in immortalized
fibroblasts expressing v-Src and v-Fos reduces tumorigenicity in nude mice [130]. The
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oxidative enhancement of Src-family tyrosine kinases and certain PKC isoforms as well
as the dissociation of the JNK/GSTp and ASK1/Trx complexes may together contribute
to the redox sensitivity of these pathways. These and other data suggest that signaling
through the A-Raf/JNK pathway is very responsive to redox regulation and mediates
oncogenic signals and supports cell proliferation in the absence of stress.

ERK: In addition to the ability of E2 to promote ER-dependent gene transcription, it
rapidly activates ERK-1 and ERK-2 [130-134]. The activation mechanism by which this
rapid signaling event occurs is unclear. The activation is extremely fast and it is believed
that they are initiated at the plasma membrane and do not involve ER-mediated gene
transcription. Several investigators have concluded that estrogen-induced MAPK
activation is promoted by membrane bound ERα or ERß [135-137]. There are no known
functional motifs within the structure of the ER that can promote second messenger
signaling [138]. Most of the studies investigating rapid MAPK activation by estrogen
have employed estrogen responsive cells including MCF-7 breast cancer cells [133;139],
osteosarcoma cells [140], and neuroblastoma cells [141]; yet these studies have not
directly addressed the roles of ERα andß ER
in promoting estrogen

-induced ERK

activation. There are reports which show no correlation betweenß ERα/
expression
patterns and the activation of ERK-1/-2 in estrogen treated breast cancer cell lines. Both
estrogen and the pure antiestrogen ICI182780 activate ERK-1/-2 in human SKBR3 breast
carcinoma cells, which lack ERαß/ protein and m RNA [131]. Other researchers have
suggested that a membrane-associated ER-like G protein is responsible for nongenomic
estrogen signaling [142-144]. They showed evidence that cellular expression of the
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orphan receptor, GPR30, is sufficient for estrogen-induced activation of ERK-1/-2. Based
on these observations, it is not clear which membrane protein or how the membrane
proteins (ER or GPR30) activate ERK signaling in estrogen exposed normal or cancer
cells.

In many cells, extracellular H2O2 alone activates ERK-1/-2. As discussed previously,
studies have shown that estrogen exposure rapidly activates ERK and our work indicates
that both estrogen and H2O2 rapidly inactivate Cdc25A and activate the ERKs in MCF-7
cells. Inactivation of Cdc25A by its inhibitor Cpd5 results in the activation of EGFR
tyrosine kinase and more recently was shown to activate ERK-1/2 in hepatoma cells
[113]. Both EGFR and ERK have been shown to form protein complexes with Cdc25A
in hepatoma cells [145]. Since ERK can interact with and phosphorylate EGFR, Cdc25AERK interaction could be responsible for EGFR activation. Moreover, napthoquinone
based inhibitors inactivate Cdc25A by covalently binding to cysteine residues at the
active sites of Cdc25A [146]. Thus, it is possible that ERK may be activated by inhibiting
its association with Cdc25A or inactivating Cdc25A through its redox regulation by
estrogen-induced ROS.

AKT: AKT (also called PKB) is a serine-threonine protein kinase. It is a downstream
target of PI3-kinase. AKT binds to the products of PI3-kinase. AKT affects numerous
downstream targets either directly or indirectly, including the pro-apoptotic proteins Bad
and Caspase 9, the growth-inhibitory proteins glycogen synthase kinase-3β, the forkhead
transcription factors, the kinase IKKα, and the kinase mTOR [147;148]. AKT has
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recently been identified to control NRF1 activity [149]. Several investigators have
concluded that estrogen-induced AKT activation is promoted by membrane bound ERα
or ERβ [150;151]. There are no known functional motifs within the structure of the ER
that can promote second messenger signaling. There are reports which show no
correlation between ERα/β expression patterns and the activation of AKT-1/-2 in
estrogen treated breast cancer cell lines. 17α-estradiol, through an ER independent
mechanism, activates PI3K-AKT signaling [152]. Recently Lee et.al., [151] reported that
up-regulation of PI3K/AKT signaling by E2 is mediated through activation of ERα, but
not ERβ. In ovarian cancer cells, 4-OH-E2 induces AKT phosphorylation while 2-OH-E2
did not [153].Our study showed that 4-OH-E2 increased AKT poshphorylation in ERα
lacking MCF-10 cells. Based on these observations, it is not clear which membrane
protein and/or how the membrane proteins activate AKT in estrogen exposed normal
cells. AKT activity depends on its phosphorylation, which is positively regulated by PI3K
and negatively regulated by a class of protein phosphatases (PPs) [154]. AKT can be
activated by both E2 and H2O2 [118;149-151]. ROS reversibly regulate cysteine-based
phosphatases [119]. There are indirect evidences indicating that AKT associates with
Cdc25. For example, AKT phosphorylates Cdc25s [155]. AKT activation suppresses
Cdc25 inhibitor napthoquinone- and methylating agent temozolomide –induced G2 arrest
and cell death [156;157]. A recent study indicate that Cdc25A interacted with AKT
[158]. The reversible inactivation of Cdc25A or PTEN by estrogen-induced ROS appears
to be a potential key player in the activation of AKT.
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Activation of redox sensitive transcription factors by estrogen-induced oxidants
signaling: A significant number of transcription factors, including estrogen receptor, are
redox sensitive. Some of these transcription factors contain critical cysteine residues that
can be affected by ROS. As described above, signaling pathways are targeted by ROS,
which result in the activation of kinases through inactivation of redox sensitive
phosphatases. The active kinases, in turn, regulate phosphorylation of transcription
factors. Regulation of AP-1, NF-kB, and CREB by both estrogen and ROS is widely
accepted and their redox regulation by ROS has been discussed [9;118]. We have focused
our discussion mainly on NRF1 in this section.

ER: A large class of DNA-binding proteins such as the glucocorticoid receptor (GR), ER,
and early growth response factor-1 (egr-1), contain zinc finger domains [159], which
consist of at least two zinc-coordinated thiolates. Oxidation of a zinc finger converts
cysteine thiol groups to disulfide releasing zinc from the protein and resulting in a change
in protein conformation that may affect protein function. Interestingly, oxidative stress
has been reported to modulate ERα and ERβ expression in various cell lines. In human
breast cancer cells MCF-7 and T-47D, exposure to 2.5µM of H2O2 increased the protein
level of ERα while having a minimal effect on ERβ [160]. Endogenous oxidative stress
induced by PMA (100 ng/ml) in the macrophage cell line, J774A1 also increased the
expression of ERα [75] and it was found that Ras mitogenic activity is, in part,
superoxide dependent.

A recent study showed that at least 75 genes out of 891

estrogen/ER-regulated genes were responsive to oxidants and ERα silencing. The
oxidant-sensitive subset of estrogen/ER-responsive breast cancer genes are linked to cell
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growth and invasion pathways. Findings of this study suggest that oxidant sensitive
signaling pathways contribute to the development of an aggressive subset of ER+ breast
cancers [161]. Although protein kinases are known to participate in phosphorylation
signal cascades, they may also participate in redox signaling networks due to these zinc
finger domains, e.g., ROS can activate PKC that triggers the release of zinc ions
[162;163]. Another protein kinase, c-Raf, known to participate in the MAPK signal
cascade was also demonstrated to be redox-activated at the zinc finger domain [162;164].
As zinc-finger domains within these kinases have been reported to act as oxidant sensors,
a mode of cross-communication appears to exist between redox and phosphorylation
networks. Like serine-thereonine phosphatases as discussed above, ROS can inhibit some
of the protein tyrosine phosphatases by reversible oxidation of their cysteine residues and
enhance protein kinases, such as Src, c-Jun amino-terminal kinase (JAK), Ras, PKC, and
MAPK [21]. These kinases are involved in modulating ER signaling [165;166]. Thus,
ROS-mediated signaling represents another means by which ER function can be
modulated by oxidants, and may be responsible for the clinical phenotype of ER breast
cancer. Rapid effects of estrogen have been demonstrated to mediate the DNA binding
activity and phosphorylation of transcription factors. For instance, a 10 nM estradiol
treatment of rat adipocytes doubles AP-1 DNA binding in 15 min [167]. In addition,
CREB protein is phosphorylated rapidly by estradiol (10nM) treatment within 15 min.
Given that estradiol can stimulate mitochondrial ROS generation and that the
transcription factors AP-1, NF-kB, and CREB are targets of oxidative stimuli [167;168],
it is possible that estrogen-specific effects at the level of the mitochondria can activate
these

transcription

factors

by
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pathways.

Mitochondrial generation of ROS leading to the activation of transcription factors AP-1,
NF-kB, and CREB has downstream consequences for apoptosis, cell cycle progression,
cell transformation, cell migration and cell invasion.

AP-1 and

CREB: Growth factors and TPAactivate AP-1-dependent transcriptional

activation and evidence is accumulating that ROS and 4-Hydroxy-2-nonenal (4HNE)
increase the DNA binding activity of AP-1 [169-174]. The initial increase is not
dependent upon protein synthesis and probably involves post–translational modifications
of previously existing AP-1 complexes; however, increased synthesis of Fos and Jun also
occurs rapidly upon stimulation [175]. Jun transcription is controlled by TRE and MEF2
sites while Fos transcription requires SRE and CRE sites that are regulated by all three
MAPK cascades [176]. Binding of AP-1 to DNA can occur without phosphorylation, but
increased binding and transcriptional activation are both signaled by phosphorylation of
Fos and Jun [177]. Several transcription factors, including c-Fos and Elk-1 are
phosphorylated by ERK1/2. The JNK and p38MAPK are more strongly activated by
stress signals and their activation occurs through similar phosphorylation cascades. The
c-Jun family of transcription factors are specifically phosphorylated by the JNK at Ser 63
and Ser 73 in a two-step process that requires binding to the delta subdomain prior to
efficient phosphorylation at the NH2 -terminal activation domain[178]. JNK also binds
and phosphorylates the Elk-1 and ATF-2 transcription factors [179;180]. The
phosphorylation of Jun at the N-terminus by JNK not only is required for transcriptional
activation [181;182] but also seems to protect Jun against degradation by ubiquitination
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[183]. This results in an increase in the half-life and accumulation of Jun that may
contribute to the JNK-stimulated AP-1 transcriptional activity.
In addition to phosphorylation, the AP-1 complex is regulated by redox mechanisms. Fos
and Jun have a single conserved cysteine residue located in the basic region of DNA–
binding domains that must be reduced for DNA binding activity [184]. The transcription
factor AP-1 is strongly responsive to redox regulation. The exact nature of the redox
change is not clearly identified. Recent in vitro data indicate that reversible Sglutathiolation of the conserved cysteine may be involved [185]. Others suggest that the
reversible redox regulation of AP-1 is mediated by Trx and the nuclear protein Ref1,
which both increase AP-1 binding activity [186;187]. Direct association between Trx and
Ref-1 has been reported [188]. Recently we have demonstrated the evidence for the
involvement of redox signaling with estrogen-induced cell proliferation [28;75].
Physiological concentrations of E2 stimulate a rapid production of intracellular ROS
which lead to the phosphorylation of c-jun and CREB. Although direct ER transcription
factor effects are required to promote DNA synthesis, our recent data showed that MCF-7
cell growth and cyclin D1 expression are suppressed by antioxidants and mitochondrial
blockers. This observation supports our novel finding that nongenomic estrogen-induced
mitochondrial ROS modulate the early stage of cell cycle progression [28].

It has

become evident that regulation of the cellular redox environment is critical for estrogenmediated signaling. Thus, ROS may regulate AP-1 activity through several targets. ROS
can modulate effector molecules such ERK and the c-fos/c-jun heterodimer (AP-1); and
these effector molecules are known to participate in growth signal transduction [28;30]. It
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is possible that JNK pathway may be involved in the AP-1 binding and transcriptional
activation induced by mitochondrial oxidants produced upon exposure to estrogen.
Although the ERK pathway has been shown to be involved in AP-1 activation by other
agonists, we think that it may not participate in this case, based on the inability of H2O2
alone to stimulate the ERK pathway in MCF-7 cells [189]. JNK is activated by stress
stimuli through an activation module that may include the MAP3K apoptosis-signal
regulating kinase (ASK-1) [85].Interestingly, recent data suggest that ASK-1 is activated
by ROS either through Trx oxidation [190] or through dimerization [191]. Thus, ROS can
either activate the JNK module or induce the formation of 4HNE, which may directly
activate JNK [173].
The expression of early G1 genes, c-myc, c-fos, c-jun, cyclin D1, and NRF1 are regulated
by ROS [192;193]. The mRNAs of some of these genes are induced by estrogen-induced
ROS and H2O2 as well as other inducers of oxidative stress [114;130;192;194]. As
described above c-Fos and c-Jun comprise part of the transcription factors AP-1; and AP1 binding activates the expression of down-stream target genes. In this regard, the
induction of c-Fos, c-Jun and cyclin D1 is an ideal paradigm for studying the role of early
response genes in response to oxidative stress-induced by estrogen. The mRNAs of c-Fos
and c-Jun are induced by estrogen and also by relatively small amounts of H2O2,
superoxide, NO, and other inducers of oxidative stress [114;192]. The earliest known
growth-regulatory gene activated by E2 is c-Myc. Increased transcription of myc, as
measured by accumulation of mRNA, occurs within 30 min, and peak protein levels are
observed within 1–3 h of treatment with E2 of MCF-7 cells [114]. Recent studies indicate
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that Myc protein is stabilized by E2, up to 12 h after its addition, well past the decline in
mRNA levels. Myc expression elicits active cyclin E-Cdk2 and S-phase entry in growtharrested MCF-7 cells. Although Myc is clearly implicated in E2 action, it was not found
in a genetic screen for E2-responsive genes in MCF-7 cells. Myc is induced by exposure
to ROS [114]. Cyclin D1 is a well-defined target of E2 action in MCF-7 cells, and in
rodent breast epithelial tissue, ovary and uterine endometrium. In MCF-7 cells, addition
of E2 to G0/G1-arrested cells results in a two- to three-fold induction of cyclin D1 mRNA
within 1-3 h and a three- to five-fold increase in synthesis and steady-state levels of
cyclin D1 protein within 3-6 h. Given that cyclin D1-knockout mice are fertile, the
physiologic relevance of ER as a target of cyclin D1 is uncertain. Cyclin D has a half
ERE. Planas-Silva et. al., demonstrated that E2 transiently upregulates synthesis of c-Fos
and c-Jun in MCF-7 cells, but not in hER-transfected HaCa T nontransformed human
keratinocytes [195]. Earlier studies indicated, however, that E2 increases AP-1 activity
without increased synthesis of c-Jun or c-Fos and without the synthesis of any new
proteins. Foster and Wimalasena demonstrated that ligand-activated ER is fully active at
8–10 h after E2 treatment [114]. The products of at least two E2 target genes, c-Myc and
cyclin D1, can independently promote G1/S transition in MCF-7 cells and activate cyclin
E–Cdk2 coincident with formation of high molecular mass cyclin E–Cdk2–p130
complexes depleted in p21CIP1 and p27KIP1. The expression of c-fos and c-myc did not
depend on the presence of growth factors, suggesting that integrins alone through ROS
could regulate the Go/G1 transition. Furthermore, integrin clustering in the absence of
cell spreading was sufficient to induce expression of early genes (jun B and ras) involved
in the Go/G1 transition and were able to trigger G1/S transition through modulating

40

cyclin D1 expression [196;197]. Integrins, through ROS, control the expression of these
cell cycle genes, and it is now obvious that cell adhesion and integrin ligation are
obligatory processes for regulation of cdks and cyclins. JNK and p38 also have been
shown to cooperate with ERK in pp60(v-src)-induced cyclin D1 expression in breast
cancer cells [114]. However, an unresolved issue regarding E2-mediated signaling is
whether E2 receptors themselves actually initiate signal that can intervene in the Go/G1
and G1/S transitions. The expression of early G1 genes, c-myc, c-fos, c-jun , cyclin D1
are regulated by ROS [192]. Low and intermediate levels of RO/NS regulate cellular
signaling and play an important role in normal cell proliferation [9;196]. Constant
activation of AP-1 transcription factor appears to be one functional role of elevated ROS
levels during tumor progression [198]. Based on these data, estrogen-induced ROS may
control the expression of genes involved in cell cycle progression.

NF-kB: Activation of NF-kB is another well-studied model of redox regulation. The
oxidation of a conserved cysteine residue in the DNA-binding region adjacent to the
leucine zipper in AP-1 abolishes its binding to DNA [185]. The DNA binding activity of
AP-1 is restored by Trx and the nuclear signaling protein redox factor-1 (Ref-1) [188]
and enhanced by transient overexpression of Trx in vivo. Compared with NF-kB, AP-1 is
less sensitive to oxidative inhibition by glutathione disulfide in vitro but more sensitive to
oxidized Trx. Thus, in intact cells, the elevation of intracellular oxidized glutathione
(GSSG) levels by inhibition of glutathione reductase inhibits selectively the DNAbinding activity of NF-kB and not that of AP-1 [199]. The protein NF-kB is regulated by
its interactions with the inhibitory co-factor, which sequesters NF-kB to the cytoplasm.
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AKT is known to phosphorylate an upstream kinase, IKKβ, which stimulates the
degradation of Ik-B [130]. As AKT can participate in the activation of IKKβ, it may be
possible for estrogen-induced mitochondrial ROS to stimulate the transcription activity of
NF-kB via the AKT pathway.

NRF1: The human alpha-palindromic nuclear respiratory factor -1 binding protein
(NRF1) is a 503 amino acid (aa) transcription factor [200;201], located on chromosome
7q32.2 [202] and codes for 68 kDa nuclear proteins [200;203]. Several compounds that
induce cellular oxidative stress have been shown to increase NRF1 expression and
increase in mitochondria proliferation. For example, the bacterial lipopolysaccharide and
tertiary butyl hydroperoxide have both been demonstrated to induce cellular oxidative
stress which upregulates NRF1 expression and mitochondria biogenesis in rat liver cells
[149;193]. Likewise, rat liver cells overexpressing NRF1 have been shown to induce
ROS production and increase in mitochondria proliferation [149]. Similarly, exposures of
human lung fibroblast cell line, MRC-5, with H2O2 at concentrations of 90-360 µM
induced increases in mtDNA and mitochondria biogenesis in exposed cells [204]. The
role of oxidative stress and NRF1 expression were further corroborated by works done by
Miranda et. al., which revealed that HeLa cells depleted of mtDNA were under oxidative
stress which induced expression of NRF1 and mitochondrial biogenesis [205]. Lastly,
estrogen exposure has been reported to increase NRF1 overexpression which increased
mitochondria biogenesis in MCF-7 malignant mammary epithelial cells, and human
bronchial epithelial cells from female patients [206;207].
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Oxidants modulate NRF1 expression and mitochondria biogenesis; antioxidants
conversely inhibit intracellular ROS and NRF1 expressions. For example, oral
administration of vitamin C has been demonstrated to inhibit NRF1 expressions with
reduction in mitochondria biogenesis and diminished endurance training capacity [208].
In addition, catalase overexpressions have been shown to reduce NRF1 expressions and
mitochondria content in heart muscles of aged mice which attenuated age related diseases
observed in mice [209]. These studies imply that cellular oxidative status modulates
NRF1 expression. Activated NRF1 expressions in response to ROS can lead to enhanced
mitochondria biogenesis and increased bioenergetics, as well as regulation of genes
involved in apoptosis and cell cycle progression.

NRF1 expression in MCF-7 (or any ER+ cell types) may not be entirely due to cell’s ER
status. Estrogens concentration of 10 nM has been reported to induce oxidative stress in
MCF-7 cells [210;211]. In a similar manner, the pro-oxidative compound sodium
butyrate [212;213] has also been shown to induce NRF1 expression in MCF-7 cells
[214]. Sodium butyrate lacks estrogenic property. In addition, oxidative stress has been
reported to induce NRF1 expressions in ER- breast cancer cell line such as MDA-MB468 as well as in ER- human bone osteosarcoma (U2OS) cells [215]. Likewise, SERMs
such as TAM, RAL and Fulvestrant which are also pro-oxidant upon chronic exposures
[216], also increase NRF1 expressions in SERM resistant MCF-7 cells [217]. These
studies suggest that estrogen inductions of NRF1 in estrogen responsive breast cancer
cells are not exclusive to ER status. It implies that perhaps estrogen induced oxidants also
mediate NRF1 expressions in breast cancer cells irrespective of ER status. This point is
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important when considering mechanisms by which estrogen induce mammary
carcinogenesis and growth of breast cancer cells.

This observation is supported by several findings. For example it has been reported that
exposures of rat cardiomyocytes and liver cells to sublethal levels of pro-oxidative
compounds such as LPS or t-BOOH induced oxidative stress, NRF1 expressions,
mitochondria biogenesis, and promoted cell’s survival and growth [193;218]. Conversely,
silencing of complex II, one of the primary genes regulated by NRF1, inhibited
OXPHOS, ROS production and augmented cell growth [219]. In similar manner,
exogenous addition of oxidants to hepatoma cells depleted of mitochondria induced
NRF1 expressions and cell proliferation [149]. These findings imply that oxidant induced
NRF1 regulation promotes cell growth by coupling mitochondria bioenergetic with cell
proliferation. This is further supported by findings in our laboratory that chronic
exposures of non-tumorigenic, ER- mammary cells (MCF-10A) with 100 ng/ml estradiol
or its catechol derivatives, 4-OH-E2 but not 2-OH-E2, induced oxidative stress, mammary
transformations as well as up-regulations of NRF1. However silencing of NRF1 inhibited
estrogen induced oxidative stress and inhibition of cell’s transformation [49;50]. Similar
observations were also reported in pre-malignant primary fibroblast cells. In these cell
lines, it was observed that NRF1 and other mitochondria genes were among the
transcription factors over-expressed during malignant transformation [220]. However in
this study, high NRF1 expressions were likewise linked to oxidative stress and energy
demand by proliferating cells. These studies imply that for cells to survive in elevated
oxidative environment, they must be able to up-regulate NRF1 expression, which in turn
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increases mitochondria biosynthesis and OXPHOS. However, it is counterintuitive to upregulate pro-oxidative mechanisms during periods of oxidative stress. It is therefore
speculated that high ROS levels serve other purposes such as clonal selection of
neoplastic cells, and induction of apoptosis in non-neoplastic cells [221;222]. Similar
mechanism might be in play during estrogen induced mammary carcinogenesis. In
population of initiated cells, oxidative stress and NRF1 expression may serve to provide a
pro-tumorigenic selective environment as well as the energy necessary for these cells to
proliferate and grow, irrespective of ER status.

Though estrogens have been reported to modulate NRF1 expressions via E2/ER binding
to ERE on NRF1 promoter regions in a number of cell lines [206;207], we demonstrated
that prolonged treatment of MCF-7 cells with estrogen also induced NRF1 expression,
increased cell proliferation and colony formation in soft agar assays (Okoh et al,
unpublished data). Interestingly, the silencing of NRF1 or pretreatment of cells with NAC
significantly reduced NRF1 expression and inhibited estrogen induced cell proliferation
and anchorage independent growth (Okoh et al, unpublished data). Conversely,
overexpression of NRF1 in the same cell line increased cell proliferation independently
of estrogen action. These findings from our laboratory therefore imply that NRF1
expression observed in MCF-7 cells treated with estrogen is redox based as antioxidants
abolish NRF1 expressions. It also suggests that redox expressions of NRF1 due to
estrogen exposure may contribute to breast cancer cell growth independent of E2/ER/ERE
mechanisms. If this is the case, it can be surmised that estrogen induced ROS contributes
in part to growth of malignant cells in a manner unrelated to ER activations. This
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assertion may therefore explain why oxidative stress is positively correlated with
tumorigenesis [223;224], aggressive breast cancer phenotypes [225], and therapeutic
resistance of breast cancer patients [226].

ROLE OF ESTROGEN-INDUCED REDOX SIGNALING IN THE DEVELOPMENT
OF BREAST CANCER
ROS affects generation of new phenotypes of cells during the development of breast
cancer through its influence on the regulation of protein kinases and signal transduction
pathways. Here we describe how estrogen-induced ROS may contribute in the generation
of different cell phenotypes required for the development of breast cancer.

Estrogen-induced ROS as potential mediator of cell transformation and generators of
human breast cancer stem cells: A delicate intracellular interplay between oxidizing and
reducing equivalents allows ROS to function as second messengers in the control of cell
proliferation and cell transformation [227;228]. Many studies implicate ROS in cell
transformation and in the uncontrolled growth potential of tumor cells [224;229-233]. We
also find that estrogen stimulates the growth of TM3 and HEK 293 cells in an ERindependent manner [9;30]. In another study estradiol-induced kidney tumor incidence in
Syrian hamsters treated with antioxidants was effectively reduced by ebselen, sodium 2mercaptoethanesulfonate (Mesna, a cytoprotective thiol-containing agent), NAC and
vitamin-C administration [17;18]. Also, cotreatment with pentoxifylline, an inhibitor of
IL-1β and Tumor necrosis factor (TNFα) synthesis, prevents estrogen-induced testicular
and uterine cancers [9]. Superoxide dismutases (SODs) are the first and the most

46

important line of antioxidant enzyme defense against ROS and particularly superoxide
(O2-) radical. Overexpression of the enzyme responsible for mitochondrial superoxide
detoxification, manganese superoxide dismutase (MnSOD), inhibits the malignant
phenotype [234-236]. MnSOD knockout mice exhibit increased oxidative DNA damage
[237]. Soini et al.,2001 reported that MnSOD expression is less frequent in the tumor
cells of invasive breast carcinomas than in in situ carcinomas or non-neoplastic breast
epithelial cells. Several epidemiologic studies have shown an increased risk of breast
cancer in the MnSOD Ala-Val polymorphic populations [238;239]. In a recent study it
was shown that genetic polymorphism in the MnSOD gene may be associated with
increased risk of breast cancer among Chinese women with high levels of oxidative stress
or low intake of antioxidants [240]. Studies also show that there is no positive relation
between genetic variation in MnSOD and breast cancer [241]. Our preliminary study
showed that MCF-10A cells treated with 4-OH-E2 rapidly produce ROS, which is
preceded by an increase in the level of Ca2+. The accumulation of 4-OH-E2 as recently
reported in the human breast tissue in cancer subjects [46;242] will allow increased ROS
and Ca2+ levels in the target organ of cancer in a sensitive subpopulation. Later,
overexpression of catalase and MnSOD prevented 4-OH-E2-induced anchorageindependent growth of MCF-10A cells. These data together indicate that 4-OH-E2induced cell transformation may be mediated, in part, by ROS signal transduction
pathways that are different from the classical nuclear ER genomic signaling pathway
(Fig. 4).
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Estrogen-induced ROS as mediators of cell cycle progression: As shown in Figure 3, high
ROS levels induce oxidative damage and arrests cells in G0/G1. However, low
physiologic ROS levels are utilized by cells for cell-to-cell communication and in
proliferation [28]. The rapid stimulation of intracellular ROS by PDGF, EGF, and NGF
suggests that this underlying mechanism of cell growth may be shared by other growth
factors or mitogens, including estrogen [243]. Exogenous addition of low concentrations
of H2O2 and/or O2.- has been demonstrated to stimulate cell growth in a variety of cell
types including fibroblasts and prostate cancer cells [159]. Although these phenomena
have been overshadowed by studies concentrating on the role of ROS in the pathology of
various diseases and apoptosis, they suggest that outcomes other than apoptosis may be
coupled to the signaling event represented by the estrogen-induced generation of ROS.
Cell cycle progression is regulated by an intricate web of signaling pathways mostly
requiring growth factor stimulation and ultimately involving cyclins, cyclin-dependent
kinases (cdks), and cell cycle inhibitors. Constant activation of redox sensitive
transcription factors appears to be one functional role of elevated ROS levels during
tumor progression [198]. The results of our more recent studies show that ebselen (a
substance with glutathione peroxidase-like activity), and inhibitors of mitochondrial
replication and protein synthesis prevent estrogen-induced G1 to S transition. Low and
intermediate levels of ROS regulate cellular signaling and play an important role in
normal cell proliferation [196]. These data suggest that redox signaling supports cell
proliferation in the presence of estrogen-induced ROS.
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Several lines of indirect evidence support a role for mitochondrial oxidants in estrogeninduced cell proliferation. Isoforms of Trx, Trx-2 and thioredoxin reductase (TrxR2),
which regenerates the reductant form of Trx, have been detected in mitochondria
[89;244].

Dominant-negative inhibition of TrxR2 causes an increase in H2O2

accumulation, which activates cell proliferation [245] and increased expression of cell
cycle genes involved in the G1 and S phases of the cell cycle [244-247]. In vitro
treatments of primary human endometrial stromal cells with estrogen at different
concentrations (10nM-100nM) result in an increase in Trx protein and mRNA expression
which implicates Trx in cell growth and differentiation of estrogen responsive tissue
[247]. Alterations in the cellular redox status due to increased expression of TrxR2 have
been suggested to play a role in the growth of hepatocellular carcinomas [248]. Whether
estrogen can specifically increase the expression or activity of Trx2 and/or TrxR2 is not
known, but these findings suggest that estrogen may modulate signal transduction of
mitochondrial derived ROS via the thioredoxin system. Indirect evidence is also provided
by the overexpression of the MnSOD enzyme responsible for mitochondrial ROS
detoxification, which inhibits breast tumor growth [235]. As H2O2 is a highly diffusible
signaling molecule and both MnSOD and NOS are modulated by estrogen [249;250], it is
plausible that estrogen-induced ROS signaling at the level of mitochondria contributes to
cell proliferation.
Many of the genes associated with high-risk breast tumors appeared to be involved in
cell-cycle regulation, including Cdc2 and PRC1 [251]. Integrins through ROS control the
expression of cell cycle genes; and cell adhesion and integrin ligation are obligatory
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processes for regulation of cdks and cyclins [182-184]. Recently, an NRF1 and CREB
pair has been identified as a key regulator of the transcriptional program of the cell cycle
in human cells because this pair of transcription factors show a significant co-occurrence
rate on promoters of cell cycle regulated genes [252;253]. NRF1 appears to play an
important role as a regulator of cell cycle genes because NRF1 binding site has been
identified by comparing genome-wide locations on genes involved in DNA replication,
mitosis, and cytokinesis. Some of the genes which contain NRF1 binding sites on their
promoters include Cdc2 [254], guanine-nucleotide exchange factor, RCC1, DNA
polymerase-α, ornithine decarboxylase, GADD153, growth-arrest and DNA-damageinducible protein153 [252]. Mammary carcinogenesis is characterized by an increased
expression of NRF1, which may be linked, with increased energy demand by rapidly
proliferating cells [255;256]. However, NRF1’s role in mammary carcinogenesis may be
more than mere energy modulators. NRF1 has been reported to be over-expressed in a
number of malignant tissues including breast cancer tissues where its levels are higher in
disease regions compared to adjacent normal regions suggesting that NRF1 may play a
role in mammary carcinogenesis [256]. For example microarray study of genes expressed
during mammary tumorigenesis in MMTV-neu mouse model reveals that NRF1 were
among the transcription factors over-expressed in tumor tissues compared to adjacent
normal tissue [257]. Similarly, another microarray analysis of NRF1 expression in human
tissues reveals that while normal mammary tissue had more NRF1 expression than most
normal tissues analyzed, (except for lung tissues), the levels of this transcription factor
were highest in breast cancer tissues compared to other cancer types [256]. Lastly, NRF1
is amongst a few sets of transcription factors whose overexpression is correlated with
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progression of mammary carcinogenesis [255]. While these findings were attributable to
increased energy demand, other evidence exist that suggest that these transcription factors
may directly or indirectly regulate genes involved in cell proliferation in manners
unrelated to mitochondria biogenesis. Whether NRF1’s role in these malignant cells is
indicative of metabolically active cells or whether it also regulates growth related genes
that promotes malignancy is yet to be investigated. NRF1 may also play major roles in
modulating cell proliferation in a manner not related to mitochondria biogenesis.

NRF1 regulates many other genes that may be involved in the development of breast
cancer than that described above. For instance, there is a striking overlap in target genes
between E2F4 and NRF1 [252;255]. E2Fs are target of both estrogen and oxidative stress
[258;259]. There is a functional interaction of E2Fs with other transcription factors, such
as FOXO1, hypoxia-inducible factor 1 (HIF-1), nuclear factor B (NFB), and peroxisome
proliferator-activated receptor (PPAR), including NRF1, during oxidative responses in
cells. NRF1 has been reported to transcriptionally regulate the expression of E2F1 [260]
and E2F6 [215] genes. Both genes belong to E2F family of transcription factors which
functions in cell cycle controls. While E2F1 is generally considered as a transcription
factor activator and E2F6 as a transcription factor repressor, the coordinated activities of
these genes are essential in regulating cell cycle control and to have a major role during
carcinogenic process [261]. Overexpression of E2F1 in mammalian cells has been
reported to induce neoplastic transformation of rat embryo fibroblasts, induce colony
formation in soft agar assay and induce tumor in nude mice [262;263]. Conversely,
under-expression of these same genes has likewise been shown to induce broad range of
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mice tumors as well [264;265]. This seemingly contradictory observation of E2F1
expressions highlights the tight regulations NRF1 must undertake to keep E2F1 gene
expression at ‘normal’ physiological levels. E2F6 is a member of the E2F family of
transcription factor involved in regulation of cell proliferation and differentiation via
target genes involved in DNA replication, DNA repair, cell cycle control and apoptosis
[261;266;267]. E2F6 expressions in cells induces growth by inhibiting cell’s exit from
the S phase, and delays re-entry into the cell cycle in quiescent cells [268;269]. Growth
arrested cells due to delayed cell cycle could accumulate pre-malignant genetic lesions
and cell transformations potentials as DNA repairs and proof reading also ceases during
quiescence.

Findings that the proliferative growth of breast cancer cells exposed to estrogens activate
E2F1 expressions an ER independent manner provide further support to the above
concept [270]. Of interest in this study is the finding that overexpression of ER
 in ER

-

breast cancer cells (MDA-MB-231) did not induce cell proliferation upon estrogen
treatment even though E2F1 was mildly activated [270]. Similarly, it was shown in ER+
ZR-75 cells that ER/Sp1/NFY interactions are

not necessary for estrogen-induced

transactivation [259]. These findings indicate that ER status is not the sole determinant of
breast cancer progression and growth due to estrogen exposures. It should be noted also
that another study with similar conditions had observed that MCF-7 cells exposed to
estrogen increased NRF1 and mitochondrial expressions via ER activation [206]. Both of
these in vitro studies with MCF-7 cells may therefore serve to elucidate the mechanism
by which estrogen induces growth of breast cancer cells, i.e. estrogens induced oxidants
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mediate NRF1 expression which may regulate E2F1 expression and promote breast
cancer cell growth.

Other than binding to promoter regions of target genes involved in mitochondria
biogenesis and OXPHOS, NRF1 also modulates genes involved in mitochondria
regulations. For example, Nrf-2 (NFE2L2), a redox sensitive gene known to regulate
antioxidants responses, has been reported to bind to antioxidant response elements on
NRF1 promoter region to regulate ROS production as well as induction of antioxidant
responses in cardiomyocytes overexpressing heme oxygenase (HO)-1 [271]. Likewise,
cMyc overexpressions and induction of apoptosis in NIH 3T3 cells depleted of serum is
also reported to be mediated by NRF1 activations [272]. Hormones such as Thyroid
hormone (T3) and estrogens (E2) have also been reported to upregulate NRF1 expressions
and mitochondria biogenesis through binding to responsive elements in NRF1 promoter
regions [273;274]. NRF1 has also been reported to transcriptionally regulate expression
of myocyte enhancer factor 2A (MEF2A) which is a muscle specific gene [275]. MEF2A
is a DNA-binding transcription factor that activates muscle-specific, growth factorinduced, and stress-induced genes such as the cytochrome c oxidase (COX) subunits 6A
(COX6A). Interestingly, MEF2A also functions in skeletal and cardiac muscle
development as well as in neuronal cell differentiation and survival. They also play
diverse roles in the control of cell growth, survival and apoptosis via p38 MAPK
signaling pathway in muscle cells [276]. Dysregulation of MEF2A is implicated in
Chinese patients with coronary artery disease [277;278] and in hepatocellular carcinoma
[279].Our recent study showed that co-exposure of inhibitors of mitochondria shown to
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control mitochondrial oxidant production prevents E2-induced expression of cell cycle
genes, cyclin B1, PCNA, and PRC1 containing NRF1 binding sites, and caused loss of
NRF1 expression and growth delay. The E2-induced stimulation of the expression of
NRF1 and these cell cycle genes, and growth were restored by removing exogenous
mitochondrial inhibitors that diminished oxidant exposure indicating that oxidative stress
stimulates these cell cycle genes in part via NRF1 activation. Cyclin D1 has recently been
reported to inhibit NRF1 expression which leads to reduced mitochondria biogenesis in
mouse embryo fibroblasts (MEFs) [280]. Overexpression of cyclin D1 is usually
associated with cancer cell growth [281]. While it is counter intuitive that rapidly
proliferating cell such as MEF would inhibit mitochondria biogenesis which is a major
source of energy production, proliferating cells do generate excess ROS because they are
metabolically active. Excess cellular ROS are known to have adverse effects of cell’s fate
ranging from apoptosis to growth retardation [228]. Therefore it is plausible that cyclin
D1 expression that drives cell cycle progression could also function to reduce
mitochondria activity during periods of excess ROS. Hence the inhibition of NRF1
expression by cyclin D1 may be a negative feedback mechanism that protects the cell
from harmful effect of mitochondrial derived ROS. This assertion is supported by the fact
that cyclin D1 expression is likewise upregulated by mitogenic E2 [282;283] as well as by
ROS [284].

Estrogen-induced ROS as a mediators of breast cancer progression: E2F1 is overexpressed in breast tumors when compared with normal mammary tissue, and that
patients with high E2F1-expressing tumors have significantly reduced disease-free status
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and overall survival compared with patients with low-expressing E2F1 tumors [285-289].
It should be also noted that NRF1 expressions are positively correlated with oxidative
stress and progressions of mouse or human mammary carcinogenesis [255-257]. E2F6 on
the other hand are transcription factor repressors and function mainly in growth inhibition
[261;268]. Interestingly, one of the target gene of E2F6 is the breast cancer gene BRCA1
[290]. BRCA1 regulates cell cycle progression, apoptosis, and DNA repair, and loss of
BRCA1 expression is linked to cell proliferation and transformation [291]. While BRCA1
overexpression has been reported to confer therapeutic resistance, BRCA1 deficiency
confers sensitivity to oxidative stress [292]. In addition, BRCA1 mutations are associated
with breast cancer progression [290]. Therefore, NRF1 dysregulation of E2F6 can lead to
BRCA1 dysfunctions with adverse consequences ranging from apoptotic cell death to
malignant transformation of breast epithelial cells.
In addition to regulation of E2F family of transcription factors, NRF1 is also known to
regulate genes that favor breast growth and metastasis. For example NRF1 tightly
regulates the expression of calpain proteases in normal cells [293]. Overexpression of this
protolytic enzyme mediates tumorigenesis, metastasis and angiogenesis in breast cancer
and other cancer types [294;295]. NRF1 also regulates expression of integrin-associated
protein [296]. Integrins are essential for a cell’s adhesion during normal development.
Dysregulation of intergrin has been shown to promote carcinogenesis in mammary cells
as well as other cells types [297]. Lastly, NRF1 has also been reported to regulate
proliferation and growth of breast cancer in response to estrogen via activations of p115,
membrane tethering protein involved in mammary development [298].
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The DNA binding domain of redox sensitive NRF1 protein has been found in the
regulatory regions of over 600 human genes [254]. Interestingly, while NRF1 expression
is usually associated with modulating energy demand in proliferating cells, it is equally
expressed in quiescence cells albeit by different mechanisms [254]. NRF1 is ubiquitously
expressed in skeletal muscles, heart muscle, brown adipose fat, kidney and liver cells,
and all cells with high energy demand [82;299;300]. NRF1 has been implicated in
regulating genes unrelated to mitochondria biogenesis as well. For example, NRF1
transcriptionally

regulates

expression

of

CXCR4,

a

co-receptor

for

human

immunodeficiency virus infection [301], GluR2, a neural subunit that controls Ca2+
permeability of AMPA receptors [302], CD155, a human polio virus receptor that
functions in cell adhesion [201], the X gene of hepatitis B virus (HPV) which functions in
HBV replication in vivo [303], integrin-associated protein which plays significant role in
neurite outgrowth [296], GalNAc-T3 genes that function in glycosylation of mucin
proteins in epithelial derived tumors [214], fragile X mental retardation 1 (FMR1) genes
[304], and visinin-like protein-1 (VSNL1), a neuronal Ca2+ sensor protein [305] whose
dysregulation is implicated in Alzheimer disease and schizophrenia [306], as well as
cancer promotion and metastasis [307] .

These findings suggest that redox sensitive NRF1 directly or indirectly participates in the
processes that favor tumorigenic conversion and aberrant cell growth either by
modulating energy demand and/or modulating expressions of genes involved in cell cycle
controls. While NRF1’s actions on these genes are associated with normal physiological
function, their dysregulation may lead to increased apoptosis or cell growth. In situations
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where NRF1 expressions or functions are dysregulated by estrogen or estrogen induced
oxidative stress, downstream genes likewise can be modulated and manifest adverse
effects on cell’s fate. These effects may range from induction of apoptosis, to malignant
transformation and growth of cancer cells. In mammary cells where aberrant cell growth
or apoptosis that have been pre-initiated during estrogen metabolism and are under
oxidative stress, oxidant induced NRF1 expression could further enhance excess growth
in subsets of initiated cells.

Estrogen induced ROS, NRF1 and therapeutic resistance: Redox sensitive NRF1 may
play an important role in therapeutic resistance of breast cancer cells. Drug resistance of a
number of cancer cells are characterized by oxidative stress and metastasis
[224;308;309]. Tumors contain a subset of cells that both self renew and give rise to
differentiated progeny. The self renewal properties of these cells are the real driving force
behind tumor growth, metastasis and recurrence as they are responsible for tumor escape
from conventional therapies resulting in disease relapse. Oxidative stress induces
apoptosis in a number of cells but in drug resistant cancer cell, the opposite is true;
oxidative stress facilitates malignant growth and metastasis of breast cancer cells by
activating MMPs such as collagenases (MMP-2) and inhibiting antiproteases such as
tissue inhibitory metalloproteases TIMP [310;311]. Interestingly high mitochondria
content and oxidative stress are not only associated with breast cancer risk, they are also
reported to be positively correlated with stages of cancer and therapeutic resistance
[308;312;313]. Whether excess NRF1 expression mediates chemoresistance and
malignant growth of cancer cells or whether increased oxidative state observed in cancer
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cells are the manifestation of metabolically active cells is unknown. For example,
treatment of several cancer cells lines with natural or synthetic flavonoids have been
shown to restore chemo-sensitivity of these cells to cancer drugs [314;315]. Similarly,
antioxidants have also been demonstrated to improve efficacies of chemo and radiotherapies in several types of human cancers [316-320]. While some epidemiological
studies confirm the effectiveness of antioxidant supplementation [321], many studies see
no effect [322]. Similarly several in vitro and in vivo studies have shown that
antioxidants can improve drug efficacies [323]. Antioxidants when enhance the anti
cancer drug effects in vitro and in animal models, implies that lowering cancer redox
status may be pertinent to its therapeutic response. If that is the case, then NRF1
modulation of cellular redox status via mitochondria regulation may be central in oxidant
mediated chemoresistance and malignant growth of cancer cells.

The MDR1 gene (multidrug resistance gene 1) is a membrane glycoprotein that functions
in effluxing drugs from within cells in a number of malignant cell types [324]. This gene
is expressed in 42% of breast cancer cases and patients with tumors expressing MDR1
gene are three times more likely to experience chemotherapy failures than patients whose
tumors were MDR1 negative [325]. TAM, one of the most popular drugs used to treat
breast cancer and which have a high failure rate after prolong usage has been reported to
up regulate MDR1 gene expression in breast cancer cells [326]. TAM exposures have
been shown to increase NRF1 expression in MCF-7 breast cancer cells as well [327].
Interestingly, NRF1 is a transcriptional regulator of MDR1 gene expression in resistant
oral cancer cells and in acute lymphoblastic leukemia (ALL) [328;329]. This could be a
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mechanism that integrates drug induced oxidative stress, NRF1 expression and
chemotherapeutic resistance in a number of cancers including breast cancer. While
evidence of such association has not been reported in drug resistant human breast cancer
cases, the rationales for such investigations are merited. There are indications that NRF1
expression may correlate with different stages of breast cancer causing possible
therapeutic failures [255;330].

SUMMARY
Until recently, it has been argued that hydroxylated metabolites of estrogen (catechol
estrogens) participate in redox cycling in the endoplasmic reticula of cells and during this
redox cycling of hyroxylated estrogens, ROS are generated. These redox reactions may
occur in vivo, if free hydroxylated metabolites are in close proximity of activating
enzymes within the target cells. Studies recently showed that estrogens or estrogen
metabolites directly acting on mitochondria of epithelial or immune cells generate ROS.
Based on the dose and time of induction, the ROS, seem to play dual functions in
epithelial cells. While higher doses of ROS induce oxidative damage in the genome of
cells leading to cell apoptosis, exposure of low levels of ROS produce genomic instability
as well as transduce signals for cell growth, cell transformation and cell invasion. This
view is consistent with findings that (i) estrogen-induced ROS can lead to increased
phosphorylation of kinases, such as ERK, AKT, with this effect being attributed to the
redox regulation of redox-sensitive phosphatses. Some of the nongenomic pathways by
which estrogen activates MAPK and AKT pathways can be explained based on estrogeninduced ROS transducing signal to their respective specific phosphatses. (ii) The
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transcription factors AP-1, NRF1, E2F, NFkB and CREB are responsive to both oxidants
and estrogen. It is possible that estrogen-induced ROS transduce signals to the nucleus
for the activation of transcription factors such as AP-1, CREB, E2F, NF-kB, and NRF1 to
regulate their downstream target genes involved in cell transformation, cell cycle,
migration and invasion (Figure 4). (iii) There is growing evidence that estrogen-induced
regulation of breast cancer cell cycle is coupled to rates of cellular metabolism, ROS
levels and mitochondrial mass. (iv) Inhibition of cell transformation, growth of breast
cancer cells and tumor formation by overexpression of ROS detoxifying genes and cotreatment with antioxidants supports the role of ROS in estrogen-dependent breast cancer.
(v) Estrogen-induced ROS by increasing genomic instability and by transducing signal
through influencing redox sensitive transcription factors contribute to initiation as well as
progression of breast cancer. It is envisioned that this is an important mechanism that
drives the carcinogenesis process, but that it occurs in the context of other processes such
as ER-mediated signaling and estrogen reactive metabolite-associated genotoxicity under
investigations that may also contribute to the process. Taken together, estrogen-induced
ROS mediated redox signaling seems to be complementary to the process of ER mediated
cell transformation, growth and carcinogenesis. On the other hand, estrogen-induced
ROS can function as independently reversible modifiers of phosphatases and activate
kinases to trigger the transcription factors of target genes which participate in cancer
progression. Further elaboration however, points to a convergence of both ER mediated
signaling and E2 induced ROS signaling effects on the transcription factors which
possibly act in synergy and contribute to the growth and cancer progression.
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FIGURES AND LEGENDS

Figure 1. Scheme showing metabolism of estrogen and redox cycling of its metabolites.
CE = Catechol estrogen, SQ = Semi quinone, Q = Quinone, Q-SG = Quinone-glutathione
conjugate.

Figure 2. Estrogen induced cellular responses including carcinogenicity and growth of
cancer cell do not correlate with the binding affinity of various estrogens to estrogen
receptor (ER) and their potency both in vitro and in vivo
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Figure 3. Dual Roles of ROS: High ROS levels induce oxidative damage and produce
cell death, where as low physiologic ROS levels facilitate cell-to-cell communication
and cell proliferation

Figure 4. Mechanism of ROS signaling in coordinated inactivation of phosphatases and
activation of kinases leading to estrogen-mediated changes in the expression of genes
involved in growth, apoptosis, transformation or invasion of cells
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CHAPTER IV
REACTIVE OXYGEN SPECIES CAUSES NEOPLASTIC TRANSFORMATION
AND XENOGRAFT GROWTH OF 4-HYDROXY ESTRADIOL-TRANSFORMED
MAMMARY EPITHELIAL CELLS VIA TRANSDUCTION OF REDOX SIGNALS
TO PI3K/AKT PATHWAY
Victor O. Okoh, Deodutta Roy
Department of Environmental and Occupational Health, Florida International University,
Miami, FL 33199-0001
ABSTRACT
Unopposed free estrogen (estrogen without progesterone) is a major risk factor for breast
tumors. The mechanism by which estrogen is involved in the development of malignant
breast lesions is not clear. We found that reactive oxygen species (ROS)- induced by
repeated exposures to 4-hydroxy-estradiol, a predominant catechol metabolite of 17 βestradiol, caused transformation of immortalized human mammary epithelial cells. This
was evident from inhibition of growth of tumors by overexpression of catalase as well as
co-treatment with ebselen. Assessment of 4-hydroxy-estradiol transformed clones in 2-D
and 3-D cell cultures showed that they formed spheroid structures in various matrices as
well acquired invasive properties. During 4-OH-E2-mediated malignant transformation
process increased AKT phosphorylation through PI3K activation was observed. This
PI3K-mediated phosphorylation of AKT in 4-OH-E2-induced malignant cells was
inhibited by ROS modifiers as well as by silencing of AKT expression. RNA interference
of AKT markedly inhibited 4-OH-E2-induced in vitro tumor formation. Among the genes
being significantly up-regulated during the 4-OH-E2-mediated malignant transformation
process well known proliferating cell nuclear antigen (PCNA) as well as the cell cycle
genes cyclinB1 and Cdc25c9 were identified. The expression of these genes was
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inhibited by ROS modifiers as well as by silencing of AKT expression and NRF1, a
transcription factor that controls mitochondrial biogenesis (a major source of ROS).
These studies demonstrate that: (i) 4-hyroxy-estradiol is one of the main estrogen
metabolites that induce mammary tumorigenesis and (ii) ROS-mediated redox signaling
leading to the activation of PI3K/AKT signaling plays an important role in 4-hydroxyestradiol-induced malignant phenotype of breast epithelial cells. In conclusion, ROS are
important signaling molecules in the development of estrogen-induced malignant breast
lesions that may be useful as therapeutic targets for prevention and treatment of breast
cancer.

INTRODUCTION
Elevated lifetime estrogen exposure is a well-known major risk factor for breast cancer.
A large body of epidemiological and experimental evidence points to a role for estrogen
in the etiology of human breast cancer (1-9). In experimental models, estrogens are
complete breast carcinogens, as they are capable of initiating and triggering growth and
selection to generate palpable malignancy (8-14). However, the signaling mechanisms
by which estrogen contributes in the initiation of breast cancer remain the subject of a
long-standing controversy.

This is due, in part, to the inability to resolve whether

estrogen or estrogen metabolites are procarcinogenic. 17β-estradiol (E2) is metabolized
to 2- and 4-hydroxy-estradiols by cytochrome p450s. We have previously shown that
E2-induced renal tumor formation is decreased in animals exposed to inhibitors of
estrogen metabolism or to hormonally potent estrogens undergoing reduced metabolic
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conversion to catechol metabolites compared to E2 (10-12, 15). Russo and others have
shown that E2 or 4-OH-E2 transform normal ERα negative breast epithelial MCF-10F
cells (17-20). 17ß-estradiol-induced transformed MCF10F cells formed tumors in SCID
mice. 4-OH-E2 is twice as capable of producing anchorage-independent growth as E2 in
MCF10F cells (18,20). In contrast, neither 2-OH-E2 nor 2-OH-E1 are carcinogenic in
vitro or in vivo (15). Similar results have been reported in MCF-10A cells exposed to 17
beta-estradiol, equilenin or its catechol metabolite, 4-hydroxyequilenin (21,22). Recently,
Parks et al (2009) demonstrated that treatment of MCF-10A cells with 4-OHE2 induced
in vitro transformation of cells (23). However, these studies in MCF-10A failed to show
in vivo tumorigenicity, invasiveness or display other salient neoplastic properties. In the
present study we have established that repeated exposure of 4-OH-E2 to MCF-10A
produced tumors both in vitro and in vivo.

Induction of estrogen receptor (ER) upon estrogen exposure is not sufficient for the
development of breast cancer. Recent studies indicate that mammary tumors can develop
in the absence of a functional ERα (24). Although tamoxifen and other antiestrogens are
thought to prevent cancer through their actions at the ER, other mechanisms cannot be
ruled out as these compounds also block metabolism and redox cycling of estrogen and
are free radical scavengers (25). 4-OH-E2 induces an estrogenic response in the uterus of
ERα null mice, and this response is not inhibited by the antiestrogen ICI182780 (26).
These findings suggest that estrogen-dependent growth of cells is regulated not only by
nuclear ER-mediated genomic signaling pathways, but also by non-ER pathway(s). We
believe that genomic and non-genomic actions of estrogen produce complementary
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effects that are required for cellular transformation. Physiologically achievable
concentrations of estrogen or estrogen metabolites directly acting on mitochondria of
mammary epithelial or immune cells generate reactive oxygen species (ROS) (27). We
previously showed that 17-β estradiol (E2)-induced DNA synthesis in breast cancer
MCF-7 cells depends on mitochondrial oxidant signaling (28). In this study, we have
extended our efforts on understanding how an E2 metabolite, 4-OH-E2 produces
malignant phenotype through ROS signaling. We investigated whether the susceptibility
of normal breast epithelial MCF-10A cells to neoplastic transformation by estrogens
depends on ROS-mediated redox signalings. We present here for the first time that
oxidants induced by E2 and 4-OH-E2 but not 2-OH-E2 exposures mediate in vitro
transformation of MCF-10A cells. 4-OH-E2 transformed cells are not only tumorigenic in
mice but also display invasive properties as well as proliferate independent of growth
factors. Co-treatments of 4-OH-E2 transformed cells with biological or chemical ROS
scavengers, or silencing of Akt1 prevented tumorigenic conversion of MCF-10A cells.
We propose a mechanism of tumorigenic conversion that involves oxidant-mediated
activation of redox sensitive PI3K/AKT signaling.

MATERIALS AND METHODS
Reagents
17β-Estradiol (E2), 2-hydroxyestradiol (2-OH-E2), 4-hydroxyestradiol (4-OH-E2),
Ebselen, N-acetyl-cysteine (NAC), and dimethylsulfoxide (DMSO) were all purchased
from Sigma (St Louis, MO, USA). All antibodies; PI3K (p110), phospho PI3K (p85),
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phospho-AKT (ser 473) and total AKT antibodies were purchased from Cell Signaling
Technology Inc. (Boston, MA). All tissue cultures reagents were purchased from
Invitrogen Corporation (CA) unless otherwise specified.

Culture of MCF-10A cells and Adenovirus gene transfer
Human mammary epithelial cells (MCF-10A) were obtained from American Type
Culture Collection (ATCC) and were routinely cultured in phenol red-free DMEM-F12
media (1:1) supplemented with 5% horse serum, hydrocortisone (0.5 μg/ml), insulin (10
μg/ml), epidermal growth factor (20 ng/ml), 100 ng/ml cholera toxin and penicillinstreptomycin (100 μg/ml each) and incubated at 37°C in a humidified atmosphere
containing 5% CO2. The cell culture media, serum, antibiotics, and growth supplements
except cholera toxin (Calbiochem, La Jolla, CA) were purchased from Invitrogen Corp
CA). For experimental purposes, culture media were changed to starvation media (serum
free media + antibiotics) and allowed to incubate for 48 hrs prior to commencement of
most experiments, unless otherwise indicated. Serum deprivation synchronizes cells in
the G0/G1 phase of the cell cycle.

The Adenovirus-CMV (empty vector), Adenovirus-MnSOD (AdCMVMnSOD), and
Adenovirus-Catalase (AdCMVCat) constructs were purchased from ViraQuest, Inc.
(North Liberty, IA, USA). The adenovirus constructs used were replication-defective,
E1- and E3-deleted recombinant adenovirus (29). Inserted into the E1 region of the
adenovirus genome was either the human MnSOD or catalase gene, both of which are
driven by a cytomegalovirus promoter. Cells were seeded in plates at 15%-70%
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confluence. The following day, cells were infected with adenoviruses over-expressing
MnSOD or catalase or vector at 100 MOI in serum free media. Control cells were treated
with 100 MOI of the adenovirus-CMV construct. This viral load was determined to
achieve greater than 50% growth arrests of MCF-10A cells without significant cell death
for the duration of experiment. Infected cells were cultured for 48 hrs after which cells
were used for experiments.

Akt1 RNAi transfections
Pre-designed and verified human shRNA for Akt1 and corresponding null vectors were
purchased from OriGene (OriGene Technologies, Inc. Rockville, MD). Transfections of
cells were carried out in a sub-confluent cell population using FuGENE 6 (Roche)
transfection reagents according to the manufacturer's protocol. Briefly, MCF10A cells
were seeded in 6 well plates with growth factor supplemented media (SM) overnight.
Post seeding, cells were transfected with 2 µl of Fugene-6 (Roche) preincubated for
20 min at room temperature with 0.5 µg plasmid RNAi or its null controls (sham). Forty
eight hrs post transfection, media were changed to serum-free (starvation media) media
and incubated for an additional 48 hrs, after which cells were used for various
experiments. Transfection efficiencies ranged between 60-80% as quantified by
decreased protein expression levels.

Cell viability assay
CellTiter-Fluor™ Cell Viability kit was purchased from the Promega Corporation and
used according to manufacturer’s instructions. Briefly, cells were seeded in 96 well plate
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at a density of 1.0x104 cells/well, serum starved for 48 hrs and treated with estrogens or
ROS modifiers. At the end of treatment procedure, substrate reagents (GF-AFC) were
mixed with substrate buffer and dispensed into wells. This assay measures protease
activity in live cells as opposed to MTT or MTS assay kits that measure formation of
formazon crystals by mitochondrial enzymes. Plates were read on a fluorescence plate
reader at 380–400 nm excitation and 505 nm emission and data is expressed as mean of
three experiments +/- SD.

Cell transformation
The cell transformation was carried out by a modified protocol of Russo’s group (18).
Briefly, MCF-10A cells were seeded at 30% density in a 10 cm dish. After 24 hrs of
seeding, media were replaced with stavation media and allowed to culture for 48 hrs, and
then cells were subjected to two treatment cycles with E2 or its catechol metabolites. A
treatment cycle includes a 48 hr starvation period, 48 hr treatment period (100 ng/ml of
either E2, 2-OHE2, and 4-OHE2), and 48 hr recovery period in growth media containing
10% horse serum (HS) and no growth supplements. At the end of two treatment cycles,
cells that would be used for immunoprecipitation and Western blot analysis were treated
for an additional 30 mins with estrogens, lysed with RIPA buffer, immunoprecipitated
and processed for western analysis. For anchorage independent growth assay 5000
cells/well were used for colony formation assays in soft agar.
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Anchorage independent growth
Anchorage independent growth, an indicator of neoplastic transformation of cells, was
assessed as previously described by Zhou et al (30). Briefly, base support agar were made
fresh by diluting 1.0% molten agarose mixed with 1:1 2x culture media (2x DMEM/F12
media, 20% HS, 2x Penicillin-Streptomycin and 200 pg/ml estrogens) to a final 0.5%.
Molten agar was left at 42 oC in a water bath until dispensed at 200 ul/well in 48 well
plates, then allowed to solidify for 4 hrs at room temperature. Top agarose overlay was
made fresh by mixing 0.7% molten agarose with 2x culture media containing appropriate
5000 cells/well, then gently overlaid over base agar. Cells were incubated for a minimum
of 21 days in a 37°C incubator with 5% CO2. Cultures were fed every week with top
agar layer and colony formation was assumed when cell masses were 100 micron or
greater as measured on a Nikon TE2000U inverted microscope (Nikon Corp., USA) with
Metamorph software (Universal Imaging, USA). Images were acquired by using an
Olympus C-5060 digital camera attached to the Nikon TE2000U inverted microscope
with a 4x objective. Four wells were enumerated for each group and data expressed as
mean of five wells +/- SD.

Invasion and ductulogenic assays
In order to determine invasiveness of transformed cells, several colonies were aseptically
picked, dissociated with trypsin and cultured for 20-30 passages in a low growth factor
media (DMEM F12, 5% FCS, 4 ng/ml EGF, 2.0 ng/ml insulin, 100 ng/ml hydrocortisone,
1x Penicillin-Streptomycin) and eventually DMEM/F12 with 5% HS media, and 1x
Penicillin-Streptomycin. Cells (5.0 x 103 cells/ml) for invasion assays were seeded over
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8 μm pore transwell filter insert (Transwell, Coastar Cambridge, MA) precoated with
Matrigel (Collaborative Research, Bedford, MA). Chemoattractants used were reduced
growth factor supplemented media or media with 10% FBS media positive control cells
MDA MB 231. Matrix invasion was allowed for 16 hrs at 37 °C in a CO2 incubator. The
non-invaded cells inside chambers were wiped off with a cotton swab, and the filters
were fixed, stained by Diff Quick (Sigma, St. Louis, MO), cut out and mounted onto
glass slides. The total number of cells that crossed the membrane were counted under a
light microscope, enumerated and expressed as fold increase compared to parent cell line.
The experiments were repeated five times and results are expressed as the mean ±S.D.

For ductulogenesis, 1.0x103 cells/ml of transformed cells (p121 and screened from 3x
Matrigel), MDA MB 231 and

parental MCF-10A cells were mixed with collagen

(Collagen Co., Palo Alto, CA, USA) and seeded in chamber slides precoated also with
collagen. Cells were incubated for three weeks with bi-weekly feeding with 5% HS
media. To confirm spheroid formation from collagen matrix, we diluted HuBiogel, a
human matrix mimetic (VIVO Biosciences Inc.), 1:3 with media and coated 0.22 micron
pore transwell filter inserts for 6 hrs at 37 oC incubator. Cells (1.0 x 103) were seeded into
each insert and chemoattractant media (DMEM/F12, 5% HS, 1x Penicillin-Streptomycin)
were added at bottom of insert. Cells were cultured for 14 days with media changed twice
weekly. Images were acquired with a Olympus C-5060 digital camera under an inverted
microscope with 4x objective as described above.
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Chemical antioxidant treatments
The treatment procedure for Ebselen (a glutathione peroxidase mimetic which also
removes both H2O2 and peroxynitrite) or NAC (a precursor of glutathione and scavenger
of ROS) (31, 32) varies according to the experiments design. For all experiments, 40 μM
Ebselen and 1.0 mM NAC were used for cell treatments. For example, in DCF assays,
antioxidants were pre-loaded onto cells for 2-4 hrs before ROS measurement commences.
For BrdU assays, cells were cultured with the chemical antioxidants throughout the
experimental procedure. For transformation regimen, antioxidants were applied to cells
each time cells were treated with estrogens. For anchorage independent growth assays,
antioxidants were added to soft agar matrix media and during weekly feeding of colonies.

Measurement of reactive oxygen species (ROS)
Cellular ROS were measured on a 96 well plate reader and confocal fluorescence
microscopy as previously described by Felty et al (27). Briefly MCF-10A cells were
seeded at a concentration of 1.0 × 104 cells per well in black 96-well flat bottom plates
(ThermoFisher Scientific Inc. USA) and allowed to adhere overnight. Post seeding, cells
were serum starved for 48 hrs after which they were pretreated for 4 hrs with chemical
antioxidants Ebselen or NAC (Sigma USA) diluted in Hank's balanced salt solution
(HBSS) followed by incubation with 10 µM 2',7'-dichlorofluorescin diacetate (DCFHDA) (Invitrogen Corp) for 20 min. Cells were rinsed with HBSS followed by various
estrogen treatments as described in the figure legends. DCFH-DA is a non-fluorescent
cell-permeable compound, which is acted upon by endogenous esterase that removes the
acetate groups generating DCFH. In the presence of intracellular ROS, DCFH is rapidly
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oxidized to the highly fluorescent 2',7'-dichlorofluorescein (DCF). The oxidative products
were measured with a Tecan Genios 96 well microplate reader using 485 and 535 nm as
excitation and emission filters respectively or fluorescence images were acquired on a
Nikon TE2000U inverted fluorescence microscope equipped with a Nikon D-Eclipse C1
laser scanning confocal microscope system (Nikon Corp., USA). The built-in Nikon EZC1 software was used for confocal image acquisition and analyses. DCFH-DA stock
solutions were diluted at a 1:1 ratio with Pluronic F-127 (20% w/v). Data are expressed
as mean of three experiments +/- SD.

Immunoprecipitation and Western Blot Analysis
After the respective treatments, cells were rinsed twice with ice cold phosphate buffered
saline (PBS), harvested with lysis buffer (150 mM NaCl, 0.5% deoxycholate, 0.1%
Nonidet P-40, 0.1% SDS, 50 mM Tris) containing protease and phosphatase inhibitors
(Roche). Samples were diluted to 500 µg of protein in 1 ml of lysis buffer, and precleared for 1 hr at 4 °C with 10 µl of 1:1 slurry of protein A-agarose beads (Invitrogen
Corp) in lysis buffer. After a brief centrifugation to remove pre-cleared beads, 2 µg of
desired capture antibodies were added to each supernatant and incubated on a rocking
platform at 4 °C overnight and captured proteins were precipitated with 40 µl of protein
A-agarose beads for 2 hr. The beads were washed five times with lysis buffer and
resuspended in 40 μL sample loading buffer, subjected to electrophoresis and electroblotted onto a PVDF nylon membrane. Primary antibodies used for Western blots were
diluted 1:1000 in phosphate buffered saline Tween-20, PBST

and horseradish

peroxidase-conjugated secondary antibodies were diluted 1:50,000 in PBST. Blots were
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treated with ECL reagents (Amersham Biotech), and proteins were detected by
autoradiography. Band intensity was quantified with Bio-Rad Gel Doc Imaging System.

Immunofluorescence labeling
MCF-10A cells were seeded and treated in chamber slides as indicated in legends to the
figures. Post treatment, cells were fixed with ice cold methanol for 15mins, and
permeabilized with 0.5% Triton X-100 for 30 mins. Cells were blocked with 1% normal
goat sera for 1 hr after which they were probed with antibodies diluted 1:500 for Akt and
1:500 for phospho AKT. Alexa Fluor labeled secondary antibody directed against AKT
antibody was diluted 1:1000. The confocal fluorescence images were scanned on a Nikon
TE2000U inverted fluorescence microscope equipped with a Nikon D-Eclipse C1 laser
scanning confocal microscope system (Nikon Corp., USA). The z-series scanning was
done at every 1 μm up to a z-depth of 10 μm by using a Nikon 40 x 1.30 NA DIC H/N2
Plan Fluor oil immersion objective. The built-in Nikon EZ-C1 software was used for
confocal image acquisition and analyses.

RESULTS
Exposure of MCF-10A cells to 17β-estradiol (E2) and its metabolites produces a rapid
increase in ROS levels: Before carrying out cell transformation, we characterized normal
human mammary epithelial cells for their ability to produce ROS in response to 17 betaestradiol (E2) exposure. These cells respond to E2 in terms of producing ROS very
similar to breast cancer cells. ROS production by E2 and its metabolites, 2-OH-E2 and 4-
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OH-E2 in normal human mammary epithelial MCF-10A cells was dose-dependent (Fig. 1
A,B). 4-OH-E2 induced significantly more ROS in these cells compared to E2 and 2OHE2. The abilities of these estrogens to produce ROS were inhibited by overexpression
of catalase or treatment with Ebselen or NAC (Fig. 1C). When MnSOD were overexpressed in these cells, ROS levels increased significantly compared to cells treated with
estrogen alone (Fig. 1C). We also measured the cellular protease activities to rule out the
possibility that the differential ROS levels were not as a result of differential cell
densities or viability. Our results indicate that 4-OH-E2 is the most effective in
generating intracellular ROS in MCF-10A cells. Mitochondria may be the major source
of estrogen induced intracellular ROS, because overexpression of MnSOD, a
mitochondria superoxide dismutase that converts super oxides to hydrogen peroxide,
increased the ROS content maximally.

Exposure of MCF-10A cells to 17β-estradiol (E2) and its catechol metabolites induced
dose-dependent colony formation: Both MCF-10F and MCF-10A cells are spontaneously
immortalized, ER negative normal human breast epithelial cell lines that are non
tumorigenic in vivo. We used the anchorage independent growth (AIG) assay to examine
cell transforming ability of E2 by detecting AIG positive colony formation. E2 exposure
to MCF-10A cells produced dose dependent increase in colony formation. We found that
repeated treatments of MCF-10A cells with various doses of E2 or its catechol
metabolites induced in vitro transformation of MCF-10A cells in a dose dependent
manner (Fig 2). 4-OH-E2 is more potent in transforming normal mammary epithelial
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cells compared to E2, while 2-OHE2 is a weakly transforming metabolite of MCF-10A
cells (Fig 2).

Clonogenic expansion and invasiveness of 4-OH-E2 transformed MCF-10A cells: Since
4-OH-E2 induced the highest transforming frequency, we further examined whether 4OH-E2 induced colonies are clonogenic. We picked several colonies from each soft agar
at the end of 21days and cultured them in media with 10% FBS (designated as a regular
media -RM). Several of these clones did not survive beyond the 10th passage in RM.
However, of the 5 that survived up to the 21st passage, we determined whether these cells
have acquired anchorage independent growth properties, a hallmark for transformed cells
and whether these clones also respond to estrogens. Cells were fed twice per week and
cultured for 21days. Colonies were counted from quadruplicate wells, (± SD). One of our
clones was highly clonogenic (P21) and responsive to E2. We labelled this clone as
MCF-10T15 (Figure 3A). Analysis of the invasive property of this clone MCF-10T15 by
invasion assay showed that it is highly invasive (Fig. 3B).

3-D Spheroid formation of 4-OH-E2 transformed clone: To assess whether 4-OHE2
transformed MCF-10A cells are neoplastic, we picked few colonies from anchorage
independent growth assay and cultured them repeatedly in growth factor reduced media,
then assessed cells periodically for their ability to form spheroid structures in collagen
coated 0.22 μm transwell inserts, or in a rotary vessel using HuBiogel, a memetic of
human stromal matrix. We found that over progressive passages, the clones in collagen
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matrix assumed a more heterogeneous population with small masses (p0) as opposed to
homogenous population with aggressive phenotype (p200) (Fig. 4).

The tumorigenic conversion ability of 4-OH-E2-transformed MCF-10A cells was further
investigated by 3-D culture using HuBiogelTM. For 3-D culture, anchorage-independent
MCF-10A human mammary gland epithelial cells transformed by 4-OH-E2 treatment
were mixed with 3D HuBiogelTM matrix containing DMEM-F12, seeded into 55 ml
rotating-wall vessels and incubated at 37°C for 16 days. These conditions allow for the
spontaneous formation of tissue-like spheroids (Fig 4).

Loss of ductulogenicity in 4-OH-E2 transformed cells: The ability to form ductile
structures are characteristic of normal mammary epithelial in collagen matrix. Loss of
this ability is a hallmark of transformed cells. Assessment of transformed cells in a
collagen matrix indicates that these cells have indeed lost their ability to form ductile
structures upon repeated treatment with 4-OHE2 (Fig 5A). This phenotypic change was
evident right from p0 cell population and continued even at p121.

Aggressive phenotype enrichment: Initial invasion assessment of fifteen colonies from
soft agar assay indicates that three colonies have acquired the ability to invade Matrigel
matrix. These clones were subsequently cultured in growth factor reduced media over
several generations and assessed periodically for invasive phenotype. We observed that
successive passage of these clones increased their ability to invade Matrigel matrix. One
of the clones termed clone c (MCF-10Ac) had actually acquired invasion capability that
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is about 30% that of MDA MB 231 cell line at passage (Fig 5B). The other clones had
lesser invasive abilities compared to MCF-10Ac (data not shown).

4-OH-E2 treatment causes epithelial to mesenchymal transition (EMT) in MCF10A cells:
We found that the 4-OH-E2 transformed clones looked very different from WT both in
morphology, size and time it takes to form a sheet upon seeding. Figs. 5C, 1,2 shows that
transformed clones were bigger than their WT counterpart in monolayer culture just after
seeding (3 hrs). In addition, transformed cells displayed an abnormal differentiation
pattern and loss of cell polarity, all phenotypes of cancer cells (Fig. 5C 3,4). The majority
of clones exhibited morphological changes that resembled epithelial to mesenchymal
transition. As shown in Figure 8b, MCF10A cells showed highly organized cell-cell
adhesion and cell contact, whereas 4-OH-E2 transformed-MCF10A cells had an
elongated and refractive appearance with cell scattering and loss of cell-cell contacts. The
cobblestone-like morphology of MCF10A cells at confluency was replaced in 4-OH-E2
transformed-MCF10A cells by a spindle-like fibroblastic morphology.

Inhibition of 4-OH-E2-induced cell transformation by ROS modifiers: In cells
overexpressed with adenovirus construct containing catalase and MnSOD that lowers
oxidant production as well as in mtTFA silenced cells, E2 produced fewer colonies
compared to E2 alone (Fig 6). Treatment of cells with chemical ROS scavenger (Ebselen
or NAC) significantly inhibited the abilities of E2 or 4-OHE2 to induce neoplastic
transformation of MCF-10A cells as assessed by inability to form colonies and grow in
soft agar assays (Fig 6). This implies that oxidants induced by E2 and 4-OHE2 are
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necessary for tumorigenic transformation of MCF-10A cells and when oxidant levels
were scavenged by biological and chemical antioxidants, estrogen induced transformation
of mammary cells was inhibited.
The growth of the E2-induced transformed clone was highly responsive to E2 and was
inhibited by Ebselen and N-acetyl cysteine. Antioxidants reduce E2-induced DNA
synthesis in MCF-10A transformed cells (Figure 7). As shown in Figure 8, treatment with
E2 produced spheroids (Left Upper Panel). Overexpression of catalase and Ebselen
inhibited E2-induced tumor spheroid formation. Cells were labeled with CFSE using the
Vybrant kit for checking viability. All spheroids showing the green fluorophore (Fig. 8
Right Upper Panel) indicate that cells in tumor spheroids are alive.

4-OHE2 induced ROS activates PI3K/AKT signaling pathway: Consequences of elevated
ROS in cells are apoptotic cell death, quiescence or cell transformation and neoplastic
growth (33,34) The signaling pathway associated with survival of cells under oxidative
stress is attributed in part to activation of PI3K and AKT signaling pathways (34, 35).
Therefore, we determined whether estrogen induced oxidants in normal mammary
epithelial cells activate PI3K and AKT signaling pathways during neoplastic
transformations of MCF-10A. We found that repeated treatments of MCF-10A cells with
E2 and 4-OHE2 increased phosphorylation of both PI3K and AKT in cells treated with
regimen of estrogen which produced cell transformation (Fig 9). Phosphorylation of both
PI3K and AKT was attenuated by co-treatment with either biological or chemical ROS
modifiers (Fig 5). The activation of PI3K and AKT activation by 4-OHE2 were about
30% and 120% higher than E2 or 2-OHE2 respectively (Fig 10). Interestingly, we also
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observed that silencing of Akt1 (Fig 11A), the downstream recipient of PI3K activation
and Akt1 regulates proliferation and growth of mammalian cells significantly diminished
4-OHE2 induced neoplastic transformations of MCF-10A cells (Fig 11B). These data
support that intracellular ROS induced by 4-OHE2 may activate AKT signaling pathway
which favors survival and proliferation of cells, both required for malignant
transformation.

4-OH-E2-induced ROS modulates cell cycle genes through a nongenomic, ER
independent signaling pathway:

We investigated whether 4-OH-E2-induced ROS

signaling is involved in the modulation of cell cycle genes in the conversion of normal
breast epithelial cells to malignant cells. Using a normal cell line (MCF-10A) that
develop transformed clones in response to 4-OH-E2 or E2, the expression of cell cycle
genes, cyclin D and pcna were measured by real time RT-PCR (Fig. 12). After exposure
of 8h following two 48 hr treatments with 4-OH-E2; we observed an approximately 1.34, and 1.54- fold increase in the mRNA expression of pcna and cyclin D1. Overexpression
of MnSOD and catalase as well as co-treatment with Ebselen and NAC markedly
decreased 4-OH-E2 induced pcna and cyclin D1 expression compared to E2 treated cells.

DISCUSSIONS
Our results showed that E2 and its metabolite, 4-OH-E2, elicited transformed phenotypes
in MCF-10A cells, which are estrogen receptor-α (ERα) negative. Similar results have
been reported in MCF-10A cells exposed to E2 or its catechol metabolite and 4hydroxyequilenin (21-23). Russo and others have shown that E2 or 4-OH-E2 transformed
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MCF-10F cells were also ERα negative (17-20). Our results are in agreement with
previous studies that 4-OH-E2 is twice as carcinogenic as E2. In contrast, neither 2-OHE2 is carcinogenic in vitro or in vivo (15). Interestingly, both 2-OH-E2 and 2-OH-E1 are
capable of producing ROS and undergo metabolic redox cycling like 4-OH-E2. The lack
of carcinogenicity of 2-hydroxylated estrogen metabolites in vivo may be due to their
rapid inactivation by COMT-mediated O-methylation, rapid clearance, and weak
estrogenic hormonal activity as compared with 4-OH-E2 (10-12, 36,37).

Most

importantly, it may be due to 2-MeO-E2, the major product of COMT-mediated Omethylation of 2-OH-E2 that possesses unique anti-tumorigenic activity. These studies
support the concept that E2 and its main metabolite 4-OH-E2 are carcinogenic in breast
epithelial cells.

Recent studies indicate that mammary tumors can develop in the absence of a functional
ERα (24). Although tamoxifen and other antiestrogens are thought to prevent cancer
through their actions at the ER, other mechanisms cannot be ruled out as these
compounds also block metabolism and redox cycling of estrogen and are free radical
scavengers (25). 4-OH-E2 induces an estrogenic response in the uterus of ERα null
mice, and this response is not inhibited by the antiestrogen ICI182780 (26). These
findings suggest that estrogen-dependent growth of cells is regulated not only by nuclear
ER-mediated genomic signaling pathways, but also by non-genomic pathway(s).
Genomic and non-genomic actions of estrogen may produce complementary effects that
are required for cellular transformation. Estrogen is genotoxic, as seen by the presence of
DNA adducts in mammary tissues from ERKO/Wnt-1 mice (38,39).
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Although the

formation of DNA adducts may lead to gene mutation, this type of DNA damage appears
to be a late event arising from E2 metabolism. We have recently shown that estrogen
induces rapid formation of ROS in MCF-7 cells (27,40). 4-OH-E2 has been implicated in
transforming MCF-10A cells via ROS formation based on inhibition of anchorage
independent growth of MCF-10A cells (23). This study did not show in vivo tumor
formation of transformed cells. The main difference between of our work and previous
reports is that our transformed clones are tumorigenic in mice and ROS modifiers. The
overexpression of catalase that converts hydrogen peroxide to water and Ebselen, a
gluthione peroxidase mimic, inhibited cell transformation and tumor formation. This is
important because MCF-10A cells are easily transformed in an in vitro system, even by
mild stress such as reduced growth factor media or hypoxic conditions (41).
Both E2 and 4-OH-E2 treatment of MCF-10A cells, increased the formation of ROS as
compared to untreated cells, whereas 2-OHE2 induced the minimum increase in ROS
formation in MCF-10A cells. Over-expression of biological ROS modifiers and chemical
scavengers of ROS prevented 4-OH-E2-induced anchorage independent growth of MCF10A cells. We observed similar results with 3-D culture of transformed cells using
HuBiogel and xenograft tumor growth. These findings suggest that ROS induced by
repeated exposures to 4-OH-E2, a predominant catechol metabolite of E2, cause
transformation of immortalized human mammary epithelial cells with malignant growth
in nude mice. Since 4-OH-E2 induces more ROS formation compared to E2 in MCF10A
cells, the accumulation of 4-OH-E2 in the breast is expected to augment ROS formation
here as well. 4-OH-E2 strongly binds to ER (42,43) and it takes longer to dissociate from
the ER than E2 (44).

The greater ROS production, ER action, and breast tissue
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accumulation of 4-OH-E2 compared to E2 may account for its greater carcinogenicity in
MCF-10A cells.

We and others have shown that mitochondria are significant targets of estrogen (27,40).
Recently, we reported that physiological concentrations of E2 stimulate a rapid
production of intracellular ROS in epithelial cells which depends on cell adhesion, the
cytoskeleton, and integrins (27,40). These events occur earlier than ER-mediated
genomic actions. E2-induced ROS production does not depend on the presence of ER on
breast cancer cells as ER-cell lines MDA-MB 468 produced ROS equal to or more than
that of ER+ MCF7, T47D, and ZR75cell lines (27).

It has been wrongly concluded by Parks et al (23) that redox cycling of catechol estrogen
is the source of ROS. Catechol estrogens, particularly 4-OH-E2, via nonenzymatic
autoxidation, may undergo redox cycling to produce reactive semiquinone and quinone
intermediates with concomitant production of ROS (10-12). However, this redox reaction
of catechol estrogens is enhanced in the presence of Cu2+ or Fe3+ ions and by enzymatic
catalysis by cytochrome P450 oxidases or peroxidases, which is accompanied with an
increased generation of ROS. Furthermore, Parks et al (23) implied the contribution of
redox cycling of catechol estrogen generating ROS based on indirect evidence using a
non-specific inhibitor of cytochromes P450, SKF525A and dicumarol, an inhibitor of
quinine reductase. Dicumarol can also inhibit mitochondrial diaphorase, which is
involved in reduction of Coenzyme Q10 in the mitochondria (45). Similarly, SKF-525A
inhibits mitochondrial oxidative metabolism in intact cells and isolated mitochondria

113

(46). Lower ROS formation observed in the presence of SKF525A and dicumarol may be
as a result of inhibition of the mitochondrial electron transport chain. Increased ROS
formation is observed within 30 seconds of E2 treatment (40). Due to the speed of ROS
production as observed in our study, it is unlikely that redox cycling of 4-OHE2 is the
source of these oxidants. Furthermore, in our studies of E2-induced ROS generation in
MCF-7 and other cells, hydroxylated estrogen metabolites or adducts immediately after
addition of E2 were not detected which also rules out the possibility of ROS generation
by redox cycling of hydroxylated estrogens.

Little is known about the potential direct involvement of ROS signaling in breast cancer
development. However, we and others have recently discovered that estrogen-induced
oxidative bursts occur exclusively in perinuclear regions. This surge in ROS production
may target inducible promoters, signaling transcription-initiation complex assembly and
subsequently, driving estrogen-induced gene expression (28). While studying
mitochondrial regulators of cell cycle progression, we discovered that E2-induced G1 to
S phase transition is associated with an increase in intracellular ROS levels (28). These
findings strongly support the idea that both E2-induced ROS and ER activity are required
for breast cancer cell proliferation (28). When produced at high levels, ROS levels
induce oxidative damage and G0/G1 arrest.

However, when present at physiologic

levels, ROS mediate essential cellular functions such as cell-to-cell communication and
proliferation. For example, estrogen-generated ROS mediate early G1 gene expression,
as seen by the ability of antioxidants to block this effect (28). We now know that the
delicate intracellular interplay between oxidizing and reducing equivalents allows ROS to
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function as second messengers in signaling pathways controlling cellular proliferation
and transformation (47,48).

Recent studies implicate a role for ROS in cell

transformation and several lines of indirect evidence support a role for ROS in the
development of breast cancer (49,50),

We recently found that, in Syrian hamsters,

estradiol-induced kidney tumor formation was reduced by the antioxidants Nacetylcysteine, vitamin C, sodium 2-mercaptoethanesulfonate (cytoprotective thiolcontaining agent), and Ebselen (51,52). Consistent with this finding, estrogen-induced
testicular and uterine cancers are prevented by pentoxifylline, a compound with
antioxidant effects stemming from its ability to block synthesis of the inflammatory
mediators, IL-1β and TNFα (49). Overexpression of manganese superoxide dismutase
(MnSOD), the mitochondrial enzyme responsible for superoxide detoxification, blocks
the appearance of malignant phenotypes (53), and the loss of this enzyme partly
contributes to malignant phenotypes (54,55). Not surprisingly, MnSOD knockout mice
exhibit increased oxidative DNA damage (56). MnSOD expression is less frequently
found in tumor cells of invasive breast carcinomas than in non-neoplastic breast epithelial
cells (57).

Several epidemiological studies have shown that MnSOD polymorphic

populations have an increased risk of breast cancer (59-60). The recent findings that 4OH-E2 accumulates in the breast tissue of cancer subjects (61-63) and predominant 4hydroxylation of E2 occurs in the target organs of cancers (64-66) suggest that the target
organ of cancer would be particularly sensitive to 4-OH-E2-induced ROS formation. In
our studies, overexpression of catalase and antioxidants (N-acetyl cysteine and Ebselen)
prevented 4-OH-E2-induced anchorage independent growth of MCF-10A cells. These

115

results indicate that 4-OH-E2-induced cell transformation may be mediated, in part, by
redox-sensitive signal transduction pathways.

Both AKT and ERK are redox sensitive kinases. Thus, 4-OH-E2-generated ROS may
activate ERK or AKT, which could then directly phosphorylate and activate transcription
factors controlling cell cycle, cell migration or cell invasion genes. Several investigators
have concluded that estrogen-induced AKT activation is promoted by membrane bound
ERα or ERβ (67,68). There are no known functional motifs within the structure of the ER
that can promote second messenger signaling. There are reports which show no
correlation between ERα/β expression patterns and the activation of AKT-1/-2 in
estrogen treated breast cancer cell lines. 17α-estradiol, through an ER independent
mechanism, activates PI3K-AKT signaling (69). Recently, Lee et.al. (67) reported that
up-regulation of PI3K/AKT signaling by E2 is mediated through activation of ERα, but
not ERβ. In ovarian cancer cells, 4-OH-E2 induces AKT phosphorylation while 2-OH-E2
did not (70). Our study showed that 4-OH-E2 increased AKT poshphorylation in ERα
lacking MCF-10 cells, while 2-OH-E2 did not increase AKT phosphorylation. The PI3K
inhibitor,

LY294002,

and

ROS

modifiers

blocked

4-OH-E2-induced

AKT

phosphorylation. AKT activity depends on its phosphorylation, which is positively
regulated by PI3K and negatively regulated by a class of protein phosphatases (PPs) (71).
AKT can be activated by both E2 and H2O2 (67-73). ROS reversibly regulate cysteinebased phosphatases (reviewed in 47). The ability of E2 and H2O2 to activate AKT may be
attributable to inactivation of cysteine-based phosphatases by ROS (47, 67-73). The
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reversible inactivation of phosphatases, such CDC25A and PTEN, by estrogen-induced
ROS may be a key component of AKT activation (47,72).

The PI3K/Akt signaling pathway seems ubiquitous to carcinogenic conversions (74-76).
Oxidant mediated hyperactivation of AKT can phosphorylate and inhibit pro-apoptotic
proteins such as BAD and caspase 9 while phosphorylating and activating pro-growth
transcription factors such as ASK1 and GSK3. The outcome of this hyperactivation could
therefore be cells surviving and proliferating in a high oxidative state. If these cells have
been initiated by acquisition of pre-tumorigenic lesions by 4-OHE2 metabolism, oxidant
mediated growth of these cells could be the basis for malignant transformation of
mammary cells. The loss of PTEN activity, hyperactivation of PI3K/AKT signaling
pathway, excess estrogen exposure and oxidative stress have been implicated in breast
carcinogenesis (47). In this study, we also observed that PI3K/AKT signaling proteins
were hyperactivated in MCF-10A cells treated repeatedly with estradiol and 4-OHE2
though the activations of 4-OHE2 were more than those of E2 and 2-OHE2 respectively.
Importantly, chemical and biological antioxidant mitigated PI3K/AKT activations and
inhibited estrogen induced mammary tumorigenesis. To rule out the possibility that
antioxidant regulation of PI3K/AKT activations are not related to estrogen induced
mammary tumorigenesis, we silenced AKT1 expression, the AKT isoform implicated in
survival, growth and tumorigenesis of cells including mammary cells (74-76). We found
that silencing of this gene prevented estrogen’s ability to transform MCF-10A cells.
These data indicates that estrogen induced redox activation of PI3K/AKT signaling
pathway is essential for mammary tumorigenesis.
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A substantial number of experimental and epidemiological studies support an important
role for AKT in tumorigenesis. PI3-kinase and AKT act as oncogenic determinants in
several human cancers. AKT genes are amplified or overexpressed in gastric, ovarian,
breast, pancreatic, and prostate cancers (77,78). AKT1 levels are higher in a panel of
human breast carcinoma cell lines than in breast epithelial cells, particularly those with
higher HER2 expression. AKT1 activity is increased by either E2 or IGF-I in estrogendependent MCF-7 cells, and both factors act synergistically to increase AKT1 activity
and promote cell proliferation (79). Transgenic mice expressing AIB1 (ER co-activator)
in the mammary gland develop mammary hyperplasia and mammary carcinomas.
Increased activation of the PI3K/AKT pathway is implicated in the development of
mammary carcinoma in AIBI mice (80). AKT activation amplifies the proliferation
induced by cyclin D1 or HPV E7 during morphogenesis and cooperates with these
oncoproteins to promote proliferation and morphogenesis in the absence of growth factors
(81). H-ras transformation of MCF-10A cells results in upregulation of MAP kinase and
PI3-kinase signals (82). Similarly benzo(a)pyrene quinone is reported to induce
anchorage-independent growth of MCF-10A cells which depends on the activation of
PI3K/AKT activation (83). Chronic activation of AKT2 leads to an increase of the events
associated with tumorigenesis (84). Most importantly, AKT activation disrupts mammary
acinar architecture and enhances proliferation in an mTOR-dependent manner (80). Our
study showed that the exposure of 4-OH-E2 or E2 to normal human breast epithelial
MCF-10A cells produced transformed phenotypes. These cells show increased AKT and
increased cell number in the absence of EGF or insulin. The 4-OH-E2-induced cell
proliferation was attenuated by the antioxidant N-acetylcysteine. Overexpression of
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catalase and MnSOD also reduced the extent of 4-OH-E2-dependent increased cell
growth and AKT activation. Taken together, these data indicate that 4-OH-E2-induced
ROS activates the AKT pathway in MCF-10A cells to support the growth of cells in
growth factor deficient conditions.
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FIGURES AND LEGENDS

Fig. 1. 17β-estradiol and its catechol metabolites induce ROS production in MCF-10A
cells in a dose dependent manner. Cells were seeded at 1.0 × 104 cells per well. 24 hrs
post seeding, cells were serum starved for 48 hrs in DMEM/F12 (1:1) with 1x penstrep.
For the groups that were treated with NAC or ebselen, these cells were pre-treated with
1.0 mM NAC, pH 7.0 or 40 µM ebselen for 4 hrs before DCF assay. For the groups that
were treated with catalase or manganese super dismutase (MnSOD), these cells were
infected with adenovirus over-expressing these ROS modifiers at moi 100 for 48 hrs prior
to seeding for DCF assay. At end of starvation and antioxidant treatments, cells were
preloaded with 10 µM 2',7'-dichlorofluorescin diacetate (DCFH-DA) diluted in Hanks
Balance Saline Solution (HBSS), and incubated for 20 mins in 37oC incubator. Post DCF
treatment, cells were washed with HBSS and treated with various concentrations of
estrogens diluted in HBSS and fluorescence emission read on Tecan Genios microplate
reader using 485 and 535 nm as excitation and emission filters respectively. Fluorescence
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images were acquired on confocal microscopy. To determine whether observed ROS
modification by estrogens or antioxidant were due to differential cell density or viability,
duplicates plates were seeded and treated with ROS modifiers as described above, then
challenged with 100 ng/ml 4-OHE2. Instead of loading DCF, cells were treated with
CellTiter-Fluor™ as described by manufacturer. This reagent measures protease activity
as an indication of cell viability. Plates were read on fluorescence plate reader at 400nm
excitation and 505nm emission and data expressed as mean of three-five experiments +/SE. (A) Histogram of fluorescence emitted by the oxidation of DCFH-DA by estrogens
and read on Tecan plate reader in 5 min. Data is expressed as mean of +/- SE of five
experiments. (*) Indicates significantly different from control (DMSO) groups while (#)
indicates significant different from 4-OHE2, (P<0.05). (B) Confocal images of cells
preloaded with 1.0 μM DCF and treated with 100 pg/ml of various estrogens, and
fluorescence image acquired 5 min after treatment. (I) DMSO, (II) E2, (III) 4-OHE2, (IV)
2-OHE2. (C) Histogram of ROS modulation by 4-OHE2 versus viable cells. (**)
Indicates significantly different from control (DMSO) groups while (#) indicates
significant different from 4-OHE2, (P<0.05)

Fig. 2. E2 and 4-OHE2, but not 2-OHE2 transforms MCF-10A cells in a dose dependent
manner. MCF-10A cells were seeded at sub-confluence and serum deprived for 48 hrs
after which they were exposed to various doses of E2 or its catechol metabolites for two
treatment cycles of 48 hrs each, interspersed with 48 hrs recovery period. (I) DMSO, (IIIII) 5.0 and 50.0 μg/ml BaP as positive controls respectively. We used estrogen
concentrations of 0.1, 10.0 and 100.0 ng/ml respectively for transformation experiments;
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IV-VI) E2; VII-IX) 4-OHE2 and X-XII) 2-OHE2 treatments. Fig 2B) Fold differences in
colony formations were compared to colonies from 0.1ng/ml estrogen treatments. Data
expressed as mean of four wells +/- SD. (**) Indicates significantly different from control
0.1 ng/ml groups while (#) indicates significant different from 100.0 ng/ml 4-OHE2
treated group, (P<0.05)

Fig. 3. Clonogenic expansion and invasiveness of 4-OH-E2 transformed MCF-10A cells:
A. For colonogenic expansion analysis, we picked several colonies from each soft agar at
the end of 21days and cultured them in media with 10% FBS, designated regular media
(RM). Several of these clones did not passage beyond 10th passage in RM. However, of
the 5 that survived up to the 21st passage, we seeded these cells at 50 k cells/well in soft
agar to determine whether these cells have acquired anchorage independent growth
properties, a hallmark for transformed cells and whether these clones also respond to
100pg/ml estrogens. Cells were fed twice per week and cultured for 21days. Colonies
were counted from quadruplicate wells, (± SD). B. To assess invasive properties of the
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clones derived from 4-OH-E2 induced MCF-10A transformed cells, we seeded 10K
MCF-10T15 cells, a clone from MCF-10A transformation in BD BioCoat™ Matrigel™
Invasion Chambers. We also seeded these cells in glass chamber as we previously found
that MCF-10A cells don’t attach very well to glass in the first 16-24hrs. For the invasion
assay (a), the chemotractant is either growth supplemented media ( SM) or media with
only 10% FBS (RM).

Fig. 4. Spheriod Formation in Collagen and HuBiogel
Single colony from anchorage independent growth were aseptically picked at end of 21st
day of culture. Clones were grown in growth factor reduced media (DMEM F12, 5%
FCS, 4 ng/ml EGF, 2.0 ng/ml insulin, 100 ng/ml hydrocortisone, 1x penstrep) for 40-60
generations, then in growth factor depleted media (DMEM F12, 5% FCS, 1x penstrep)
onward. Clones were routinely assessed on collagen and HuBiogel for phenotypic
evolutions. p0 indicates transformed cells prior to colony assay, p44-p200 are phenotypes
of clone over several passages. Images were acquired with hand held Nikon digital
camera over an inverted microscope with 20x objective.
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Fig.5. Phenotypic Assessment of Transformed Cells
Clones from p121 cells were assessed for ductulogenesis, seeding phenotype and
invasiveness. A) Ductulogenic assay on collagen matrix. B) Invasive characteristics of
clone compared to MDA-MB 231 on matrigel 16 hrs post seeding. Data normalized to
MDA-MB, +/- SD. Histogram of invaded cells expressed as mean invaded cells per field.
C 1-II) Phenotypic assessment of clone versus wild type - 3 hrs post seeding and III-IV)
24 hrs post seeding.

Fig . 6. ROS Scavengers Attenuates Cell Transformation. To determine whether ROS
scavenger attenuates in vitro transformations of MCF-10A cells, we infected cells with
adenovirus over-expressing catalase or MnSOD at moi 100. Post infections, cells were
subjected to transformation regimen. For group that were treated with chemical
modifiers, this group were treated continuously with 40.0 uM ebselen throughout
transformation period except during recovery times. At end of transformations
procedures, cells were seeded for soft agar colony formation at 7.5 x 104 cells/well in 48
well plate. Assays were fed weekly for 3 weeks. Colonies formed in 4 wells were
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enumerated and scored as mean +/- SD. Images were captured with Nikon digital camera
over in inverted microscope with 4x objective. Fig 3A: (I) DMSO, (II) 4-OHE2, (III)
catalase infected cells, (IV) Catalase+4-OHE2, (V) MnSOD infected cells, (VI) MnSOD
infection+4OHE2, (VII) Ebselen treated cells (VIII) Ebselen treated cells + 4-OHE2. Fig
3B: Number of colonies per well. Data are means +/- SD of five plates. (**) Indicates
significantly different from control (DMSO) groups while (*) indicates significant
different from 4-OHE2, (P<0.05)

Figure 7. The growth of E2-induced transformed clone was inhibited by both
antioxidants, ebselen and N-acetyl cysteine. Cells were grown in 96-well plates for 2
days in 10% FBS DMEM/F12 and serum starved 2 days prior to addition of E2 for 18 h48 h unless specified otherwise. Bromodeoxy uridine (BrdU) incorporation assay was
used to measure DNA synthesis as indicator of apoptosis in transformed cells.
Antioxidants ebselen, NAC, and catalase were pretreated for 2 h prior to the addition of
E2. Colorimetric BrdUrd incorporation was measured at 450 nm with a plate reader.
Results are expressed as mean OD ± SD of three separate experiments with control set as
100% DNA synthesis. (**) Indicates treatment significantly different from control. (*)
Indicates treatment significantly different from E2. (P<0.05)
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Figure 8. E2-induced 3-D tumor spheroid formation was inhibited by ROS modifiers.
Spheroids were grown in a rotary vessel using HuBiogel, a memetic of human stromal
matrix in catalase over-expressing cells or ebselen treated cells. Cells were labeled with
CFSE using the Vybrant kit for checking viability. All spheroids showing the green
fluorophore (Right Upper Panel) indicate that cells in tumor spheroids are alive.

Fig. 9. Estrogen and its metabolites differentially activates PI3K/Akt signaling pathway
during mammary transformation. MCF-10A cells were seeded for transformation as
described in methods. At the end of transformation process, cells were treated for
additional 30 min with 100.0 ng/ml estrogens or its catechol metabolites. Cells were
harvested and lysed with RIPA buffer and PI3K and Akt proteins were
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immunoprecipitated with respective antibodies and fractionated on 12% SDS-PAGE
electrophoresis gel. Proteins were blotted onto PVDF membrane. Membrane were then
probed with (A) p85 (p-PI3K) and p110 subunits of PI3K respectively. (B)
Phosphorylated Akt (pAkt) and total Akt. Band intensity were quantified with Biorad
GelDoc 2000 and normalized to vehicle. (**) Indicates that E2 and 4-OHE2 treatment
group is significantly different from control (DMSO) groups while (*) indicates that other
treatments groups are significantly different from 4-OHE2. (P<0.05). Results are
expressed as mean fold change of three separate experiments.

Fig. 10. 4-OHE2 Activation of PI3K/Akt Signaling Pathway is Abrogated by Chemical
and Biological ROS Modifiers. MCF-10A were seeded and treated with Ebselen or NAC
during transformation regimen, or pre-infected with adenovirus expressing Catalase or
MnSOD, then subject to transformation regimen as described in methods. At the end of
transformation process, cells were treated for additional 30 minutes with 100 ng/ml 4135

OHE2. Cells were lysed with RIPA buffer and immunoprecipitated with PI3K and Akt
antibodies respectively. IP products were fractionated on 12% SDS-PAGE
electrophoresis gel. Proteins were blotted onto PVDF membrane. Membranes were then
probed with phosphorylated PI3K (p-PI3K) and PI3K, or phosphorylated Akt (pAkt) and
total Akt. Band intensity were quantified with Biorad GelDoc 2000 and normalized to
vehicle. (A) Immunoblot of activated PI3K and its modulation by biological ROS
modifiers at the end of transformation regimen. (B) Immunoblot of activated Akt and its
modulation by biological ROS modifiers at the end of transformation regimen. (C)
Immunoblot of activated PI3K and its modulation by chemical ROS modifiers at the end
of transformation regimen. (D) Immunoblot of activated Akt and its modulation by
chemical ROS modifiers at the end of transformation regimen. (**) Indicates that 4OHE2 treatment group is significantly different from control (DMSO) treatments groups
while (*) indicates treatment is significantly different from 4-OHE2, (P<0.05). Results
are expressed as mean fold change of three separate experiments.
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Fig. 11. 4-OHE2 induced Activation of Akt1 Mediates MCF-10A Neoplastic
Transformation . To ascertain whether Akt activations are involved during estrogen
induced mammary transformation, cells were transfected with shRNA for Akt1 or it
corresponding vector, and subsequently subjected to transformation regimen. After
transformation process, cells were used for soft agar colony assay, or treated for
additional 30 minutes then used for immunoblot. Cells were also seeded for
immunofluorescence labeling with anti Akt antibodies for confocal microscopy. Panel A:
I) DMSO, II) 4-OHE2, III) Sham Akt1 knockdown, IV) Sham Akt1 knockdown + 4OHE2, V) Akt1 knockdown, VI) Akt1 knockdown + 4-OHE2. (**) Indicates that 4OHE2 treatment group is significantly different from control (DMSO) groups while (*)
indicates that other treatments groups are significantly different from 4-OHE2, (P<0.05).
Panel B: Immunoblot of transformed cells expressing total Akt. Data is expressed as fold
difference of 3 experiments, OD ± SD. (*) indicates treatment is significantly different
from 4-OHE2, (P<0.05). Panel C: Immunofluorescence label of transformed cells
expressing total Akt, I) sham kd + DMSO, II) Sham kd + 4-OHE2, III) Akt1 kd +
DMSO, IV) Akt1 kd + 4-OHE2.
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Fig. 12. 4-OHE2 induced up-regulation of cell cycle gene during neoplastic
transformation of mammary cells is inhibited by ROS modulators
MCF-10A cells were seeded for transformation as described in methods. At end of
transformation period, cells were treated for additional 18 hours with vehicles or
estrogens after which they were washed with cold PBS containing protease inhibitors.
Cells were detached with trypsin and RNA isolated from 2.0 x106 cells, and 10ng RNA
were used for qRT-PCR analysis of cell cycle genes primers on ABI Real time PCR
machine. Data represents mean of 3 different experiments +/-SE, (P<0.05). (*) indicates
treatment significantly different from DMSO while (**) indicates significant difference
from 4-OHE2. A) Fold change of PCNA transcript in 4-OHE2 transformed cells treated
with ROS modulators, or transformed cells transfected with Akt1 RNAi. B) Fold change
of cell cycle genes in 4-OHE2 transformed cells overexpressing catalase.
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CHAPTER V
ESTROGEN-INDUCED REDOX SIGNALING OF NRF1 MEDIATES IN VITRO
GROWTH AND METASTASIS OF BREAST CANCER CELLS
Victor O. Okoh, Deodutta Roy
Department of Environmental and Occupational Health; Stempel College of Public
Health and Social Work
Florida International University. Miami Fl. 33199
ABSTRACT
We have shown earlier that chronic exposure to estrogen induces ROS production and
promote growth and metastasis of breast cancer cells via ER related pathways. Recently
nuclear respiratory factor 1 (NRF1), a transcription factor, known to regulate cell’s redox
status via mitochondria biogenesis has been implicated to play a role in breast
carcinogenesis. In this study we demonstrate that estrogen induced ROS mediated
signaling activates AKt activation which phosphorylates NRF1, a transcription factor,
known to play a critical role in mitochondrial biogenesis.

This is the first report to

demonstrate that exposure of MCF-7 cells to estradiol induced phosphorylation of AKt to
activate NRF1. Activated NRF1 then modulates estrogen induced growth and invasion of
MCF-7 cells in a redox dependent manner. Treatments of cells with ROS modulators or
knockdown of NRF1 diminished NRF1 expression as well as estrogen induced growth of
MCF-7 cells. These findings suggest that estrogen-induced redox signaling of NRF1 may
be required for in vitro growth and metastasis of breast cancer cells.
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INTRODUCTION
Excess estrogen (also referred to as E2 or estrogen) exposure is associated with breast,
endometrial and testicularovarian cancer [1-3]. Estrogens promote proliferation and
growth of cancer cells by activation of estrogen receptors (ER) and non-ER activation
pathways [1;2] While ER and regulatory gene altered by estrogen exposure may promote
growth of breast cancer cells, recent evidence suggest that reactive oxygen species (ROS)
may contribute in regulating survival, proliferation, growth and metastasis of breast
cancer [4-8].

The role of ROS in breast cancer is not new. Both in vitro and in vivo studies have
suggested that malignant breast cells compared to normal cells are under intrinsic
oxidative pressures [9-12], which may correlate positively with excess estrogen exposure
[13;14] and inefficient antioxidant systems [15]. These redox imbalances result in
accumulations of oxidants, such as, hydrogen peroxide (H2O2) and hydroxyl ions (-OH )
[16;17]. These oxidants can have significant consequences on the fate of cancer cells
ranging fromfrom apoptotic cell death, to proliferation, growth, metastasis and
therapeutic resistance [18-21]. However, the mechanism (s) involved in oxidative stress
and fate of breast cancer is complex and poorly understood. Several studies however
suggest that impaired redox mechanism induces dysregulated phosphorylation and
dephosphorylation of signaling proteins which activate or deactivate redox sensitive
transcription factors [22]. NRF1 (nuclear respiratory factor-1/alpha-palindrome-binding
protein) is one of the main transcription factors which are modulated in response to
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oxidative stress. , NRF1 is a redox sensitive transcription factor known to regulate
mitochondria biogenesis as well as oxidative phosphorylation (OXPHOS) [23;24].
OXPHOS is involved in the production of most of the mitochondria ROS. Dysregulated
and increased OXPHOS activity may result in excess ROS production which can have
deleterious effects onmtDNA integrity and ETC. [25]. Simultaneously, estrogens have
been shown to induce increased NRF1 expressions,OXPHOS activity [26] and ROS
production in mammary cancer cells [27]. Therefore, breast cancer tissues with
significant oxidative damages [5;14], possibly, are the source of mitochondria derived
oxidants via estrogen induced NRF1. This may also explain why ER+ breast cancer have
high mitochondria copy numbers [28], exhibit significant mtDNA damages [29-31] and
positively correlate with NRF1 expressions in higher grades [32;33]. .

In contrast, sublethal levels of ROS induce NRF1 expression which regulates the
mitochondria/DNA retrograde communication. If dysregulated, NRF1 can turn on genes
involved in carcinogenesis and metastasis of cancer cells [34]. That is why antiestrogenic
compounds such as raloxifene and tamoxifen likely fail upon prolong usage because
these compounds act as pro-oxidant upon chronic exposures [44-47] as well as inducers
of NRF1 [48].

NRF1 is predominantly associated with mitochondria regulation in response to oxidative
stress, genome wide in silico analysis however, revealed that this gene also regulates over
400 genes involved in cell cycle progression, metabolism, DNA replication, and
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transcriptional regulation [35], as well as genes involved in cell survival and growth [36],
invasion and metastasis [37;38].

In this study, we investigate whether estrogen-induced oxidants mediate in vitro growth
and metastasis of malignant breast epithelial cells and the mechanisms involved. Our
study revealed that estrogen induced NRF1 expression and its phosphorylation and
dephosphorylation activated by redox dependent cellular signaling mediate proliferation,
anchorage independent growth and metastasis of MCF-7 cells. Further, over-expression
of biological ROS scavengers (MnSOD and Catalase) or treatments of cells with
chemical antioxidant, (N-acetylcysteine (NAC) and ebselen), inhibited estrogen induced
NRF1 expression and growth of malignant breast epithelial cells.

MATERIALS AND METHODS
Cell Line and Cell Culture
Human mammary adenocarcinoma cell line (MCF-7) were obtained from American Type
Culture Collection (ATCC) and were routinely cultured in phenol red-free DMEM/F12
media with 10% (vol/vol) FBS, 1x penstrep. DMEM/F12 Media. FBS and antibiotics
were purchased from Invitrogen corp. For experiments , cells were seeded at 10-75%
confluency depending on the experimental designs and incubated at 37°C in a humidified
incubator containing 5% CO2and 85% humidity. Cells were allowed to adhere for 24 hrs.
after which culture medium were replaced with serum-free media (SFM) containing
penicillin-streptomycin (100 μg/ml each) and cells were allowed to grow for 48 hrs.
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Serum deprivation was used to synchronize cells in the G0/G1 phase of the cell cycle
followed by treatments with estrogens or antioxidants, as described in the figure legends.

Measurement of Reactive Oxygen Species (ROS)
Cellular ROS were measured as previously described [27]. Briefly MCF-7 cells were
seeded at a concentration of 1.0 × 104 cells per well in black 96-wells plate with clear flat
bottom (ThermoFisher Scientific Inc. USA) and allowed to adhere overnight. Next day,
cells were cultured in SFM for 48 hrs. They were then pretreated for 4 hrs with chemical
antioxidants [ebselen and N-acetyl cysteine (NAC)] diluted in Hank's balanced salt
solution (HBSS), followed by incubation with 10 µM 2',7'-dichlorofluorescin diacetate
(DCFH-DA) (Invitrogen Corp.) for 20 min. Cells were rinsed with HBSS followed by
various treatments with 100 pg/ml estrogens as described in the figure legends. DCFHDA is a non-fluorescent cell-permeable compound, which is acted upon by endogenous
esterases that remove the acetate groups generating DCFH. In the presence of
intracellular ROS, DCFH is rapidly oxidized to the highly fluorescent 2',7'dichlorofluorescein (DCF). The oxidative products is then measured with a Tecan Genios
microplate reader using 485 and 535 nm as excitation and emission filters, respectively.
DCFH-DA stock solutions were diluted at a 1:1 ratio with Pluronic F-127 (20% w/v).

RNAi transfections
Pre-designed and tetracycline inducible human shRNA for mitochondria transcription
factor A (TFAM) and Akt1 shRNA with corresponding vectorcontrol were purchased
from OriGene (OriGene Technologies, Inc. Rockville, MD). Pre-designed NRF1 siRNA
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and corresponding scrambled constructs were purchased from Ambion (Applied
Biosystems/Ambion, Austin, TX). Plasmid over-expressing NRF1 were custom made by
OriGene (Rockville MD) and FLAG tagged DN-NRF1 is a kind gift from Dr. Liu. All
purified plasmids were transfected into 35% confluent MCF-7 cells using FuGENE 6
(Roche) transfection reagents according to the manufacturer's protocol. Transfection
efficiencies for all plasmid were determined by protein expression levels which ranged
from 50% to 80% reductions in respective gene expressionsThe concentration of
plasmids used for transfections in all experiments was as recommended by Roche and
were based on surface area of dishes used for each experiment. Post transfection, cells
and their lysates were used for western blot analysis, BrdU, soft agar assays and invasion
assays as described in subsequent sections.

BrdU cell proliferation assay
MCF-7 cells were seeded in 96-well plates at a density of 3,500 cells/well and incubated
overnight. Cells were plated in quadruplicate for each experimental group. After 24 hrs of
incubation cells were cultured in SFM for 48 hrs. Cells cells were the treated with E2
(100 pg/ml) in the presence or absence of antioxidants for 18 hrs. Cell proliferations were
measured by colorimetric immunoassay of BrdU incorporation into the DNA using
Roche BrdU cell labeling kits as recommended by manufactures (Roche Molecular
Biochemical, Indianapolis, IN). Briefly, cells were pulsed with BrdU labeling reagent for
3 hrs followed by fixation in FixDenat solution for 30 min at room temperature.
Thereafter, cells were incubated with 1:100 dilution of anti- BrdU-POD for 1 h at room
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temperature. Finally, the immunoreaction was detected by adding the substrate solution
and the color developed was read at 370 nm with a Tecan Genios microplate reader.

Adenovirus Transduction
Adenoviruses over-expressing MnSOD (SOD), Catalase (Cata) or control vectors were
purchased from ViraQuest, Inc. (North Liberty, IA, USA). MCF-7 cells were seeded into
appropriate dishes at 15-70% confluence depending on the experimental design. Next
day, cells were infected with Adenovirus over-expressing SOD, Catalase or vector at
either moi 50 to 400 in SFM. Cells were cultured for 48 hrs after which they were used
for various experiments.
Chemical antioxidant treatments
The treatment procedure for Ebselen (a glutathione peroxidase mimetic which also
removes both H2O2 and peroxynitrite) and NAC (a precursor of glutathione and
scavenger of ROS [49;50] differs according to the experiments to be performed. For
example, in DCFH assays used to measure intracellular ROS in live cells, 40 µM and 1.0
mM ebselen and NAC respectively were pre-loaded onto cells 2-4 hrs before ROS
measurement were commenced. For BrdU assays, cells were treated with 40 uM and 1.0
mM ebselen and NAC respectively throughout the culture periods. For anchorage
independent growth assays, antioxidants were mixed with cells and agar matrix before
assay commenced, and added to media during bi-weekly feeding of colonies. For
immunoprecipitations (IP) and western blot analysis, cells were exposed to a single
treatment with these antioxidants during 48 hr culture in SFM before western analysis. .
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Cell viability assay
CellTiter-Fluor™ Cell Viability kit were purchased from promega corporation and
according to manufacturer’s instructions assay was conducted. Briefly, cells were seeded
in 96 well plate at 1.0x104 cells/well, culyuired in SFM for 48 hrs post seeding, and
treated accordingly with estrogens and antioxidants. At the end of the treatments ,
substrate reagent (GF-AFC) were mixed with substrate buffer and dispensed into well.
This assay measures cell’s protease activities as quiescent and growth arrested cells are
still viable even if mitochondria activities or oxidant levels are diminished. Plates were
read on fluorescence plate reader at 380–400 nm excitations and 505 nm emissions.
Western Blot Assays
Cells for western blot analysis were seeded in T-75 flasks and grown to 70% confluence
and manipulated according to experimental designs. Post treatments, cells were harvested
in radioimmune precipitation buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% Nonidet P40, 0.1% SDS, 50 mM Tris) containing protease and phosphatase inhibitors (Roche).
Equal amounts of total cellular protein were mixed with loading buffer (25% glycerol,
0.075% SDS, 1.25% 2-mercaptoethanol, 10% bromphenol blue, 3.13% stacking gel
buffer) and fractionated by electrophoresis on 12% polyacrylamide, 0.1% SDS resolving
gels. Rainbow marker (Biorad USA) was used as the molecular weight standard. Proteins
were transferred to PVDF Immobolin-P transfer membranes (Millipore) using transfer
buffer [25 mM glycine, 25 mM ethanolamine, and 20% methanol]. The membranes were
blocked one hour at RT with blocking buffer [1×phosphate buffered saline, 0.1% Tween-
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20 with 5% (w/v) nonfat dry milk (PBS-T)]. Blots were subsequently incubated for 2 hr
at room temperature with various antibodies as indicated in legends.

Immunoprecipitation
For experiments to determine epigenetic modifications of NRF1, cells were seeded in T75 and grown to 70% confluence. Post treatments, cells were rinsed twice with PBS,
harvested with lysis buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% Nonidet P-40, 0.1%
SDS, 50 mM Tris) containing protease and phosphatase inhibitors (Roche). Whole cell
lysates (WCL) were diluted to 500 µg of protein in 1 ml of lysis buffer, and samples
were pre-cleared for 1 hr at 4 °C with 40 µl of a 1:1 slurry of protein A-agarose beads
(Invitrogen Corp) in lysis buffer and 1 µg of rabbit IgG. After a brief centrifugation to
remove pre-cleared beads, 0.5 µg of anti-NRF1 antibody was added to each sample and
incubated on a rocking platform at 4 °C overnight. Captured proteins were pulled down
(precipitated??) by the addition of 10 µl of protein A-agarose beads to each sample and
the slurries were incubated on the rocking platform at 4 °C for 2hrs. The beads were then
washed five times with lysis buffer and resuspended in 40 μL of 1×SDS electrophoresis
sample buffer [50 mM Tris–HCl (pH 6.8), 100 mM dithiothreitol, 2% SDS, 0.1%
bromophenol blue, and 10% glycerol], resolved on 12% SDS-PAGE electrophoresis and
transferred onto a PVDF nylon blotting membrane. To determine whether serine residues
of NRF1 are phosphorylated due to treatment, blot was probed with 1-5000 mouse
monoclonal antibody against phosphoserine residue (Santa Cruz Biotech). To determine
whether treatments induced modulations of NRF1 correlates with TFAM, one of its
effector, WCL from same group were immunoprecipitated with rabbit anti mtTFA and
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probed with mouse against mtTFA. All primary antibodies were diluted 1:1000 and
detected after incubation with horseradish peroxidase(HRPO)-conjugated secondary
antibody diluted 1:50,000 PBS-T. Blots were treated with ECL reagents (Amersham
Biotech), and all proteins were detected by autoradiography.

Anchorage independent Growth
Anchorage-independent growth assays were performed as previously described [51].
Briefly, base support agar were made fresh by diluting 1.0% molten agarose mix with 1:1
with 2x culture media (2x DMEM/F12 media, 20% HS, 2x Penstrep antibiotics and 200
pg/ml estrogens) to a final of 0.5%. molten agar were maintained at 42 oC water bath
until dispensed at 200 l/well in 48 well plates, then allowed to solidify for 4 hrs at room
temperature. Top agarose overlay were made fresh by mixing 0.7% molten low melting
point (LMP) agarose with 2x culture media containing appropriate 5000 cells/well, then
gently overlaid over preformed base agar. Cells were incubated for a minimum of 21
days in 37°C incubator with 5% CO2. Cultures in 48 well plate were fed once every
week with 200l of 0.5% melted agar in growth media.

Colonies of separate cell

aggregates at 100M or greater in size, as measured with metamorph software (Nikon
Corporation, USA) were counteds. Images were acquired by Olympus C-5060 digital
camera under an inverted microscope with 4x objective.

Invasion Assay
The in vitro invasion assay was carried out to examine tumor cell invasiveness as
described previously [52] with some modifications. Briefly, 24-well Transwell unit with
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8 μm polycarbonate Nucleopore filters (Corning) were coated with 60 μL of 0.8 Matrigel.
MCF-7 cells (1 × 105) transfected with plasmid overexpressing NRF1 or null were placed
in the upper compartment, and the medium containing 10% fetal bovine serum was added
to the lower compartment. For group treated with NAC, the chemical ROS modifier was
added to media in the lower chamber to a concentration of 1.0 mM. The Transwell plates
were incubated at 37°C for 48 and 72 hrs accordingly. Cells invaded to the lower surface
of the membrane were stained with Giemsa staining and observed using light microscope.
The invading cells were stained and counted per insert and photographed. Experiment
were conducted in triplicates and repeated three times.

Statistical analysis
Results are expressed as mean ± S.D. Differences between means were evaluated by twotailed Student's t-test. ANOVA was used to determine differences between groups.

RESULTS
Estrogen induced ROS levels mediate proliferation and growth of MCF-7 cells in vitro
Estrogens have been reported to modulate mitochondria ROS production in MCF-7 cells
and other cell types [27;53]. These ROS are postulated by us and other [20;47;54;55] to
mediate proliferation and growth of subsets of breast cancer cells. To test this hypothesis,
biological ROS modulators (MnSOD and catalase) were oveerexpressed in MCF-7 cells ,
or cells were pretreated with chemical ROS modulators, 40 μM ebselen or 1.0 mM
NAC). These cells were then challenged with 100 pg/ml estrogens. Data reveals that
treatment of cells with estrogen alone increased ROS production and DNA synthesis
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whereas treatment with catalase alone (moi 50) diminished ROS production and DNA
synthesis. However, co-treatment of cells with catalase (moi 50) and estrogen
significantly increased ROS level and DNA synthesis beyond catalase alone infected
groups. Interestingly, similar trends were observed in MnSOD infected cells at moi 50
though the magnitude in ROS production and DNA synthesis is significantly more than
that observed in estrogen or catalase treated groups (Fig. 1A). Both chemical ROS
modulators used in this experiment also diminished ROS production and DNA synthesis.
However, when cells were infected with adenoviruses at moi of 200, catalase diminished
estrogen induced ROS production and DNA synthesis while

MnSOD significantly

increased ROS production and dramatically reduced DNA synthesis compared to cells
treated with moi 50 (Fig 1B). To resolve the inverse correlation of MnSOD overexpression at moi 200 and DNA synthesis, we infected cells with various viral loads of
MnSOD expressing viruses; and as control, we also infected cells transfected with control
adenovirus vectors at moi 50. Infected cells were then used for colony assay and
monitored for anchorage independent growth for three weeks. We observed that low viral
MnSOD load (moi 5-50) promoted increased number and size of colonies (Fig. 2B, C)
whereas viral load higher than moi 50 induced diminished cell growth (Fig 2D-G).
Adenovirus containing control vectors at moi 50 did not induce growth advantage over
corresponding MnSOD expressing adenoviruses indicating that it’s the overexpressed
MnSOD that is modulating cell growth. However, to ascertain whether the observed
cancer growth retardation of MnSOD infection is higher than moi 50 is due to cell
lethality, we stained single cell population from all virus infected groups (control,
catalase and MnSOD) with trypan blue solution and found that over 70% of the cells
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infected with virus up to moi 200 were viable whereas 90% of moi 400 and above
infected cells were not viable after 21 days of cultures in soft agar assay (data not
shown). Since moi 200 infected cells were viable up to 21 days, we chose this viral load
for subsequent experiments. The effects of ROS modulators on estrogen induced growth
of breast cancer were further evaluated byco-treatment of MCF-7 cells with estrogen and
biological or chemical ROS modulator. It wasfound that these antioxidants significantly
inhibited estrogen induced growth of MCF-7 cells in vitro (Fig 3).

Estrogen induced oxidants activate Akt signaling pathway which contributes to in vitro
growth of MCF-7 breast cancer cells
The mechanisms by which estrogen induce cell proliferations and growth of estrogen
responsive breast cancer cells are attributable to ER mediated process. It has been shown
that upon estrogen stimulations, cells secrete growth factors which activate receptor
tyrosine kinases and initiation of complex signaling cascade of phosphorylationdephosphorylation reactions that subsequently leads to cancer cell growth and metastasis
[56]. One such signaling pathway activated by estrogen exposure that leads to survival
and growth of MCF-7 cells is the PI3K/Akt signaling pathways [57;58]. Oxidants such as
superoxides and hydrogen peroxides have likewise been reported to activate this
signaling pathway which mediates survival and growth of exposed cells [18-20]. To
determine whether E2 induced oxidants can activate PI3K/Akt signaling pathway and
whether ROS scavengers or inhibitors of PI3K would mitigateAkt phosphorylation,
MCF-7 cells were either infected with biological antioxidants, or pretreated with
chemical ROS scavengers (ebselen, NAC) prior to estrogen treatments as described in
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methods. Whole cell lysate were resvolved on 12% SDS-PAGE gel, and probed with
appropriate antibodies. Data reveals that 100 pg/ml estrogen treatment induced Akt
activation which were inhibited by chemical or biological antioxidants as well as by
LY294002, an inhibitor of PI3K which regulates Akt activations (Fig 4). These findings
support the hypothesis that oxidant (ROS) induced by estrogen exposures can activate
Akt signaling proteins and activated Akt has been demonstrated to favor survival,
proliferation and growth of cells during periods of oxidative stress [59;60].

Estrogen induced Akt activation phosphorylates NRF1 which promotes growth of
responsive cells
Cellular responses to oxidants are mediated in part, by redox activation of NRF1 which
regulates mitochondria biogenesis and cellular antioxidant responses [61;62]. NRF1 has
been reported to be trans-activated by Akt phosphorylation of its serine/threonine residue
in response to growth factors and oxidative stress [62-64]. Trans-activated NRF1 are
believed to mediate cellular responses to oxidative stress such as mitochondria
biogenesis, restoration of redox homeostasis and induction of survival and proliferation
mechanisms of cells [42].
Similarly, treatments of MCF-7 cells with 100 pg/ml estrogen for 45 minutes induced
rapid serine phosphorylation of NRF1 (Fig 5) which were abrogated by both chemical
and biological ROS modulators.

In addition, silencing of Akt1, the Akt isoform

implicated in mediating cell survival and growth [65-67] likewise reduced NRF1
phosphorylation, and anchorage independent growth of MCF-7 cells (Fig 6). These
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findings imply that estrogen induced oxidants modulate NRF1 expressions. It also
implies that redox activations of Akt signaling in response to estrogen exposures
phosphorylate and tran-sactivates NRF1. The absence of Akt1 expression leads to
reduced NRF1 phosphorylation and reduced growth of MCF-7 cells exposed to estrogen.
NRF1 expression promotes in vitro proliferation and growth of estrogen responsive
breast cancer cells
In order to show that NRF1 are implicated in the mediation of growth of breast cancer
cells in vitro, NRF1 was silenced in MCF-7 cells. Cells were then cultured with or
without estrogens for 21days. Colony formation, growth and viability of cells in soft agar
assays were measured. Data reveals that estrogen increased colony formation growth in
control knockdown groups (Null kd) comparable to the untransfected cells (Fig 7B i-iv).
However, estrogen fails to induce colony formation or colony growth of NRF1 silenced
cells implying that NRF1 are essential in the mediation of estrogen induced in vitro
growth of MCF-7 cells (Fig 7B v,vi). To test whether reduction in growth is due to cell
death because of NRF1 knockdown, cells from soft agar plates were counted for cell
viability per 1000 cells using trypan blue exclusion assays. We found that while there
were differences in cell death due to NRF1 status, differences were not significant to
account for observed lack of colony formations or growth of cells in NRF1 knockdown
versus Null kd cells (data not shown). In addition, immunoprecipitation analysis of NRF1
expression and phosphorylation status revealed that Null kd cells expresses increased
NRF1 protein and exhibit increased phosphorylation in response to prolonged estrogen
exposure (Fig 7A,B). Silencing of NRF1 however, inhibits its expression or
phosphorylation in response to chronic exposures to estrogens (Fig 7C). To confirm that

153

NRF1 is indeed responsible for this observation, the expression levels of mtTFA, one of
the genes targeted by NRF1 expression [68] was assessed. Western blot analysis of cell
lysates from Null kd vs NRF1 knock down revealed a positive correlation between NRF1
and mtTFA expressions; i.e. up regulation of NRF1 leads to up regulation of mtTFA and
vice versa (Fig 7). To confirm NRF1’s role in growth regulation of MCF-7 exposed to
estrogens, we overexpressed NRF1 (NRF1ox) or its DN-NRF1 and assessed in vitro
proliferation and growth in response to estrogens. We observed that while overexpressing NRF1 enhanced estrogen induced proliferation and growth of MCF-7 cells,
over-expressing DN-NRF1 actually reduced estrogen mediated proliferation and growth
of MCF-7 cells (Fig. 8). Interestingly however, the effects of NRF1ox alone were
significantly greater than E2 treated control cells in both soft agar and BrdU assays.

NRF1 over-expression modulates invasion of MCF-7 cells
NRF1 has been implicated in the modulation of various protease expressions involved in
cell migration and spreading. Proteases include the calpains [37] whose over-expression
is implicated in tumorigenesis, metastasis and angiogenesis in breast cancer and other
cancer types [69;70], GalNAc-T3 genes that function in glycosylation of mucin proteins
in epithelial derived tumors [71] which is also plyas a central role in invasive mammary
[72] and colorectal [73] carcinoma. In this study, in vitro invasion assay of MCF-7 cells
overexpressing NRF1 displayed a threefold increase in invading cells compared to vector
or non transfected (NT) group (Fig. 9A). NRF1ox cells when transfected with DN-NRF1
or treated with ebselen showed significantly higher number of cells compared to the
control MCF-7 cells trasnfected with vector/DN-NRF1 alone and also treated with
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ebselen. (Fig. 9B). In addition, groups treated with estrogen also had significantly more
invading cells and mucosal environment compared with groups treated with vehicle (Fig
9B). These findings indicate that NRF1 participates in cell invasion in a redox dependent
manner.

DISCUSSIONS
Estrogens are chemicals capable of promoting growth of breast cancer cells via ER and
non-ER mediated pathways. Estrogens induce ROS via mitochondria biogenesiss. At
sublethal levels, these ROS induce redox signaling that participate in growth of estrogen
exposed breast cancer cells [27;74;75]. In this study, we provide evidence that estrogen
induced ROS are essential for proliferation and malignant growth of estrogen responsive
breast cancer cells. We also report that the mechanism involves redox activation and
phosphorylation of NRF1 because over-expression of biological ROS scavengers or
treatment of cells with chemical antioxidants inhibited NRF1 activation which in turn
reduced estrogen mediated growth and metastasis of breast cancer cells.

The role of estrogen induced oxidants in breast carcinogenesis has long been established
[76-79]. However, the role of these oxidants in mediation of growth of cancer cell
remainscontroversial. In this study, we observed that treatments of MCF-7 cells with a
dose comparable to physiological level of estrogen induced intracellular ROS which
promoted in vitro growth of breast cancer cells. Conversely pre-treatment of cells with
chemical or biological antioxidant prior to estrogen exposure inhibited induced ROS
formation and in vitro growth of cells. These observations implies that the growth
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promoting properties of estrogen in breast cancer cells are mediated in part by estrogen
induced oxidants as ROS scavengers abolished estrogen induced growth of breast cancer
cells. These findings are in line with other reports which indicate that sublethal levels of
oxidants induce significant mitogenic effects on a number of gynecological cancers [8082] including breast cancer [4;54;83]. It may also explain the aggressive nature of breast
cancer attained after therapeutic failures because these therapeutic agents also act as prooxidant upon their prolonged use [44-47]. Nonetheless, the initial antiproliferative
responses of these chemotherapeutic agents may be due to their antioxidant properties
[84-87].

Our group and others have reported that mitochondria is a major source of estrogen
induced ROS [27;75] in breast cancer cells. We investigated whether altering
mitochondria MnSOD activity would modulate estrogen induction of intracellular ROS
and growth of breast cancer cells. We found that infection of MCF-7 cells with
adenovirus overexpressing MnSOD at moi 50 increased intracellular ROS production, as
well as increased proliferation and growth of MCF-7 cells. However, when cells were
infected with adenovirus at moi 200, ROS production increased significantly compared to
ROS from moi 50 infected cells, but cell proliferation and growth decreased significantly.
ROS production from moi 50 infected cells correlated positively with DNA synthesis and
growth of MCF-7 cells, however, the effects of estrogen exposure on MnSOD expressing
cells were statistically insignificant. This implies that the mitogenicity observed in these
cells are due entirely to mitochondria ROS and not by estrogens exposures. Therefore,
while we were able to show a direct correlation between intracellular ROS production
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and cell growth in response to estrogen exposure, we were unable to show any significant
combinational effects between estrogen exposures, MnSOD overexpression and cell
growth even though our data does indicates a correlation between MnSOD expression
and cell proliferation.
It has been reported that ROS mediates mitogenic activation of the PI3K/Akt signaling
pathway which promotes survival and growth of exposed cells [88;89]. Estrogens has
likewise been demonstrated to activate PI3K/Akt signaling pathway in endometrial and
breast cancer cells, in an ER dependent and independent manner [90;91]. However,
whether oxidants mediate estrogen induced activation of PI3K/Akt signaling in breast
cells and whether Akt activation is linked with growth of these cells is not clear. In our
study, we observed that estrogen induced Akt activation in breast cancer cells were
diminished by catalase over-expression and by chemical ROS scavengers. Whether
oxidant activation of Akt in estrogen exposed cells is associated with proliferation and
growth regulation is not known. To investigate this possible link, we silenced Akt1, an
Akt isoform known to be involved in regulating mammary tumorigenesis and growth of
cancer cells [65;92]. Wefound that knocking down this gene diminished estrogen induced
proliferation and growth of MCF-7 cells. While Akt is a global activator of a number of
transcription factors with diverse physiological functions, our data suggest that estrogen
activation of Akt in breast cancer cells are also ROS mediated and activation of Akt
signaling cascades are essential in transducing signaling processes that favors survival
and growth of breast cancer cells.
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Activated Akt promotes cell survival and growth via a number of mechanisms. For
example, Akt phosphorylates and deactivates pro-apoptotic factors such as BAD,
Caspase-9, and Forkhead transcription factors (FKHR) as well as other pro-survival
transcription factors [93]. Other targets of activated Akt in response to oxidative stress
includes NRF1, a redox sensitive gene known to regulate transcription of genes involved
in antioxidant responses, apoptosis, as well as regulation of mitochondrial biogenesis
[62;94-96]. Oxidant mediated phosphorylation of NRF1 are thought to induce nuclear
translocation and transcriptional regulation of various cellular response such as
restoration of redox homeostasis, enhancement of cell survival and growth, as well as
regulation of mitochondria biogenesis [97]. Prolong estrogen exposure has likewise been
reported to up-regulate NRF1 expressions via ER alpha (ERα) mediated mechanisms in
MCF-7 cells which leads to increased mitochondria biogenesis in these cells [26]. While
this observation is novel, others have reported that sodium butyrate, a non estrogenic but
pro-oxidative compound [98] also induces NRF1 expression in MCF-7 cells [71].
Furthermore, SERMs such as TAM, RAL and Fulvestrant which are all pro-oxidant upon
chronic exposures [99], also increases NRF1 expression in SERM resistant MCF-7 cells
[100]. These studies all suggest that estrogen inductions of NRF1 in estrogen responsive
or resistant breast cancer cells are not exclusive to ER status. It implies that perhaps
estrogen induced oxidants may also mediate NRF1 expression in breast cancer cells
irrespective of ER status.

Here, we report that exposure of MCF-7 cells to estrogen not only up-regulates NRF1
expressions, but it also induces NRF1 phosphorylation by Akt in a redox dependent
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manner. Treatment of cells with ROS modulators or silencing of NRF1 fail to mediate
estrogen induced NRF1 expressions and phosphorylation, and inhibited growth of breast
cancer cells. While ERα is believed to regulate estrogen induced NRF1 expression in
MCF-7 cell line [26], our data indicates that estrogen induced oxidants are essential for
NRF1 expressions and phosphorylation. Upon phosphorylation, this transcription factor
is believed to translocate into the nucleus where they regulate mitochondria biogenesis,
oxidative phosphorylation and mediates oxidant induced survival and growth of breast
cancer cells, by unknown mechanism. These observation are in agreement with reports
that have shown NRF1 is phosphorylations by oxidants in rat hepatoma cells promoting
survival and growth of during periods of oxidative stress [62]. Our data may also explain
the observation that despite the high oxidative environment of breast cancer cells in vivo
[11], these cells survive, proliferate and grow as opposed to undergoing apoptosis and
cell death. Activated NRF1 may also cause cancer cell metastasis, therapeutic failures
and poor prognosis of breast cancer patients as oxidative stress are associated with
metastasis and drug failures in a number of malignancies including breast cancer
[101;102]. In addition, it has been reported that estrogen and insulin induce proliferation
and growth of MCF-7 cells via NRF1 activation [103], but insulin, with estrogens also,
act as pro-oxidants [104;105] and activate Akt signaling pathways [106;107] in a variety
of cells types. It is therefore feasible that the pro-oxidative properties of estrogen alone or
in combination with insulin promote survival and growth of breast cancer cells through
persistent expressions and phosphorylation of NRF1.
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In summary, overexpression of MnSOD and Catalase or treatment with antioxidant
ebselen selectively inhibited cell proliferation and invasion of MCF-7 cells that were
transfected with NRF1. Also, knocking down Akt isoform in estrogen treated cells that
has been shown to phsphorylate NRF1 reduced the rate of cell proliferation. It appears
therefore, that the level of NRF1 expression indicates a redox state of breast cancer cells
and activation of NRF1 via Akt pathway is a key modulator of estrogen induced breast
cancer cell proliferation and metastasis.
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FIGURES AND LEGENDS

Fig. 1. Estrogen induced ROS mediates in vitro proliferation of MCF-7 breast cancer
Cells. 3500 cells/well were seeded in 96well plate for BrdU cell proliferation assays and
1.0x10^4cells/well for ROS production assays. Next day, cells were infected with
Adenovirus over-expressing MnSOD or Catalase at either moi 50 or 200 in serum free
media. Other group of cells was treated with 40μm ebselen and 1mM NAC diluted also in
serum free media. Cells were cultured for 48hrs and assayed for ROS production or BrdU
assays. For ROS assays, cells were pretreated for 4hrs before assay with ebselen and
NAC after which 10μM DCF were loaded onto the cells for 20mins, then cells were
challenged with 100pg/ml estrogen, and ROS readings were taken every 5mins on Tecan
plate reader. For cell proliferation assays, 48hrs post infections, wells were challenged
with 100pg/ml estrogen and allowed to incubate for additional 18hrs after which BrdU
assay were carried out with Roche BrdU assay kit. (A) MCF-7 cells infected with
catalase or MnSOD at moi 50, or treated chemical antioxidant, then challenged with
estrogen. (B) MCF-7 cells infected with catalase or MnSOD at moi 200, or treated
chemical antioxidant, then challenged with estrogen. ROS production upon E2 challenge
was compared with DNA synthesis. Data is expressed as standard error of mean of three
experiments, (+/- SE). (*) indicates significant different from control group. (*#)
indicates treatment significantly different from E2 treated group. (P<0.05)
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Fig. 2. Differential effects of ROS production on in vitro growth of MCF-7. MCF-7 cells
were infected with various concentrations of MnSOD over-expressing viruses for 24hrs
after which cells were detached and seeded for soft agar assays such that each well in 48
well plate had 5000cells/well. Cells were incubated for 5weeks with weekly feeding.
Colony numbers and sizes were scored using Nikon metamorph software and expressed
as mean of five wells, +/- SD. (*) indicates significant difference from control group (null
moi 50), (P<0.05). Representative Images were acquired with hand held Nikon camera
over an inverted microscope with 4x objective. A) AdEmpty (Null) moi50, B)
AdMnSOD Moi 5, C) AdMnSOD moi 10, D) AdMnSOD moi 50, E) AdMnSOD moi
100, F) AdMnSOD moi 200, G) AdMnSOD moi 400, H) Mean colony and size numbers
compared to null vector.

Fig 3. ROS Scavengers inhibits E2 induced growth of MCF-7 cells. Cells were infected
with biological antioxidants for 24hrs in serum free media and allowed to recover
afterwards. 1.0x10^4 cell pellet was resuspended with 500ul 2x culture media containing
100 pg/ml E2 or 40 µM ebselen. Cell suspensions were then mixed 1:1 with 0.5% molten
agarose and over layered on precast bottom agarose in 48 well plate. Cultures were
allowed to incubate for 3-5wks with weekly feeding and images were acquired with a
hand-held Nikon digital camera over 4x inverted microscope. Qudruplicate wells were
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counted and expressed as mean three experiments +/- SE. (Panel A: Chemical antioxidant
treatment group) (I) DMSO, (II) 100pg/ml E2, (III) Ebs, (IV) Ebs/E2, (V) NAC, (VI)
NAC/E2. (Panel B: Biological antioxidant treatment group) (I) DMSO, (II) 100pg/ml
E2, (III) Cata, (IV) Cata/E2, (V) MnSOD, (VI) MnSOD/E2. (*) indicates significant
difference from control group. (**) indicates significant difference from E2 treated
group, (P<0.05).

Fig. 4. Estrogen induced activation of Akt is abrogated by ROS scavengers. MCF-7 cells
were either pre-infected with MnSOD or catalase at moi 50 and cells seeded for
experiment, or cells were seeded and treated with 40 µM ebselen, 10μmol/L LY294002
(LY) and 1.0μM Rotenone for 48 hrs in starvation media. At end of starvation periods,
cells were harvested and lysed with RIPA buffer, and 100 ug total proteins were
fractionated in SDS PAGE electrophoresis gel. Blots were probed for phosphorylated Akt
(pAkt) and total Akt and band intensity were quantified with Biorad GelDoc 2000 and
normalized to vehicle. (A) Representative Immunoblot probed for pAkt and total Akt. (B)
Densitometry of pAkt normalized with total Akt and expressed as fold change vs.
DMSO. (**) indicates significant difference from control group. (*) indicates significant
difference from E2 treated group, (P<0.05).
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Fig. 5. Estrogen induced NRF1 activation is abrogated by ROS scavengers. To determine
whether ROS scavengers mitigates estrogen induced activations of NRF1 in breast
cancer, MCF-7 cells were seeded, infected with catalase or MnSOD, or with 40uM
ebselen and estrogen as previously described. Lysate were immunoprecipitated with
NRF1 and immunoblot probed with anti serine antibody (pNRF1) or NRF1 antibody. For
loading control, 50 ug whole cell lysate (WCL) were fractionated and blot probed with
beta actin (actin). Band intensity of pNRF1 was compared with NRF1, and then
normalizes with DMSO from NT group. Representative data of 3 experiments is
presented above. (Panel A) Non transfected group (NT) treated DMSO or E2, (Panel B,
C) Catalase or MnSOD infected groups respectively, and then treated with DMSO or E2.
(Panel D) Ebselen and E2 co-treated group. (E) Densitometry of pNRF1 normalized with
total NRF1 and expressed as fold change vs. DMSO in NT group. (**) Indicates that E2
treatment group is significantly different from control (DMSO) groups while (*) indicates
that other treatments groups are significantly different from E2 treatment groups. Data is
expressed as mean of 3 experiments, OD ± SE, (P<0.05).
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Fig. 6. Akt phosphorylate and activate NRF1 which mediate in vitro growth of MCF-7
cells. To determine role of Akt and NRF1 phosphorylation in estrogen induced growth of
breast cancer cells, MCF-7 cells were transfected with pre-designed and verified Akt1
shRNA plasmid or its vector for 72 hrs with FuGENE 6 transfection reagent without
change of media. Post transfection, cells were seeded for colony assay, or challenged
with 100 pg/ml estrogen or DMSO for 30 mins. Cells were then harvested with RIPA
buffer and 500 ug total protein was IP with NRF1, fractionated on SDS-PAGE and blots
probed with serine antibody. 50 ug of WCL was also fractionated on SDS-PAGE gel and
probed for total Akt, and β actin as experimental loading control. Band intensity were
measured with Biorad versadoc 2000 software and expressed as fold change from
DMSO. (Panels A and B) Western blot analysis of vector and Akt1 shRNA plasmid
transfected into MCF-7 cells then treated with DMSO or E2. (C D) Band intensity of
NRF1 phosphoserine (pNRF1) normalized to total NRF1, and Akt normalized to actin
respectively. (E-J) Representative pictures colonies from soft agar assay after 3 weeks
incubation, and expressed as mean +/- SE of three experiments. (E) DMSO, (F) E2, (G)
vector- kd/DMSO, (H) vector- kd/E2, (I) Akt1 kd/DMSO, (J) Akt1 kd/E2, (K) Fold
increase of colony formation versus DMSO. (**) Indicates that E2 treatment group is
significantly different from control (DMSO) groups while (*) indicates that other
treatments groups are significantly different from E2 treatment groups. Data is expressed
as mean of 3 experiments, OD ± SE, (P<0.05).
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Fig. 7. Silencing of NRF1 attenuates estrogen induced in vitro growth of MCF-7.
MCF-7 cells were transfected with shRNA vector or NRF1 shRNA plasmid for 96 hrs.
Post transfection, cells were seeded for colony assays or treated with DMSO or 100 pg
E2 for 30mins, then harvested and lysed with RIPA buffer. 500 ug total proteins were coimmunoprecipitated with anti NRF1 antibody, and blots probed with either anti NRF1,
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anti phosphoserine and anti mtTFA antibodies. (Panel A) Non transfected cells (NT)
probed with anti serine, anti NRF1, anti mtTFA and anti actin respectively. (Panel B)
Vector transfected cells probed with anti serine, anti NRF1, anti mtTFA and anti actin
respectively. (Panel C) NRF1 kd cells probed with anti serine, anti NRF1, anti mtTFA
and anti actin. (D-F) Densitometry of NRF1 knocked on (D) phosphorylated NRF1
compared to total NRF1, (E) total NRF1 compared to actin. (F) mtTFA expression
compared to actin. (G) Representative pictures of colony assay of MCF-7 cells with
NRF1 knockdown + estrogens treatment; (i) NT-DMSO, (ii) NT-E2, (iii) vector-DMSO,
(iv)vector-E2, (v) NRF1-kd-DMSO, (vi) NRF1-kd-E2. (H) Fold change of colonies
compared to NT-DMSO. (*) Indicates that E2 treatment group is significantly different
from control (DMSO) groups while (**) indicates that other treatments groups are
significantly different from E2 treatment groups. Data is expressed as mean of 3
experiments, OD ± SE, (P<0.05)

.
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Fig. 8. NRF1 expressions modulates estrogen induced proliferation and growth of MCF-7
cells. MCF-7 cells were transfected with plasmid either over-expressing or underexpressing NRF1 (NRF1-ox and NRF1-kd for 48hrs. Transfected cells were subsequently
used for colony assay, with or without 100 pg/ml E2 treatments for 21 days. (A) Colonies
formed by MCF-7 cells transfected with NRF1 modulating plasmid with vector control.
(i) NT-DMSO, (ii) NT-E2, (iii) Vector-DMSO, (iv) vector-E2, (v) NRF1-ox-DMSO, (vi)
NRF1-ox-E2, (vii) NRF1-kd-DMSO, (viii) NRF1-kd-E2. (B). Enumerated colony count
were expressed as percentage change from NT treatment group +/- SD of three
experiments. (*) indicates treatment significantly different from E2. (**) indicates
treatment significantly different from control. (P<0.05)
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Fig. 9. NRF1 over-expression modulates invasion of MCF-7 cells. MCF-7 cells were
transfected with either Null vector (Vector) or NRF1 over-expressing vector (Ox). In a
separate experiment, cells were also co-transfected with Ox, Ox+ vector, Ox+NRF1
knockdown plasmids (Ox+Kd). 1.0 x 104 cells were seeded on matrigel invasion chamber
with 8.0 µM pore size and 10% FBS media with or without 100 pg/ml estrogen were
added to the bottom of wells as chemoattractant. Cells were cultured for 72 hrs in CO2
incubator. Invaded cells at bottom of wells were stained and images were acquires with
Nikon microscope over 20x objective, and metamorph software. Data represents invaded
cells over 5 fields, +/- SD. (A)Invasion of NRF1ox expressing cells; i) DMSO, ii) vector,
iii) NRF1ox. (B) Invasion of Co-transfected NRF1ox plasmid with or without estrogen as
chemoattractant; i) Ox+DMSO, ii) Ox+E2, iii) Ox+vector+DMSO, iv) Ox+vector+E2,
v) Ox+ NRF1 kd+ DMSO, vi) Ox+NRF1+E2. (*) indicates treatment significantly
different from Ox/DMSO. (**) indicates treatment significantly different from
Ox/Null/E2. (*#) indicates treatment significantly different from Ox/Null/DMSO.
(P<0.05)
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CHAPTER VI
THE ACTIVATION OF NRF1 BY ESTROGEN IS NECESSARY FOR BREAST CELL
SUSCEPTIBILITY TO DEVELOP A MALIGNANT PHENOTYPE AND FOR
INVASIVE GROWTH OF BREAST TUMORS
Victor O. Okoh, Alok Deoraj, Jai Parkash and Deodutta Roy
Department of Environmental and Occupational Health; Stempel College of Public
Health and Social Work
Florida International University. Miami Fl. 33199

ABSTRACT
Understanding the contribution of NRF1 activation to the susceptibility for the
development of malignant phenotype cells by estrogen is the focus of this study.
Consistent with the redox-sensitivity of NRF1, 4-OH-E2-induced NRF1 expression and
its phosphorylation and acetylation were inhibited by the glutathione peroxidase mimic,
ebselen and by overexpression of ROS modifying genes, catalase and MnSOD. NRF1
was bound to the promoters of the cell cycle genes pcna, cyclin b1, and cdc25c, and prc1,
confirming the prediction that these promoters contain NRF1 elements. The exposure of
MCF10 A cells to a carcinogenic dose of 4-OHE2 increased the binding of NRF1 to the
promoters of these genes and that 4-OHE2-induced binding could be inhibited by
cotreatment with ebselen (antioxidant), or over expression of catalase (H2O2 scavenger).
These results suggest that 4-OH-E2-generated oxidants, particularly H2O2, may mediate
NRF1 binding to these gene promoters. Decreasing NRF1 protein levels via specific
siRNA Knock down of NRF1, PCAF and AKT inhibited 4-OH-E2 induced generation of
malignant phenotype. Together, these data suggest that ROS accelerate cell-cycle
progression and anchorage-independent growth in 4-OH-E2-transformed cells by
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controlling the expression of cell cycle genes in an NRF1-dependent manner. In
summary, estrogen-mediated activation of a redox sensitive signaling pathway regulates
NRF1 phosphorylation and acetylation events. These two events enhance its activating
function by increasing its localization close to nuclear targets and its affinity for
promoters of target genes. This, in turn, contributes to the susceptibility of normal breast
epithelial cells to develop malignant phenotype.

INTRODUCTION
NRF1/α-PAL

(nuclear

respiratory

factor-1/α-palindrome-binding

protein)

is

a

transcription factor (1-3). Initially, this transcription factor was mostly famous for
controlling nuclear-mitochondrial interactions that coordinate regulation of nuclear and
mitochondrial genes during organelle biogensis. A genome-wide analysis has revealed
that NRF1 binding elements are present in genes involved in DNA replication, mitosis,
and cytokinesis, suggesting that NRF1 plays an important role in cell cycle regulation
(4,5). Interestingly, the NRF1 recognition site is one of the seven transcription factor
binding sites which are most frequently found in the proximal promoters of ubiquitous
genes, indicating a broader spectrum of target genes for NRF1. NRF1 overexpression has
been observed in hepatoma, neuroblastoma and thyroid oncocytoma (6-8). In B cell
chronic lymphocytic leukemia (CLL) patients, the mRNA expression of the
mitochondrial biogenesis factors NRF1 and TFAM in the majority of leukemic cells is
higher than normal lymphocytes (9). While there are more than 20 Oncomine studies
with NRF1 over expression, the (actual) role NRF1 plays in breast cancer remains the
least studied of all transcription factors. We have recently meta-analyzed 18 published
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breast cancer microarray data (10). From our study, we found that: 1) NRF1 was
significantly overexpressed in ER+ tumors compared to ER- tumors; and 2) NRF1 was
significantly overexpressed as breast tumor’s grade increased. Investigation of the role of
NRF1 in breast carcinogenesis is the central focus of this study.

Elevated lifetime estrogen exposure is a well-known major risk factor for breast cancer,
however the underlying mechanisms of breast susceptibility to estrogen’s carcinogenic
effect remain elusive. In human breast cancer cells, the expression of almost 15% of the
genes significantly affected by E2 contains the NRF1 binding element, and the NRF1
binding signature is significantly enriched in the promoters of genes induced by estrogen
treatment (11). Recently, Klinge’s group reported that the NRF1 promoter contains a half
imperfect ERE, and E2 stimulates NRF1 expression (12) through the ER pathway. Motifs
bound by ELK1, E2F, NRF1 and NFY positively correlate with malignant progression of
breast cancer (13). From these studies, it appears that NRF1 may contribute to estrogeninduced malignant transformation of breast epithelial cells. Therefore, we first
investigated in this study whether NRF1 influences the susceptibility of the breast
epithelial cells to develop tumors in response to exposure to a well known major breast
cancer risk factor, estrogen. 4-OH-E2 is the most prevalent E2 metabolite in human
breast tumor tissues, with tumor tissue concentrations exceeding normal tissue
concentrations by several folds (14-16). Moreover, 4-OH-E2 is strongly carcinogenic,
while E2 is weakly carcinogenic and the other E2 metabolite, 2-OH-E2, is noncarcinogenic. Based on these data, 4-OH-E2 was used as the main model compound in
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this study to produce malignant phenotype in breast epithelial cells differentially
expressing NRF1.

NRF1 is highly redox sensitive protein (17,18-22). Similar to the other transcription
factors, the activation of NRF1 is essential for its optimal binding to the promoters of
target genes. NRF1 can bind to DNA in the absence of its phosphorylation. However,
both phosphorylation and acetylation increase NRF1 DNA binding to the promoters and
transcriptional activation (23,24). We and others have shown that estrogen exposure to
breast cells produce reactive oxygen species (ROS) (18,25,26,27). We have shown that
NRF1 binding to its promoter is inhibited by mitochondrial inhibitors as well as by
antioxidants (18). Thus, estrogen-generated ROS may also regulate NRF1 expression.
Therefore, we also examined whether a carcinogenic dose of 4-OH-E2 increases NRF1
phosphorylation and acetylation in MCF-10A cells and that these changes are inhibited
by antioxidants or overexpression of catalase. Our findings revealed that activation of
NRF1 by phosphorylation and acetylation depended on estrogen-induced ROS formation.
This is essential for NRF1 to contribute to the susceptibility of breast epithelial cells to
estrogen’s carcinogenic effect. We further determined whether NRF1 over-expression
converts non-aggressive breast tumors to aggressive and invasive tumors, and a dominant
negative suppressor of NRF1 is sufficient to prevent aggressive and invasive tumor
formation in vivo. We confirmed our in vitro findings of the role of NRF1 in breast
cancer invasion by in vivo.
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MATERIALS AND METHODS
Reagents
17β-Estradiol (E2), 2-hydroxyestradiol (2-OH-E2), 4-hydroxyestradiol (4-OH-E2),
Ebselen, N-acetyl-cysteine (NAC), Dimethylsulfoxide (DMSO) were all purchased from
Sigma (St Louis, MO, USA). All antibodies; PI3K (p110), phospho PI3K (p85),
phospho-Akt (ser 473) and total Akt antibodies were purchased from Cell Signaling
Technology Inc. (Boston, MA). All tissue cultures reagents were purchased from
Invitrogen Corporation (CA) unless otherwise specified.

Culture of cells and MCcells and Adenovirus Gene Transfer
Human mammary epithelial cells (MCF-10A) and breast cancer MCF-7 and MDA-MB
231 cells were obtained from American Type Culture Collection (ATCC). MCF-10A
cells were routinely cultured in phenol red-free DMEM-F12 media (1:1) supplemented
with 5% horse serum, hydrocortisone (0.5 μg/ml), insulin (10 μg/ml), epidermal growth
factor (20 ng/ml), 100 ng/ml cholera toxin and penicillin-streptomycin (100 μg/ml each)
and incubated at 37°C in a humidified atmosphere containing 5% CO2. Breast cancer
cells were cultured in DMEM-F12 Media with 10% fetal calf serum. The cell culture
media, serum, antibiotics, and growth supplements except cholera toxin (Calbiochem, La
Jolla, CA) were purchased from Invitrogen Corp CA). For experimental purposes, culture
media were changed to starvation media (serum free media + antibiotics) and allowed to
incubate for 48 hrs prior to commencement of most experiments, unless otherwise
indicated. Serum deprivation synchronizes cells in the G0/G1 phase of the cell cycle.
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The Adenovirus-CMV (empty vector), Adenovirus-MnSOD (AdCMVMnSOD), and
Adenovirus-Catalase (AdCMVCat) constructs were purchased from ViraQuest, Inc.
(North Liberty, IA, USA). The adenovirus constructs used were replication-defective,
E1- and E3-deleted recombinant adenovirus. Inserted into the E1 region of the adenovirus
genome was either the human MnSOD or catalase gene, both of which are driven by a
cytomegalovirus promoter. Cells were seeded in plates at 15%-70% confluence. The
following day, cells were infected with Adenoviruses over-expressing MnSOD or
catalase or vector at 100 MOI in serum free media. Control cells were treated with 100
MOI of the adenovirus-CMV construct. This viral load were determined to achieve
greater than 50% growth arrests of MCF-10A cells without significant cell death for
duration of experiment. Infected cells were cultured for 48 hrs after which cells were
used for experiments.

Akt1 and NRF1 RNAi transfections
Pre-designed and verified human shRNA for Akt1 or NRF1 and corresponding null
vector controls were purchased from OriGene (OriGene Technologies, Inc. Rockville,
MD). Transfections of cells were carried out in sub-confluent cell population using
FuGENE 6 (Roche) transfection reagents according to the manufacturer's protocol.
Briefly, MCF10A cells were seeded in 6 well plates with growth factor supplemented
media (SM) overnight. Post seeding, cells were transfected with 2 µl of Fugene-6
(Roche) preincubated for 20 min at room temperature with 0.5 µg plasmid RNAi or its
null controls (sham). Forty eight hrs post transfection, media were changed to serum-free
(starvation media) media and incubated for additional 48 hrs, after which cells were used

184

for various experiments. Transfection efficiencies ranged between 60-80% as quantified
by decreased protein expressions levels.

Cell viability assay
CellTiter-Fluor™ Cell Viability kit was purchased from promega corporation and used
according to manufacturer’s instructions. Briefly, cells were seeded in 96 well plate at a
density of 1.0x104 cells/well, serum starved for 48 hrs and treated with estrogens or ROS
modifiers. At the end of treatments procedure, substrate reagent (GF-AFC) were mixed
with substrate buffer and dispensed into well. This assay measures protease activities in
live cells as opposed to MTT or MTS assay kits that measure formations of formazon
crystals by mitochondrial enzymes. Plates were read on a fluorescence plate reader at
380–400 nm excitation and 505 nm emission and data is expressed as mean of three
experiments +/- SD.

Cell transformation
The cell transformation was carried out by a modified protocol of Russo’s group (18).
Briefly, MCF-10A cells were seeded at 30% density in a 10 cm dish. After 24 hrs of
seeding, media were replaced with stavations media and allowed to culture for 48 hrs,
and then cells were subjected to two treatment cycles with E2 or its catechol metabolites.
A treatment cycle includes 48 hrs starvation period, 48 hrs treatment period (100 ng/ml of
either E2, 2-OHE2, and 4-OHE2), and 48 hrs recovery period in growth media containing
10% horse serum (HS) and no growth suppliments. At the end of two treatments cycles,
cells that would be used for immunoprecipitation and Western blot analysis were treated

185

for additional 30 mins with estrogens, lysed with RIPA buffer, immunoprecipitated and
processed for western analysis. For anchorage independent growth assay 5000 cells/well
were used for colony formation assays in soft agar.
Anchorage independent Growth
Anchorage-independent growth, an indicator of neoplastic transformations of cells, was
assessed soft agar assay. Briefly, base support agar were made fresh by diluting 1.0%
molten agarose mixed with 1:1 2x culture media (2x DMEM/F12 media, 20% HS, 2x
penstrep antibiotics and 200 pg/ml estrogens) to a final 0.5%. Molten agar was left at 42
oC in a water bath until dispensed at 200 ul/well in 48 well plates, then allowed to
solidify for 4 hrs at room temperature. Top agarose overlay were made fresh by mixing
0.7% molten agarose with 2x culture media containing appropriate 5000 cells/well, then
gently overlaid over base agar. Cells were incubated for a minimum of 21 days in 37°C
incubator with 5% CO2. Cultures were fed every week with top agar layer and colony
formation was assumed when cell masses are 100 micron or greater as measured on a
Nikon TE2000U inverted microscope (Nikon Corp., USA) with Metamorph software
(Universal Imaging, USA), Images were acquired by using an Olympus C-5060 digital
camera attached to the Nikon TE2000U inverted microscope with 4x objective. Four
wells were enumerated for each groups and data expressed as mean of five wells +/- SD.

Invasion Assay
In order to determine invasiveness of cells NRF1 overexpressing, cells (5.0 x 103
cells/ml) were seeded over 8 μm pore transwell filter insert (Transwell, Coastar
Cambridge, MA) precoated with Matrigel (Collaborative Research, Bedford, MA).
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Chemoattractants used were reduced growth factor supplemented media or media with
10% FBS media positive control cells MDA MB 231. Matrix invasion were allowed for
16 hrs at 37 °C in a CO2 incubator. The non-invaded cells inside chambers were wiped
off with a cotton swab, and the filters were fixed, stained by Diff Quick (Sigma, St.
Louis, MO), cut out and mounted onto glass slides. The total number of cells that crossed
the membrane were counted under a light microscope, enumerated and expressed as fold
increase compared to parent cell line. The experiments were repeated five times and
results are expressed as the mean±S.E.

Chemical antioxidant treatments
The treatment procedure for Ebselen (a glutathione peroxidase mimetic which also
removes both H2O2 and peroxynitrite) or NAC (a precursor of glutathione and scavenger
of ROS) (31, 32) varies according to the experiments design. For all experiments, 40 μM
ebselen and 1.0 mM NAC were used for cell treatments. For example, in DCF assays,
antioxidants were pre-loaded onto cells for 2-4 hrs before ROS measurement commences.
For BrdU assays, cells were cultured with the chemical antioxidants throughout the
experimental procedure. For transformation regimen, antioxidants were applied to cells
each time cells were treated with estrogens. For anchorage independent growth assays,
antioxidants were added to soft agar matrix media and during weekly feeding of colonies.

Immunoprecipitation and Western Blot Analysis
After the respective treatments, cells were rinsed twice with ice cold phosphate buffered
saline (PBS), harvested with lysis buffer (150 mM NaCl, 0.5% deoxycholate, 0.1%
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Nonidet P-40, 0.1% SDS, 50 mM Tris) containing protease and phosphatase inhibitors
(Roche). Samples were diluted to 500 µg of protein in 1 ml of lysis buffer, and precleared for 1 hr at 4 °C with 10 µl of 1:1 slurry of protein A-agarose beads (Invitrogen
Corp) in lysis buffer. After a brief centrifugation to remove pre-cleared beads, 2 µg of
desired capture antibodies were added to each supernatant and incubated on a rocking
platform at 4 °C overnight and captured proteins were precipitated with 40 µl of protein
A-agarose beads for 2 hr. The beads were washed five times with lysis buffer and
resuspended in 40 μL sample loading buffer, subjected to electrophoresis and electroblotted onto a PVDF nylon membrane. Primary antibodies used for Western blots were
diluted 1:1000 in phosphate buffered saline Tween-20, PBST

and horseradish

peroxidase-conjugated secondary antibodies were diluted 1:50,000 in PBST. Blots were
treated with ECL reagents (Amersham Biotech), and proteins were detected by
autoradiography. Band intensity was quantified with Bio-Rad Gel Doc Imaging System.

Immunofluorescence Labeling
MCF-10A cells were seeded and treated in chamber slides as indicated in legends to the
figures. Post treatments, cells were fixed with ice cold methanol for 15mins, and
permeabilized with 0.5% Triton X-100 for 30. Cells were blocked with 1% normal goat
sera for 1 hr after which they were probed with antibodies diluted 1:500 for Akt and
1:500 for phospho Akt. Alexa Fluor labeled secondary antibody directed against Akt
antibody was diluted 1:1000. The confocal fluorescence images were scanned on a Nikon
TE2000U inverted fluorescence microscope equipped with a Nikon D-Eclipse C1 laser
scanning confocal microscope system (Nikon Corp., USA). The z-series scanning were
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done at every 1 μm up to a z-depth of 10 μm by using a Nikon 40 x 1.30 NA DIC H/N2
Plan Fluor oil immersion objective. The built-in Nikon EZ-C1 software was used for
confocal image acquisition and analyses.

RESULTS
Estrogen-induced ROS regulate NRF1 expression: Recently, Klinge’s group reported that
the NRF1 promoter contains a half imperfect ERE, and E2 stimulates NRF1 expression
(12) through the ER pathway. ROS is an important mediator of mitochondrial biogenesis
by controlling the expression of the nuclear respiratory factor-1 and mitochondrial
transcription factor A. NRF1 expression is increased by menadione, lipopolysaccharide
(LPS), tertiary butyl hydroperoxide (t-BH), and H2O2 (19,20). Using physiologically
achievable E2 concentration of 1 nM, which corresponds to the estrogenic menstrual
peak, we have shown that E2 induces rapid formation of ROS in MCF-7 cells (21,22).
Therefore, we tested the effect of carcinogenic regimen of 4-OH-E2 on the NRF1
expression in presence of ROS modifiers. The expression of NRF1 was increased by
several folds by 4-OH-E2 and this increase in the expression of NRF1 was inhibited by
over-expression of catalse and MnSOD and co-treatment with Ebselen (Figures 1 and 2).
This indicated that 4-OH-E2-induced NRF1 expression is redox sensitive.

The exposure of MCF-10A cells to carcinogenic dose regimen of 4-OH-E2 increased the
phosphorylation and acetylation of NRF1 (Figures 3-5). Both phosphorylation and
acetylation of NRF1 by two independent signaling molecules may control NRF1
activation. We assessed phosphorylation and acetylation of NRF1 by Western blotting
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and confocal microscopy after treating MCF-10A cells with 4-OH-E2 in serum-free
medium in the same condition that produces malignant phenotype. Cell lysates were
immunoprecipitated with NRF1 antibody, resolved on an gel, transferred to a membrane,
and probed individually with anti-serine, anti-lysine, anti-AKT, anti-NRF1 and antiPCAF antibodies. In addition to increased phosphorylation and acetylation of NRF1 by 4OH-E2 treatment, we also detected AKT and PCAF in the NRF1 immunoprecipitates
(Fig. 3 and 4). 4-OH-E2 exposure to MCF-10A cells induced serine phosphorylation of
NRF1 and overexpression of catalase and MnSOD blocked 4-OH-E2-induced
phosphorylation of serine residues on NRF1. NRF1 phosphorylation preceded P/CAF
recruitment for acetylation, because silencing of AKT prevented acetylation of NRF1.

The exposure of MCF-10A cells to a carcinogenic dose of 4-OH-E2 increased NRF1
binding to the gene promoters for the cell cycle regulators cyclin B1, Cdc25c, and Pcna:
MCF-10 A (5x105 cells /dish) were seeded, grown for 24 hrs, serum starved for another
24 hrs, and transfected with NRF1, PCAF, and AKT RNAi, as well as with AdMnSOD
(MnSOD) and Adcatalase (Cat). They were then treated with ebselen using the cell
transformation condition as described above, and then treated with 4-OH-E2. In a
preliminary ChIP analysis, we found that NRF1 is bound to the promoters of the cell
cycle genes Pcna, Cyclin B1, and Cdc25c, confirming the prediction that these promoters
contain NRF1 elements (Fig. 6). We also found that the exposure of MCF-10A cells to a
carcinogenic dose of 4-OH-E2 increased the binding of NRF1 to the promoters of these
genes, and that 4-OH-E2-induced binding could be inhibited by cotreatment with ebselen
(antioxidant), by an over expression of catalase (H2O2 scavenger) and MnSOD, and by
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RNAi of NRF1, PCAF and AKT. These results suggest that 4-OH-E2-generated oxidants,
particularly H2O2, may mediate NRF1 binding to these gene promoters.

Silencing of NRF1 and its interacting partners (PCAF or AKT) prevented 4-OH-E2induced anchorage-independent growth of MCF-10A cells: 4-OH-E2 treatment was able
to induce AIG positive colony formation (Figures 2-4 and 7); and in NRF1, AKT, or
PCAF RNAi silenced cells, 4-OH-E2 was not able to produce any colony. The effects of
4-OH-E2 on colony formation in cells transfected with scrambled RNAi of NRF1, PCAF,
and AKT were similar to WT cells. This indicates that 4-OH-E2-dependent anchorageindependent growth of MCF-10A cells is dependent on NRF1 signaling.

DISCUSSIONS
The novel finding emerged from this study are that the increased expression of NRF1
renders support to the growth of MCF-7 cells to form tumors in vivo. Alternatively, the
knockdown of NRF1 blocks the ability of invasive ER-MD-MBA-231 breast cancer cells
to form aggressive tumors or prevents these cells to metastasize to other organs.
Phosphorylation and acetylation of NRF1, which are redox sensitive, enhanced its
binding to promoter consensus sequences of cell cycle genes and subsequently,
transcriptional activation. Therefore, it is plausible that phosphorylation and acetylation
of NRF1 could contribute to the growth as well as invasiveness of the breast tumor.

Recent studies show several genes with the ability to transform normal cells to malignant
cells that are direct downstream targets of NRF1 (HP1α, SMYD3, CAPNS1) (28,29,30).
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The overexpression of a NRF1 regulatable gene, heterochromatin protein 1 alpha (HP1α),
involved in gene silencing produces genomic instability in cells (31-33), which is
essential for cell transformation. Similarly, overexpression of another NRF1 transcription
target gene, SMYD3, produces transformed phenotypes (34). Since these genes are
overexpressed in human breast cancer tissues, we postulate that these NRF1 regulatable
genes alone or in concert with others may contribute to the estrogen-induced malignant
phenotype. Recently, Klinge’s group reported that the NRF1 promoter contains a half
imperfect ERE, and E2 stimulates NRF1 expression (12) through the ER pathway in
MCF-7 cells. Even if a small amount of ERβ present in ERα negative MCF-10A cells is
involved in an increased synthesis of NRF1, it would not explain how increased
localization close to nuclear targets or enhanced ability to bind to the promoters of target
genes will be achieved upon estrogen exposure. Furthermore, ER signaling may be under
the influence of NRF1 through its target gene, SMYD3. SMYD3 functions as a coactivator of ERα and potentiates ERα activity in response to its ligand (35).

We have shown that NRF1 binding to its promoter is inhibited by mitochondrial
inhibitors as well as by antioxidants (18). We and others have shown that estrogen
exposure to breast cells produce reactive oxygen species (ROS) (18,25-27).Thus,
estrogen-generated ROS may also regulate NRF1 expression. Both phosphorylation and
acetylation of NRF1 protein control its activation (23,24). NRF1 has been shown to be
phosphorylated by redox sensitive kinases p38MAPK, ERK, and AKT (19,20) and
acetylated by P/CAF. The protein tyrosine phosphatases (PTPs) which control ERK and
AKT phosphorylation and histone deacetylases which control histone acetyl transferase

192

(HAT) activity of P/CAF are highly sensitive to ROS (35-41). The oxidation of PTEN’s
active site by ROS makes them inactive, which, in turn, stop dephosphorylation of PI3K
to occur and thus result in an active AKT (PKB) (42-46). In fact, a higher activation of
stress-activated protein kinases has been reported in E2-treated MCF-7 cells, which is
considered to contribute to the E2-proliferative effect (47). Thus, estrogen-generated
ROS may inactivate PTEN leading to an active phosphorylated PI3K. Subsequently, the
active PI3K may activate AKT which will directly phosphorylate NRF1. By a similar
mechanism histone decetylases, such as, HDAC3 and hSirT1, are inactivated by ROS
(42-46), which in turn can allow P/CAF to acetylate NRF1. Our studies showed that a
carcinogenic dose of 4-OH-E2 increased NRF1 phosphorylation and acetylation in MCF10A cells and that these changes were inhibited by antioxidants or overexpression of
catalase. This suggests that phosphorylation and acetylation of NRF1, which are redox
sensitive, enhance its binding to promoter consensus sequences and subsequently,
transcriptional activation. Findings of this study further showed that NRF1 binding to the
promoters of

cell cycle genes, PCNA, cyclin B1 and Cdc25C was inhibited by

knockdown of NRF1, PCAF and AKT by their shRNA. Therefore, it is plausible that
phosphorylation and acetylation of NRF1 could contribute to the aggressiveness and
invasiveness of the breast tumor.
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FIGURES AND LEGENDS

Fig. 1. Redox expression of NRF1 modulates 4OHE2 induced mammary transformation.
MCF-10A cells were seeded for 24 hrs and infected with Adenovirus overexpressing
catalase, MnSOD, or null construct at moi 100. 24 hrs post infection, cells were subjected
to transformation regimen with or without 100 ng/ml estrogens. For groups treated with
chemical antioxidant, these cells were co-treated with 40 µM ebselen and estrogen for the
duration of transformation protocol except during recovery period. Post transformation,
cells were either lysed with RIPA buffer, fractionated on 12% SDS-PAGE gel, then blot
probed for NRF1 and beta actin expression, or seeded for anchorage independent growth
on soft agar. A) Immunoblot of transformed cells normalized to Null/DMSO and band
intensity quantified with Biorad geldoc 2000. B) Representative picture of colony count
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per area in 24 well plate, normalized to Null/DMSO. Data expressed as mean of 3
experiments +/- SE, (P<0.05). (I) AdNull/DMSO, (II) AdNull/4OHE2, (III)
AdCata/DMSO, (IV) AdCata + 4-OHE2, (V) AdMnSOD/DMSO, (VI) Ad/MnSOD+ 4OHE2, (VII) Ebselen, (VIII) Ebselen + 4-OHE2.

Fig. 2 NRF1 expression mediates 4OHE2 induced mammary tumorigenesis. MCF-10A
cells were seeded at 20-30% confluency overnight and transfected with NRF1 shRNA or
it corresponding null vector. Post transfection, cells were subjected to transformation
regimen as previously described. Post transfection, cells were used for western blot
analysis probed for NRF1, TFAM and actin expressions, or anchorage independent
growth assay. A) Immunoblot of transformed cells normalized to non transfrected cells
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(NT)/DMSO and band intensity quantified with Biorad geldoc 2000. (I) immunoblot of
non transfected (NT) cells; (II) immunoblot of null transfected cells (III), immunoblot of
NRF1 shRNA transfected cells; (IV) Fold change of NRF1 expression normalized to
NT/DMSO; (V) Fold change of TFAM expression normalized to NT/DMSO. (B,C)
Colonies formed after 21 days in soft agar assay were enumerated and expressed as
numbers colonies per area. Five areas from each well was averaged over 3 plates and
expressed as mean, +/- SE. (P<0.05). (*) indicate significant difference from non
transfected (NT/DMSO) group. (**) indicate significant difference from 4OHE2
treatment group. (D) Trypan blue cell viability assessment of single cell suspension from
colony assay at the end of 21 days culture per 1000 cells.
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Fig. 3. Activation of Akt phosphorylate NRF1 during mammary tumorigenesis. Cells
were transfected with Akt shRNA or null constructs, and then subjected to transformation
regimen as previously described. Post transformation, cells were either treated with
estrogen for additional 30 mins and used for co-immunoprecipitation western blot
analysis, or for used for colony assay. A) Western blot analysis of NRF1
immunoprecipitated proteins probed with anti phosphoserine (pNRF1) or anti NRF1
antibodies respectively. (I) Immunoblot of null transfected cells (sham); (II) immunoblot
of Akt1 knockdown cells (Akt1-kd); (III) phosphorylated NRF1 fold change compared to
sham/DMSO treated group; (IV) NRF1 expression fold change compared to NRF1
expression from sham/DMSO. Data expressed as mean of three experiments, +/- SE.
(P<0.05). (*) indicate significant difference from null (sham/DMSO) group. (**) indicate
significant difference from 4OHE2 treatment group. B) Immunoflorescence label of sham
or Akt1-kd transformed cells probed for Akt (green) or NRF1 (red) expression. Yellow is
co-localization of Akt and NRF1 expression. C) Anchorage independent growth assay of
transformed cells transfected with sham or Akt shRNA.
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Fig. 4. PCAF expression participates in 4OHE2 induced mammary transformation. Cells
were transfected with PCAF shRNA plasmid and cells were subjected to transformation
regimen. Post transformation, cells were either treated with estrogen for additional 30
mins and used for western blot analysis, or seeded for colony assay formation and
confocal immunoflorescence analysis. A) Immunoblot of sham or PCAF RNAi
transfected cells and the fold change of PCAF expression compared to sham/DMSO
treated group. Data expressed as mean of three experiments, +/- SE, (P<0.05). (*)
indicate significant difference from null (sham/DMSO) group while (**) indicate
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significant difference from 4OHE2 treatment group. B) Immunoflorescence label of sham
or PCAF-kd transformed cells probed for PCAF (green) or NRF1 (red) expression.
Yellow is co-localization of PCAF and NRF1 expression. C) Anchorage independent
growth assay of transformed cells transfected with sham or PCAF shRNA.

Fig. 5. Akt Phosphorylation of NRF1 induces its Acetylation during mammary
transformation. MCF-10A cells were transfected with NRF1, Akt1, PCAF or null
shRNA plasmids and the cells were subjected to transformation regimen as previously
described. Post transformation, cells were treated with estrogen for additional 30 mins
and lysed with RIPA buffer. 750 µg of whole cell lysate (WCL) were
immunoprecipitated with NRF1 antibody and eluent fractionated on 12% SDS-PAGE
gel. Blots were probed with anti serine (pNRF1), anti acetyl lysine (ANRF1), anti
NRF1(NRF1) antibodies respectively. A) Immoblot depicting the effects various RNAi
on NRF1’s phosphorylation and acetylation during MCF-10A transformation with
4OHE2. B) Densitometry of phosphorylated and acetylated NRF1 upon Akt1, PCAF and
NRF1 knockdown. Data expressed as mean of three experiments, +/- SE, (P<0.05).
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Fig. 6. Transactivation of NRF1 during mammary tranformation is redox dependent.
MCF-10A cells were co-treated with estrogens and ROS modulators as previously
described. Post transfection, cells were either seeded on chamber slide for confocal
microscopy analysis, or treated for additional 30 mims, then harvested with RIPA buffer.
750 µg of WCL were immunoprecipitated with NRF1 antibody and eluent were
fractionated on 12% SDS-PAGE gel. Blots were then probed with anti serine (pNRF1),
anti acetyl lysine (ANRF1), anti NRF1(NRF1) antibodies respectively. 50 µg of WCL
was also fractionated on SDS-PAGE gel and blot probed with beta actin anti body. A)
Immoblot depicting the effects various RNAi on NRF1’s phosphorylation and
acetylation during MCF-10A transformation with 4OHE2. B) Normalized band intensity
of phosphorylated and acetylated NRF1 upon Akt1, PCAF and NRF1 knockdown
respectively. Data normalized to vector/DMSO and expressed as mean fold change of
three experiments, +/- SE, (P<0.05). C) Immunoflorescence label of cells co-treated with
biological and chemical ROS modifiers, then probed for serine (green) or NRF1 (red) colocalization (yellow).

B
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Fig. 7. NRF1 expression is involved in invitro growth of breast cancer cells. A) Colonies
formed by MCF-7 cells transfected with NRF1 modulating plasmids, with null vector
control. (i) NT-DMSO, (ii) NT-E2, (iii) Vector-DMSO, (iv) vector-E2, (v) NRF1-oxDMSO, (vi) NRF1-ox-E2, (vii) NRF1-kd-DMSO, (viii) NRF1-kd-E2. (B). Enumerated
colony count were expressed as percentage change from NT treatment group +/- SD of
three experiments. (*) indicates treatment significantly different from E2. (**) indicates
treatment significantly different from control.
(P<0.05). B) Immunoflorescence labeling of MCF7 cells treated for 45 mins with 10 nM
estrogens, then probed for NRF1, serine, acetyl lysine antibodies respectively. NRF1
(red), serine (blue), acetyl lysine (green), merge of NRF1/serine/acelty lysine (white). C)
MCF-10A cells were seeded for transformation as described in methods. At end of
transformation period, cells were treated for additional 18 hours with vehicles or
estrogens after which they were washed with cold PBS with protease inhibitors. Cells
were detached with trypsin and 2.0 x106 cells were counted and used for either ChIP
assay or qRT-PCR analysis. PCR reactions with DNA or cDNA primers for cell cycle
regulatory genes were assembled in 25ul final volume and PCR reactions on ABI Real
time PCR machine. Data represents mean of 3 different experiments +/-SE, (P<0.05). (I)
CHiP analysis for NRF1 promoter occupancy of selected cell cycle regulatory gene. (II)
Quantitative RT-PCR (qRT-PCR) for transcriptional expression of selected cell cycle
regulatory gene.

207

VITA
VICTOR O. OKOH
EDUCATION
2010 Ph.D Student. Public Health, Environmental and Occupational Health
Florida International University

Dept.,

1998 MSPH. Toxicology, Environmental Toxicology Dept., University of Alabama,
Birmingham
1993

B.S.

Biology, Natural Science and Math, University of Alabama, Birmingham

DISSERTATION TITLE
4-Hydroxy β Estradiol-Induced Oxidants-Mediated Signaling is Involved in the
Development of Breast Cancer. Mentor: Dr. Deodutta Roy
PROFESSIONAL EXPERIENCE
2008-Present Adjunct Instructor, Environmental and Occupational Health, Florida
International University
2004-2008
Research Associate, Dept. of Environmental and Occupational Health,
Florida International University
2003-2004
Research Associate, Dept. of Pediatrics, University of Alabama,
Birmingham
1998-2004
Research Scientist, Pulmonary and Critical Care Medicine, University of
Alabama, Birmingham
1996-1998
Sr. Clinical Research Scientist, Haynes Immunogenetics. Baptist Medical
Center Princeton. Birmingham Alabama
1994-1998
Research Assistant, Dept. of Pathology, University of Alabama
Birmingham
TEACHING
2008-Present Biological Basis of Environmental Pollution and Public Health, Florida
International University
1992-1993
Alabama

Teacher’s Assistant, Human Anatomy and Physiology, University of

208

1991-1992
Teacher’s Assistant, Dept of Chemistry, University of Alabama
Birmingham
PUBLICATIONS
2005 Lawrence S. Prince, Heather I. Dieperink, Victor O. Okoh, German A. FierroPerez. Toll-like receptor signaling inhibits structural development of the distal fetal
mouse lung. Developmental Dynamics 233:553–561, 2005.
2004 Prince LS, Okoh VO, Moninger TO, Matalon S. Lipopolysaccharide increases
alveolar type II cell number in fetal mouse lungs through Toll-like receptor 4 and NFkappaB. Am J Physiol Lung Cell Mol Physiol. 2004 Nov;287(5):L999-1006.
2004 Okoh V.; Young G.D.; Winokur T.S.; Garver Jr R.I.
A Novel Assay for the Quantification of Invasion from Raft Cultures of Lung Carcinoma.
Clinical and Experimental Metastasis, 2004, vol. 21, iss. 1, pp. 1-6(6).
2002 Young GD, Winokur TS, Cerfolio RJ, Van Tine BA, Chow LT, Okoh V, Garver
RI Jr. Differential expression and biodistribution of cytokeratin 18 and desmoplakins in
non-small cell lung carcinoma subtypes. Lung Cancer. 2002 May;36(2):133-41.
1999 X Wu, K Goldsmith, V Okoh and RI Garver, Jr. Antineoplastic ‘Multimodality
Adenovirus’ containing E1A and a Therapeutic Transgene. Tumor Targeting (1999) 4,
170-178.
ABSTRACTS AND MEETINGS
Deodutta Roy, Quentin Felty, Victor Okoh, and Nana-Aisha Garba.
Inhibition of Estrogen-Induced Growth of Breast Cancer Cells by Modulating In Situ
Oxidant Levels. Poster Presentation at DoD Era of Hope Breast Cancer Research
Program, 2008.
Deodutta Roy, Quentin Felty, Joyce Slingerland, Nana-Aisha Garba, Rosalind Penny, and
Victor Okoh. Reversible Inactivation of CDC25A by Estrogen and Antiestrogen-Induced
Reactive Oxygen Species may be Involved in the Phosphorylation of P27. Poster
Presentation at DoD Era of Hope Breast Cancer Research Program, 2008.
HONORS
Phi Kappa Phi Honor society.
Golden Key International Honour Society
Several Dean’s List

209

